TransporterID,Gene_name,MOA,phenotype,regulation_phenomenon,class,Regulating_factor_type,factor_uniform_name,Source,SpeciesName32,strain_subname,in vivo_1,in vitro_1,Description_all,Related_drugs,Tissue
DTD0036,ABCA1,Up regulating,Atherosclerosis,Up regulating of ABCA1 expression in atherosclerosis condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,"3,4-Dihydroxybenzoic acid",Dietary cyanidin-3-O--glucoside metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,"The metabolite 3,4-dihydroxybenzoic acid generated from the metabolism of dietary cyanidin-3-o--glucoside by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCA1.",.,Blood
DTD0036,ABCA1,Up regulating,.,Up regulating of ABCA1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Trimethylamine oxide,L-carnitine metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite trimethylamine oxide generated from the metabolism of l-carnitine by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCA1.,.,Liver
DTD0003,ABCB1,Down regulating,Colon adenocarcinoma,Down regulating of ABCB1 expression in colon adenocarcinoma condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Lactobacillus murinus,Ligilactobacillus murinus,Ligilactobacillus murinus,.,Sprague-Dawley specific pathogen free rats,Human colon adenocarcinoma cells (Caco-2),The Ligilactobacillus murinus has been reported to decrease the expression of the drug transporter ABCB1.,Glycyrrhizic Acid,Colon
DTD0003,ABCB1,Down regulating,Colon adenocarcinoma,Down regulating of ABCB1 expression in colon adenocarcinoma condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Salmonella enterica subsp. enterica serovar Typhimurium,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium,.,Madin-Darby canine kidney cells (MDCKII),The Salmonella enterica subsp. enterica serovar Typhimurium has been reported to decrease the expression of the drug transporter ABCB1.,Digoxin,Colon
DTD0003,ABCB1,Sequestration substrate,.,Sequestration of human ABCB1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Escherichia coli,Escherichia coli,Escherichia coli,str. K-12 substr. MG1655,.,.,"The Escherichia coli str. K-12 substr. MG1655 has been reported to sequester the drug Chloramphenicol and Tetracycline, which limits the distribution of the drug in the body and its binding to the drug transporter ABCB1, thereby affecting the efficacy, safety, or bioavailability of the drug.",Chloramphenicol; Tetracycline,.
DTD0003,ABCB1,Co-transporter,.,Co-transport of human ABCB1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ompF,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhi 1895,.,.,"The protein ompF of Salmonella enterica subsp. enterica serovar Typhi 1895 has been reported to transport similar substrates/drugs of ABCB1, which affects the distribution of its substrate/drug in vivo.",Chloramphenicol,.
DTD0003,ABCB1,Co-transporter,.,Co-transport of human ABCB1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ompF,Escherichia coli,Escherichia coli,JM712,.,.,"The protein ompF of Escherichia coli JM712 has been reported to transport similar substrates/drugs of ABCB1, which affects the distribution of its substrate/drug in vivo.",Norfloxacin; Tetracycline; Chloramphenicol,.
DTD0003,ABCB1,Up regulating,Conventional mice compared with germ-free mice,Up regulating of ABCB1 expression in conventional mice compared with germ-free mice,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,3-Indolepropionic acid; L-tryptophan,Indole metabolite from Clostridium sporogenes,Clostridium sporogenes,.,Swiss Webster germ-free mice,Human kidney human embryonic kidney 293T cells (HEK 293T),The metabolite 3-indolepropionic acid and l-tryptophan generated from the metabolism of indole by the Clostridium sporogenes has been reported to increase the expression of the drug transporter ABCB1.,.,Small intestine
DTD0003,ABCB1,Down regulating,Conventional mice compared with germ-free mice,Down regulating of ABCB1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Bacteroides thetaiotaomicron,Bacteroides thetaiotaomicron,Bacteroides thetaiotaomicron,.,Germ-free mice,.,The Bacteroides thetaiotaomicron has been reported to decrease the expression of the drug transporter ABCB1.,.,Intestine
DTD0003,ABCB1,Up regulating,Colon cancer,Up regulating of ABCB1 expression in colon cancer condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Bifidobacterium adolescentis,Bifidobacterium adolescentis,Bifidobacterium adolescentis,.,.,Human colon adenocarcinoma cells (Caco-2),The Bifidobacterium adolescentis has been reported to increase the expression of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Down regulating,Type 1 diabetes mellitus,Down regulating of ABCB1 expression in type 1 diabetes mellitus condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Clostridium_sensu_stricto_1 isolates,Unclassified Clostridium,Unclassified Clostridium,stricto 1,Diabetic sprague-dawley rats,Human colon adenocarcinoma cells (Caco-2),The Unclassified Clostridium stricto 1 has been reported to decrease the expression of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Up regulating,Colon cancer,Up regulating of ABCB1 expression in colon cancer condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Escherichia coli Nissle 1917,Escherichia coli,Escherichia coli,Nissle 1917,.,Human colon adenocarcinoma cells (Caco-2),The Escherichia coli Nissle 1917 has been reported to increase the expression of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Down regulating,Type 1 diabetes mellitus,Down regulating of ABCB1 expression in type 1 diabetes mellitus condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Lachnoclostridium isolates(down),Unclassified Lachnoclostridium,Unclassified Lachnoclostridium,.,Diabetic sprague-dawley rats,Human colon adenocarcinoma cells (Caco-2),The Unclassified Lachnoclostridium has been reported to decrease the expression of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Down regulating,Type 1 diabetes mellitus,Down regulating of ABCB1 expression in type 1 diabetes mellitus condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Prevotellaceae_NK3B31_group,Unclassified Prevotellaceae,Unclassified Prevotellaceae,.,Diabetic sprague-dawley rats,Human colon adenocarcinoma cells (Caco-2),The Unclassified Prevotellaceae has been reported to decrease the expression of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Down regulating,Type 1 diabetes mellitus,Down regulating of ABCB1 expression in type 1 diabetes mellitus condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Prevotellaceae_UCG-001,Unclassified Oscillospiraceae,Unclassified Oscillospiraceae,.,Diabetic sprague-dawley rats,Human colon adenocarcinoma cells (Caco-2),The Unclassified Oscillospiraceae has been reported to decrease the expression of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Down regulating,Type 1 diabetes mellitus,Down regulating of ABCB1 expression in type 1 diabetes mellitus condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Romboutsia isolates,Unclassified Romboutsia,Unclassified Romboutsia,.,Diabetic sprague-dawley rats,Human colon adenocarcinoma cells (Caco-2),The Unclassified Romboutsia has been reported to decrease the expression of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Down regulating,Type 1 diabetes mellitus,Down regulating of ABCB1 expression in type 1 diabetes mellitus condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Ruminococcaceae_UCG-005 isolates,Unclassified Oscillospiraceae,Unclassified Oscillospiraceae,.,Diabetic sprague-dawley rats,Human colon adenocarcinoma cells (Caco-2),The Unclassified Oscillospiraceae has been reported to decrease the expression of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Down regulating,Type 1 diabetes mellitus,Down regulating of ABCB1 expression in type 1 diabetes mellitus condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Turicibacter isolates,Unclassified Turicibacter,Unclassified Turicibacter,.,Diabetic sprague-dawley rats,Human colon adenocarcinoma cells (Caco-2),The Unclassified Turicibacter has been reported to decrease the expression of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Down regulating,Type 1 diabetes mellitus,Down regulating of ABCB1 expression in type 1 diabetes mellitus condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Unclassified_f_Prevotellaceae isolates,Unclassified Prevotellaceae,Unclassified Prevotellaceae,.,Diabetic sprague-dawley rats,Human colon adenocarcinoma cells (Caco-2),The Unclassified Prevotellaceae has been reported to decrease the expression of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Up regulating,.,Up regulating of ABCB1 expression in the health condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Eubacterium,Unclassified Eubacterium,Unclassified Eubacterium,.,C57BL/6J mice,Human lung mucoepidermoid carcinoma cells (NCI-H292),The Unclassified Eubacterium has been reported to increase the expression of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Up regulating,.,Up regulating of ABCB1 expression in the health condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Lactobacillus,Unclassified Lactobacillus,Unclassified Lactobacillus,.,C57BL/6J mice,Human lung mucoepidermoid carcinoma cells (NCI-H292),The Unclassified Lactobacillus has been reported to increase the expression of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Inhibition,.,Inhibition of ABCB1 function in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Glycochenodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite glycochenodeoxycholic acid generated from the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCB1.,Salmon calcitonin,Intestine
DTD0003,ABCB1,Up regulating,Conventional mice compared with germ-free mice,Up regulating of ABCB1 expression in conventional mice compared with germ-free mice,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,3-Indolepropionic acid,L-tryptophan metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J germ-free mice,.,The metabolite 3-indolepropionic acid generated from the metabolism of l-tryptophan by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.,.,Small intestine
DTD0003,ABCB1,Up regulating,Colon cancer,Up regulating of ABCB1 expression in colon cancer condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Chenodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human colon adenocarcinoma cells (HT-29),The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Up regulating,Colon cancer,Up regulating of ABCB1 expression in colon cancer condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Deoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human colon adenocarcinoma cells (HT-29),The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Inhibition,Colon cancer,Inhibition of ABCB1 function in colon cancer condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Sodium taurocholate,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human colon adenocarcinoma cells (Caco-2),The metabolite sodium taurocholate generated from the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Down regulating,Conventional mice compared with germ-free mice,Down regulating of ABCB1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6N mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCB1.,.,Small intestine
DTD0003,ABCB1,Up regulating,Hypoxia,Up regulating of ABCB1 expression in hypoxia condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Sprague-Dawley rats,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.,.,Liver
DTD0003,ABCB1,Up regulating,.,Up regulating of ABCB1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,3-Indolepropionic acid,L-tryptophan metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J conventionally-raised mice,.,The metabolite 3-indolepropionic acid generated from the metabolism of l-tryptophan by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.,.,Ileum
DTD0003,ABCB1,Up regulating,.,Up regulating of ABCB1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,3-Indolepropionic acid,L-tryptophan metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J conventionally-raised mice,.,The metabolite 3-indolepropionic acid generated from the metabolism of l-tryptophan by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.,.,Jejunum
DTD0003,ABCB1,Up regulating,.,Up regulating of ABCB1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Butyrate,Dietary food metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,Human lung mucoepidermoid carcinoma cells (NCI-H292),The metabolite butyrate generated from the metabolism of dietary food by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Up regulating,.,Up regulating of ABCB1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Chenodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,Mouse precursor T cell lymphoblastic lymphoma cells(EL4),The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.,.,Ileum
DTD0003,ABCB1,Up regulating,.,Up regulating of ABCB1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Cholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,Mouse precursor T cell lymphoblastic lymphoma cells(EL4),The metabolite cholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.,.,Ileum
DTD0003,ABCB1,Activation,.,Activation of ABCB1 function in health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Deoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,Human lung mucoepidermoid carcinoma cells (NCI-H292),The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to activate the function of the drug transporter ABCB1.,.,Lung
DTD0003,ABCB1,Up regulating,.,Up regulating of ABCB1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Deoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,Mouse precursor T cell lymphoblastic lymphoma cells(EL4),The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.,.,Ileum
DTD0003,ABCB1,Activation,.,Activation of ABCB1 function in health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Lithocholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,Human lung mucoepidermoid carcinoma cells (NCI-H292),The metabolite lithocholic acid generated from the host unspecified microbiota has been reported to activate the function of the drug transporter ABCB1.,.,Lung
DTD0003,ABCB1,Up regulating,.,Up regulating of ABCB1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Lithocholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,Human lung mucoepidermoid carcinoma cells (NCI-H292),The metabolite lithocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Up regulating,.,Up regulating of ABCB1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,L-Tryptophan,Dietary food metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J conventionally-raised mice,.,The metabolite l-tryptophan generated from the metabolism of dietary food by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.,.,Duodenum
DTD0003,ABCB1,Inhibition,.,Inhibition of ABCB1 function in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Sodium 12-Oxochenodeoxycholate,Generated by Host unspecified microbiota,Host unspecified microbiota,.,.,Rat brain microvascular endothelial cells (RBE4),The compound sodium 12-oxochenodeoxycholate generated by host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCB1.,.,Brain
DTD0003,ABCB1,Inhibition,.,Inhibition of ABCB1 function in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Taurochenodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite taurochenodeoxycholic acid generated from the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCB1.,.,Intestine
DTD0003,ABCB1,Inhibition,.,Inhibition of ABCB1 function in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Taurolithocholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite taurolithocholic acid generated from the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCB1.,.,Intestine
DTD0003,ABCB1,Down regulating,.,Down regulating of ABCB1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Urolithin A,Dietary polyphenols metabolite from Host unspecified microbiota,Host unspecified microbiota,.,NRGS mice,Human colon carcinoma cells (HCT-116),The metabolite urolithin a generated from the metabolism of dietary polyphenols by the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCB1.,.,Colon
DTD0003,ABCB1,Activation,.,Activation of ABCB1 function in health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Ursodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,Human lung mucoepidermoid carcinoma cells (NCI-H292),The metabolite ursodeoxycholic acid generated from the host unspecified microbiota has been reported to activate the function of the drug transporter ABCB1.,.,Lung
DTD0003,ABCB1,Up regulating,.,Up regulating of ABCB1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Ursodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,Human lung mucoepidermoid carcinoma cells (NCI-H292),The metabolite ursodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.,.,Colon
DTD0014,ABCB11,Up regulating,Metabolic dysfunction-associated fatty liver disease,Up regulating of ABCB11 expression in metabolic dysfunction-associated fatty liver disease condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Akkermansia muciniphila,Akkermansia muciniphila,Akkermansia muciniphila,ATCC BAA-835,C57BL/6 mice,.,The Akkermansia muciniphila ATCC BAA-835 has been reported to increase the expression of the drug transporter ABCB11.,.,Liver
DTD0014,ABCB11,Up regulating,Conventional mice compared with germ-free mice,Up regulating of ABCB11 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6N mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB11.,.,Liver
DTD0014,ABCB11,Down regulating,.,Down regulating of ABCB11 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Chenodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCB11.,.,Liver
DTD0014,ABCB11,Down regulating,.,Down regulating of ABCB11 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Cholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCB11.,.,Liver
DTD0014,ABCB11,Down regulating,.,Down regulating of ABCB11 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Deoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCB11.,.,Liver
DTD0014,ABCB11,Down regulating,.,Down regulating of ABCB11 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Hyodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCB11.,.,Liver
DTD0014,ABCB11,Down regulating,.,Down regulating of ABCB11 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Lithocholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCB11.,.,Liver
DTD0056,ABCC10,Up regulating,Conventional mice compared with germ-free mice,Up regulating of ABCC10 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC10.,.,Jejunum
DTD0056,ABCC10,Down regulating,.,Down regulating of ABCC10 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Urolithin A,Dietary polyphenols metabolite from Host unspecified microbiota,Host unspecified microbiota,.,NRGS mice,Human colon carcinoma cells (HCT-116),The metabolite urolithin a generated from the metabolism of dietary polyphenols by the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC10.,.,Colon
DTD0002,ABCC2,Up regulating,Diabetes,Up regulating of ABCC2 expression in diabetes condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Bifidobacterium lactis,Bifidobacterium animalis,Bifidobacterium animalis,subsp. lactis,Sprague-Dawley rats,.,The Bifidobacterium animalis subsp. lactis has been reported to increase the expression of the drug transporter ABCC2.,Gliclazide,Ileum
DTD0002,ABCC2,Up regulating,Diabetes,Up regulating of ABCC2 expression in diabetes condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Lactobacillus acidophilus,Lactobacillus acidophilus,Lactobacillus acidophilus,.,Sprague-Dawley rats,.,The Lactobacillus acidophilus has been reported to increase the expression of the drug transporter ABCC2.,Gliclazide,Ileum
DTD0002,ABCC2,Down regulating,Colon adenocarcinoma,Down regulating of ABCC2 expression in colon adenocarcinoma condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Lactobacillus murinus,Ligilactobacillus murinus,Ligilactobacillus murinus,.,Sprague-Dawley specific pathogen free rats,Human colon adenocarcinoma cells (Caco-2),The Ligilactobacillus murinus has been reported to decrease the expression of the drug transporter ABCC2.,Glycyrrhizic Acid,Colon
DTD0002,ABCC2,Up regulating,Diabetes,Up regulating of ABCC2 expression in diabetes condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Lactobacillus rhamnosus,Lacticaseibacillus rhamnosus,Lacticaseibacillus rhamnosus,.,Sprague-Dawley rats,.,The Lacticaseibacillus rhamnosus has been reported to increase the expression of the drug transporter ABCC2.,Gliclazide,Ileum
DTD0002,ABCC2,Up regulating,Conventional mice compared with germ-free mice,Up regulating of ABCC2 expression in conventional mice compared with germ-free mice,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,3-Indolepropionic acid; Indole,Indole metabolite from Clostridium sporogenes,Clostridium sporogenes,.,Swiss Webster germ-free mice,Human kidney human embryonic kidney 293T cells (HEK 293T),The metabolite 3-indolepropionic acid and indole generated from the metabolism of indole by the Clostridium sporogenes has been reported to increase the expression of the drug transporter ABCC2.,.,Kidney
DTD0002,ABCC2,Up regulating,Metabolic dysfunction-associated fatty liver disease,Up regulating of ABCC2 expression in metabolic dysfunction-associated fatty liver disease condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Akkermansia muciniphila,Akkermansia muciniphila,Akkermansia muciniphila,ATCC BAA-835,C57BL/6 mice,.,The Akkermansia muciniphila ATCC BAA-835 has been reported to increase the expression of the drug transporter ABCC2.,.,Liver
DTD0002,ABCC2,Down regulating,Colon cancer,Down regulating of ABCC2 expression in colon cancer condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Bifidobacterium adolescentis,Bifidobacterium adolescentis,Bifidobacterium adolescentis,.,.,Human colon adenocarcinoma cells (Caco-2),The Bifidobacterium adolescentis has been reported to decrease the expression of the drug transporter ABCC2.,.,Colon
DTD0002,ABCC2,Down regulating,Colon cancer,Down regulating of ABCC2 expression in colon cancer condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Escherichia coli Nissle 1917,Escherichia coli,Escherichia coli,Nissle 1917,.,Human colon adenocarcinoma cells (Caco-2),The Escherichia coli Nissle 1917 has been reported to decrease the expression of the drug transporter ABCC2.,.,Colon
DTD0002,ABCC2,Up regulating,Colon cancer,Up regulating of ABCC2 expression in colon cancer condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Chenodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human colon adenocarcinoma cells (Caco-2),The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC2.,.,Colon
DTD0002,ABCC2,Up regulating,Colon cancer,Up regulating of ABCC2 expression in colon cancer condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Deoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human colon adenocarcinoma cells (HT-29),The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC2.,.,Colon
DTD0002,ABCC2,Down regulating,Conventional mice compared with germ-free mice,Down regulating of ABCC2 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6N mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC2.,.,Small intestine
DTD0002,ABCC2,Down regulating,Conventional mice compared with germ-free mice,Down regulating of ABCC2 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC2.,.,Jejunum
DTD0002,ABCC2,Down regulating,Conventional mice compared with germ-free mice,Down regulating of ABCC2 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC2.,.,Liver
DTD0002,ABCC2,Down regulating,Conventional mice compared with germ-free mice,Down regulating of ABCC2 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 germ-free/conventionally-raised mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC2.,.,Jejunum
DTD0002,ABCC2,Down regulating,Conventional mice compared with germ-free mice,Down regulating of ABCC2 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J germ-free mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC2.,.,Liver
DTD0002,ABCC2,Down regulating,Conventional mice compared with germ-free mice,Down regulating of ABCC2 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Swiss Webster mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC2.,.,Ileum
DTD0002,ABCC2,Down regulating,.,Down regulating of ABCC2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,"2,3,7,8-tetrachlorodibenzofuran",Dietary dough pills metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,"The metabolite 2,3,7,8-tetrachlorodibenzofuran generated from the metabolism of dietary dough pills by the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC2.",.,Ileum
DTD0002,ABCC2,Up regulating,.,Up regulating of ABCC2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Chenodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC2.,.,Liver
DTD0002,ABCC2,Up regulating,.,Up regulating of ABCC2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Cholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC2.,.,Liver
DTD0002,ABCC2,Up regulating,.,Up regulating of ABCC2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Deoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC2.,.,Liver
DTD0002,ABCC2,Up regulating,.,Up regulating of ABCC2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Hyodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC2.,.,Liver
DTD0002,ABCC2,Up regulating,.,Up regulating of ABCC2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Lithocholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC2.,.,Liver
DTD0002,ABCC2,Down regulating,.,Down regulating of ABCC2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Urolithin A,Dietary polyphenols metabolite from Host unspecified microbiota,Host unspecified microbiota,.,NRGS mice,Human colon carcinoma cells (HCT-116),The metabolite urolithin a generated from the metabolism of dietary polyphenols by the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC2.,.,Colon
DTD0012,ABCC3,Up regulating,Metabolic dysfunction-associated fatty liver disease,Up regulating of ABCC3 expression in metabolic dysfunction-associated fatty liver disease condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Akkermansia muciniphila,Akkermansia muciniphila,Akkermansia muciniphila,ATCC BAA-835,C57BL/6 mice,.,The Akkermansia muciniphila ATCC BAA-835 has been reported to increase the expression of the drug transporter ABCC3.,.,Liver
DTD0012,ABCC3,Up regulating,Colon cancer,Up regulating of ABCC3 expression in colon cancer condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Chenodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human colon adenocarcinoma cells (HT-29),The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.,.,Colon
DTD0012,ABCC3,Up regulating,Colon cancer,Up regulating of ABCC3 expression in colon cancer condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Deoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human colon adenocarcinoma cells (Caco-2),The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.,.,Colon
DTD0012,ABCC3,Up regulating,Conventional mice compared with germ-free mice,Up regulating of ABCC3 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Swiss Webster germ-free/specific-pathogen-free mice,Mouse leukemia cells (RAW 264.7),The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.,.,Colon
DTD0012,ABCC3,Up regulating,Conventional mice compared with germ-free mice,Up regulating of ABCC3 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Swiss Webster mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.,.,Ileum
DTD0012,ABCC3,Up regulating,Conventional mice compared with germ-free mice,Up regulating of ABCC3 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Swiss Webster mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.,.,Liver
DTD0012,ABCC3,Up regulating,.,Up regulating of ABCC3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,"2,3,7,8-tetrachlorodibenzofuran",Dietary dough pills metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,"The metabolite 2,3,7,8-tetrachlorodibenzofuran generated from the metabolism of dietary dough pills by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.",.,Ileum
DTD0012,ABCC3,Up regulating,.,Up regulating of ABCC3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,"2,3,7,8-tetrachlorodibenzofuran",Dietary dough pills metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,"The metabolite 2,3,7,8-tetrachlorodibenzofuran generated from the metabolism of dietary dough pills by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.",.,Liver
DTD0012,ABCC3,Up regulating,.,Up regulating of ABCC3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Chenodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.,.,Ileum
DTD0012,ABCC3,Up regulating,.,Up regulating of ABCC3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Cholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.,.,Ileum
DTD0012,ABCC3,Up regulating,.,Up regulating of ABCC3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Deoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.,.,Ileum
DTD0012,ABCC3,Up regulating,.,Up regulating of ABCC3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Hyodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.,.,Ileum
DTD0012,ABCC3,Up regulating,.,Up regulating of ABCC3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Lithocholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.,.,Ileum
DTD0012,ABCC3,Up regulating,.,Up regulating of ABCC3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Lithocholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite lithocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.,.,Liver
DTD0015,ABCC4,Sequestration substrate,.,Sequestration of human ABCC4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Escherichia coli,Escherichia coli,Escherichia coli,str. K-12 substr. MG1655,.,.,"The Escherichia coli str. K-12 substr. MG1655 has been reported to sequester the drug Ciprofloxacin, which limits the distribution of the drug in the body and its binding to the drug transporter ABCC4, thereby affecting the efficacy, safety, or bioavailability of the drug.",Ciprofloxacin,.
DTD0015,ABCC4,Inhibition,Chronic kidney disease,Inhibition of ABCC4 function in chronic kidney disease condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,p-Cresol glucuronide,p-cresol metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human renal proximal tubule cells,The metabolite p-cresol glucuronide generated from the metabolism of p-cresol by the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCC4.,.,Kidney
DTD0015,ABCC4,Inhibition,Chronic kidney disease,Inhibition of ABCC4 function in chronic kidney disease condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,p-Cresol sulfate,p-cresol metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human renal proximal tubule cells,The metabolite p-cresol sulfate generated from the metabolism of p-cresol by the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCC4.,.,Kidney
DTD0015,ABCC4,Up regulating,Hyperuricaemia,Up regulating of ABCC4 expression in hyperuricaemia condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,ICR specific-pathogen-free mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC4.,.,Kidney
DTD0015,ABCC4,Up regulating,.,Up regulating of ABCC4 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Chenodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC4.,.,Liver
DTD0015,ABCC4,Up regulating,.,Up regulating of ABCC4 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Cholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC4.,.,Liver
DTD0015,ABCC4,Up regulating,.,Up regulating of ABCC4 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Deoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC4.,.,Liver
DTD0015,ABCC4,Up regulating,.,Up regulating of ABCC4 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Hyodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC4.,.,Liver
DTD0015,ABCC4,Up regulating,.,Up regulating of ABCC4 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Lithocholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC4.,.,Liver
DTD0016,ABCC5,Up regulating,.,Up regulating of ABCC5 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Chenodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC5.,.,Liver
DTD0016,ABCC5,Up regulating,.,Up regulating of ABCC5 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Cholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC5.,.,Liver
DTD0016,ABCC5,Up regulating,.,Up regulating of ABCC5 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Deoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC5.,.,Liver
DTD0016,ABCC5,Up regulating,.,Up regulating of ABCC5 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Hyodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC5.,.,Liver
DTD0016,ABCC5,Up regulating,.,Up regulating of ABCC5 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Lithocholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC5.,.,Liver
DTD0017,ABCC6,Down regulating,Conventional mice compared with germ-free mice,Down regulating of ABCC6 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC6.,.,Large intestine
DTD0017,ABCC6,Up regulating,Conventional mice compared with germ-free mice,Up regulating of ABCC6 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC6.,.,Ileum
DTD0017,ABCC6,Down regulating,.,Down regulating of ABCC6 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Trimethylamine oxide,L-carnitine metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite trimethylamine oxide generated from the metabolism of l-carnitine by the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC6.,.,Liver
DTD0060,ABCC7,Activation,Typhoid,Activation of ABCC7 in typhoid condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Lipopolysaccharide,Generated by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhi str. Ty2,C57BL/6 mice,Human cystic fibrosis cells (CFT1-LCFSN),The compound Lipopolysaccharide Generated by Salmonella enterica subsp. enterica serovar Typhi str. Ty2 has been reported to activate the function of the drug transporter ABCC7.,.,Lung
DTD0060,ABCC7,Up regulating,Mastitis,Up regulating of ABCC7 expression in mastitis condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Lipopolysaccharide,Generated by Escherichia coli,Escherichia coli,O111:B4,ICR mice,.,The compound Lipopolysaccharide Generated by Escherichia coli O111:B4 has been reported to increase the expression of the drug transporter ABCC7.,.,Breast
DTD0060,ABCC7,Up regulating,Diarrhea associated with infection by invasive enteric pathogens,Up regulating of ABCC7 expression in diarrhea associated with infection by invasive enteric pathogens condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Escherichia coli,Escherichia coli,Escherichia coli,O29,.,Human colon adenocarcinoma cells (HT29-Cl.19A),The Escherichia coli O29 has been reported to increase the expression of the drug transporter ABCC7.,.,Colon
DTD0060,ABCC7,Up regulating,Type 2 diabetes mellitus,Up regulating of ABCC7 expression in type 2 diabetes mellitus condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Lactobacillus casei,Lacticaseibacillus casei,Lacticaseibacillus casei,str. Zhang,Sprague-Dawley rats,.,The Lacticaseibacillus casei str. Zhang has been reported to increase the expression of the drug transporter ABCC7.,.,Heart
DTD0060,ABCC7,Up regulating,Diarrhea associated with infection by invasive enteric pathogens,Up regulating of ABCC7 expression in diarrhea associated with infection by invasive enteric pathogens condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Salmonella dublin,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Dublin,.,Human colon adenocarcinoma cells (HT29-Cl.19A),The Salmonella enterica subsp. enterica serovar Dublin has been reported to increase the expression of the drug transporter ABCC7.,.,Colon
DTD0060,ABCC7,Down regulating,Fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli,Down regulating of ABCC7 expression in fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,C57BL/6 microflora,Host unspecified microbiota,Host unspecified microbiota,.,FVB/N mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC7.,.,Colon
DTD0060,ABCC7,Down regulating,.,Down regulating of ABCC7 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Trimethylamine oxide,L-carnitine metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite trimethylamine oxide generated from the metabolism of l-carnitine by the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC7.,.,Liver
DTD0071,ABCG1,Up regulating,Atherosclerosis,Up regulating of ABCG1 expression in atherosclerosis condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,"3,4-Dihydroxybenzoic acid",Dietary cyanidin-3-O--glucoside metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,Human kidney human embryonic kidney 293 cells (HEK 293),"The metabolite 3,4-dihydroxybenzoic acid generated from the metabolism of dietary cyanidin-3-o--glucoside by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCG1.",.,Kidney
DTD0004,ABCG2,Sequestration substrate,.,Sequestration of human ABCG2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Bacteroides thetaiotaomicron,Bacteroides thetaiotaomicron,Bacteroides thetaiotaomicron,E50,.,.,"The Bacteroides thetaiotaomicron E50 has been reported to sequester the drug Rosiglitazone, which limits the distribution of the drug in the body and its binding to the drug transporter ABCG2, thereby affecting the efficacy, safety, or bioavailability of the drug.",Rosiglitazone,.
DTD0004,ABCG2,Sequestration substrate,.,Sequestration of human ABCG2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Bifidobacterium animalis subsp. lactis,Bifidobacterium animalis,Bifidobacterium animalis,subsp. lactis Bi-07,.,.,"The Bifidobacterium animalis subsp. lactis Bi-07 has been reported to sequester the drug Rosiglitazone, which limits the distribution of the drug in the body and its binding to the drug transporter ABCG2, thereby affecting the efficacy, safety, or bioavailability of the drug.",Rosiglitazone,.
DTD0004,ABCG2,Sequestration substrate,.,Sequestration of human ABCG2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Clostridium ramosum,Thomasclavelia ramosa,Thomasclavelia ramosa,113-I,.,.,"The Thomasclavelia ramosa 113-I has been reported to sequester the drug Rosiglitazone, which limits the distribution of the drug in the body and its binding to the drug transporter ABCG2, thereby affecting the efficacy, safety, or bioavailability of the drug.",Rosiglitazone,.
DTD0004,ABCG2,Sequestration substrate,.,Sequestration of human ABCG2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Escherichia coli,Escherichia coli,Escherichia coli,str. K-12 substr. MG1655,.,.,"The Escherichia coli str. K-12 substr. MG1655 has been reported to sequester the drug Ciprofloxacin and Tetracycline, which limits the distribution of the drug in the body and its binding to the drug transporter ABCG2, thereby affecting the efficacy, safety, or bioavailability of the drug.",Ciprofloxacin; Tetracycline,.
DTD0004,ABCG2,Sequestration substrate,.,Sequestration of human ABCG2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Lactobacillus paracasei,Lacticaseibacillus casei,Lacticaseibacillus casei,Lpc-37,.,.,"The Lacticaseibacillus casei Lpc-37 has been reported to sequester the drug Rosiglitazone, which limits the distribution of the drug in the body and its binding to the drug transporter ABCG2, thereby affecting the efficacy, safety, or bioavailability of the drug.",Rosiglitazone,.
DTD0004,ABCG2,Co-transporter,.,Co-transport of human ABCG2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ompC,Escherichia coli,Escherichia coli,JM712,.,.,"The protein ompC of Escherichia coli JM712 has been reported to transport similar substrates/drugs of ABCG2, which affects the distribution of its substrate/drug in vivo.",Cephalothin,.
DTD0004,ABCG2,Co-transporter,.,Co-transport of human ABCG2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ompF,Escherichia coli,Escherichia coli,JM712,.,.,"The protein ompF of Escherichia coli JM712 has been reported to transport similar substrates/drugs of ABCG2, which affects the distribution of its substrate/drug in vivo.",Norfloxacin; Tetracycline; Cephalothin,.
DTD0004,ABCG2,Down regulating,Colon cancer,Down regulating of ABCG2 expression in colon cancer condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Bifidobacterium adolescentis,Bifidobacterium adolescentis,Bifidobacterium adolescentis,.,.,Human colon adenocarcinoma cells (Caco-2),The Bifidobacterium adolescentis has been reported to decrease the expression of the drug transporter ABCG2.,.,Colon
DTD0004,ABCG2,Down regulating,Colon cancer,Down regulating of ABCG2 expression in colon cancer condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Escherichia coli Nissle 1917,Escherichia coli,Escherichia coli,Nissle 1917,.,Human colon adenocarcinoma cells (Caco-2),The Escherichia coli Nissle 1917 has been reported to decrease the expression of the drug transporter ABCG2.,.,Colon
DTD0004,ABCG2,Inhibition,Health,Inhibition of ABCG2 function in health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Urolithin A,Ellagic acid and ellagitannins metabolites from gut Host unspecified microbiota,Host unspecified microbiota,.,.,Madin-Darby canine kidney cells (MDCKII),The metabolite urolithin a generated from the metabolism of ellagic acid and ellagitannins metabolites from gut host unspecified microbiota by the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCG2.,Mitoxantrone,Kidney
DTD0004,ABCG2,Inhibition,Health,Inhibition of ABCG2 function in health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Urolithin A glucuronide,Ellagic acid and ellagitannins metabolites from gut Host unspecified microbiota,Host unspecified microbiota,.,.,Madin-Darby canine kidney cells (MDCKII),The metabolite urolithin a glucuronide generated from the metabolism of ellagic acid and ellagitannins metabolites from gut host unspecified microbiota by the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCG2.,Mitoxantrone,Kidney
DTD0004,ABCG2,Down regulating,Colon cancer,Down regulating of ABCG2 expression in colon cancer condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Chenodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human colon adenocarcinoma cells (T84),The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCG2.,.,Colon
DTD0004,ABCG2,Up regulating,Colon cancer,Up regulating of ABCG2 expression in colon cancer condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Deoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human colon adenocarcinoma cells (Caco-2),The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCG2.,.,Colon
DTD0004,ABCG2,Inhibition,Chronic kidney disease,Inhibition of ABCG2 function in chronic kidney disease condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,p-Cresol sulfate,p-cresol metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human renal proximal tubule cells,The metabolite p-cresol sulfate generated from the metabolism of p-cresol by the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCG2.,.,Kidney
DTD0004,ABCG2,Up regulating,Conventional mice compared with germ-free mice,Up regulating of ABCG2 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6N mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCG2.,.,Liver
DTD0004,ABCG2,Up regulating,Hyperuricaemia,Up regulating of ABCG2 expression in hyperuricaemia condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,ICR specific-pathogen-free mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCG2.,.,Kidney
DTD0004,ABCG2,Down regulating,.,Down regulating of ABCG2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Urolithin A,Dietary polyphenols metabolite from Host unspecified microbiota,Host unspecified microbiota,.,NRGS mice,Human colon carcinoma cells (HCT-116),The metabolite urolithin a generated from the metabolism of dietary polyphenols by the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCG2.,.,Colon
DTD0648,ATP7A,Sequestration substrate,.,Sequestration of human ATP7A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,copA,Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The protein copA of Escherichia coli str. K-12 substr. W3110 has been reported to sequester the substrate/drug of ATP7A, which may affects its substrate/drug distribution in the body.",.,.
DTD0648,ATP7A,Sequestration substrate,.,Sequestration of human ATP7A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,copZ1,Pseudomonas aeruginosa,Pseudomonas aeruginosa,PAO1,.,.,"The protein copZ1 of Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of ATP7A, which may affects its substrate/drug distribution in the body.",.,.
DTD0648,ATP7A,Sequestration substrate,.,Sequestration of human ATP7A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,corA,Rhodobacter capsulatus,Rhodobacter capsulatus,MT1131,.,.,"The protein corA of Rhodobacter capsulatus MT1131 has been reported to sequester the substrate/drug of ATP7A, which may affects its substrate/drug distribution in the body.",.,.
DTD0648,ATP7A,Sequestration substrate,.,Sequestration of human ATP7A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,corZ,Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The protein corZ of Escherichia coli str. K-12 substr. W3110 has been reported to sequester the substrate/drug of ATP7A, which may affects its substrate/drug distribution in the body.",.,.
DTD0648,ATP7A,Co-transporter,.,Co-transport of human ATP7A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ctpV,Mycobacterium tuberculosis,Mycobacterium tuberculosis,GC1237,.,.,"The protein ctpV of Mycobacterium tuberculosis GC1237 has been reported to transport similar substrates/drugs of ATP7A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0648,ATP7A,Sequestration substrate,.,Sequestration of human ATP7A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,cupA,Streptococcus pneumoniae,Streptococcus pneumoniae,TIGR4,.,.,"The protein cupA of Streptococcus pneumoniae TIGR4 has been reported to sequester the substrate/drug of ATP7A, which may affects its substrate/drug distribution in the body.",.,.
DTD0533,ATP7B,Sequestration substrate,.,Sequestration of human ATP7B substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,copA,Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The protein copA of Escherichia coli str. K-12 substr. W3110 has been reported to sequester the substrate/drug of ATP7B, which may affects its substrate/drug distribution in the body.",.,.
DTD0533,ATP7B,Sequestration substrate,.,Sequestration of human ATP7B substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,copZ1,Pseudomonas aeruginosa,Pseudomonas aeruginosa,PAO1,.,.,"The protein copZ1 of Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of ATP7B, which may affects its substrate/drug distribution in the body.",.,.
DTD0533,ATP7B,Sequestration substrate,.,Sequestration of human ATP7B substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,corA,Rhodobacter capsulatus,Rhodobacter capsulatus,MT1131,.,.,"The protein corA of Rhodobacter capsulatus MT1131 has been reported to sequester the substrate/drug of ATP7B, which may affects its substrate/drug distribution in the body.",.,.
DTD0533,ATP7B,Sequestration substrate,.,Sequestration of human ATP7B substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,corZ,Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The protein corZ of Escherichia coli str. K-12 substr. W3110 has been reported to sequester the substrate/drug of ATP7B, which may affects its substrate/drug distribution in the body.",.,.
DTD0533,ATP7B,Co-transporter,.,Co-transport of human ATP7B substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ctpV,Mycobacterium tuberculosis,Mycobacterium tuberculosis,GC1237,.,.,"The protein ctpV of Mycobacterium tuberculosis GC1237 has been reported to transport similar substrates/drugs of ATP7B, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0533,ATP7B,Sequestration substrate,.,Sequestration of human ATP7B substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,cupA,Streptococcus pneumoniae,Streptococcus pneumoniae,TIGR4,.,.,"The protein cupA of Streptococcus pneumoniae TIGR4 has been reported to sequester the substrate/drug of ATP7B, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,Cystic fibrosis,Sequestration of human CACNA1A substrates/drugs in cystic fibrosis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Pyochelin,Secreted by Pseudomonas aeruginosa,Pseudomonas aeruginosa,ATCC 15692,CD-1 mice,.,"The compound Pyochelin Secreted by Pseudomonas aeruginosa ATCC 15692 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0518,CACNA1A,Sequestration substrate,Cystic fibrosis,Sequestration of human CACNA1A substrates/drugs in cystic fibrosis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Pyoverdine F-Iib,Secreted by Pseudomonas aeruginosa,Pseudomonas aeruginosa,ATCC 15692,CD-1 mice,.,"The compound Pyoverdine F-Iib Secreted by Pseudomonas aeruginosa ATCC 15692 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0518,CACNA1A,Sequestration substrate,Lung adenocarcinoma,Sequestration of human CACNA1A substrates/drugs in lung adenocarcinoma condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salmochelin SX,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,KP20,.,Human lung adenocarcinoma cells (A549),"The compound Salmochelin SX Secreted by Klebsiella pneumoniae KP20 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0518,CACNA1A,Sequestration substrate,Pneumonia,Sequestration of human CACNA1A substrates/drugs in pneumonia condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Yersiniabactin,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,ATCC 43816,C57BL/6 mice,.,"The compound Yersiniabactin Secreted by Klebsiella pneumoniae ATCC 43816 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0518,CACNA1A,Co-transporter,Pneumonic plague,Co-transport of human CACNA1A substrates/drugs in pneumonic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feo,Yersinia pestis,Yersinia pestis,KIM6,Swiss Webster mice,.,"The protein feo of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,Lung
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,C3H/HeOuJ mice,.,"The compound Enterobactin Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,Intestine
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salmochelin SX,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,C3H/HeOuJ mice,.,"The compound Salmochelin SX Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,Intestine
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salmochelin SX,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,KPPR1,C57BL/6 mice,.,"The compound Salmochelin SX Secreted by Klebsiella pneumoniae KPPR1 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Yersiniabactin,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,KPPR1,C57BL/6 mice,.,"The compound Yersiniabactin Secreted by Klebsiella pneumoniae KPPR1 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,irp2,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein irp2 of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,psn,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein psn of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeAB,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein YfeAB of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeABCD,Yersinia pestis,Yersinia pestis,KIM6,Swiss Webster mice,.,"The protein YfeABCD of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,Lung
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound 2-oxoadipic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound 2-oxoadipic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound 2-oxoadipic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound 2-oxoadipic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound 2-Oxoadipic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound 2-Oxoadipic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound 2-Oxoadipic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound 3-methyl-2-oxobutanoic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound 3-methyl-2-oxobutanoic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound 3-methyl-2-oxobutanoic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound 3-methyl-2-oxobutanoic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound 3-Methyl-2-oxobutanoic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound 3-Methyl-2-oxobutanoic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound 3-Methyl-2-oxobutanoic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound 4-methyl-2-oxopentanoic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound 4-methyl-2-oxopentanoic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound 4-methyl-2-oxopentanoic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound 4-methyl-2-oxopentanoic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound 4-Methyl-2-oxopentanoic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound 4-Methyl-2-oxopentanoic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound 4-Methyl-2-oxopentanoic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Aerobactin,Secreted by Escherichia coli,Escherichia coli,LG1315,.,.,"The compound Aerobactin Secreted by Escherichia coli LG1315 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Alcaligin,Secreted by Achromobacter xylosoxidans,Achromobacter xylosoxidans,subsp. xylosoxydans KN 3-1,.,.,"The compound Alcaligin Secreted by Achromobacter xylosoxidans subsp. xylosoxydans KN 3-1 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Alcaligin,Secreted by Bordetella bronchiseptica,Bordetella bronchiseptica,B013N,.,.,"The compound Alcaligin Secreted by Bordetella bronchiseptica B013N has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Alcaligin,Secreted by Bordetella pertussis,Bordetella pertussis,UT25,.,.,"The compound Alcaligin Secreted by Bordetella pertussis UT25 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Anguibactin,Secreted by Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The compound anguibactin secreted by Vibrio anguillarum 775 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Aureochelin,Secreted by Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The compound aureochelin secreted by Staphylococcus aureus has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Carboxymycobactin,Secreted by Mycobacterium avium,Mycobacterium avium,CRl/69,.,.,"The compound Carboxymycobactin Secreted by Mycobacterium avium CRl/69 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Cepabactin,Secreted by Burkholderia cepacia,Burkholderia cepacia,ATCC 25416,.,.,"The compound Cepabactin Secreted by Burkholderia cepacia ATCC 25416 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Corynebactin,Secreted by Corynebacterium diphtheriae,Corynebacterium diphtheriae,C7 (beta),.,.,"The compound Corynebactin Secreted by Corynebacterium diphtheriae C7 (beta) has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Corynebactin,Secreted by Bacillus cereus,Bacillus cereus,ATCC 14579,.,.,"The compound Corynebactin Secreted by Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Corynebactin,Secreted by Bacillus thuringiensis,Bacillus thuringiensis,ATCC 33679,.,.,"The compound Corynebactin Secreted by Bacillus thuringiensis ATCC 33679 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Corynebactin,Secreted by Bacillus anthracis,Bacillus anthracis,str. Sterne,.,.,"The compound Corynebactin Secreted by Bacillus anthracis str. Sterne has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Escherichia coli,Escherichia coli,BW25113,.,.,"The compound Enterobactin Secreted by Escherichia coli BW25113 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The compound Enterobactin Secreted by Escherichia coli str. K-12 substr. W3110 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. LT2,.,.,"The compound Enterobactin Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,298/53,.,.,"The compound Enterobactin Secreted by Klebsiella pneumoniae 298/53 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Shigella sonnei,Shigella sonnei,43-GG9,.,.,"The compound Enterobactin Secreted by Shigella sonnei 43-GG9 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Escherichia coli,Escherichia coli,9.0111,.,.,"The compound enterobactin secreted by Escherichia coli 9.0111 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Escherichia coli,Escherichia coli,AB33II,.,.,"The compound Enterobactin Secreted by Escherichia coli AB33II has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Exochelin 772SM,Secreted by Mycolicibacterium vaccae,Mycolicibacterium vaccae,R877R,.,.,"The compound Exochelin 772SM Secreted by Mycolicibacterium vaccae R877R has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine B,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine B Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine E,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine E Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine G1,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine G1 Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound indole-3-pyruvic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound indole-3-pyruvic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound indole-3-pyruvic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound indole-3-pyruvic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound Indole-3-pyruvic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound Indole-3-pyruvic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound Indole-3-pyruvic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ornibactin,Secreted by Burkholderia cepacia,Burkholderia cepacia,TVV69,.,.,"The compound Ornibactin Secreted by Burkholderia cepacia TVV69 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Petrobactin,Secreted by Bacillus cereus,Bacillus cereus,ATCC 14579,.,.,"The compound Petrobactin Secreted by Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Petrobactin,Secreted by Bacillus anthracis,Bacillus anthracis,str. Sterne,.,.,"The compound Petrobactin Secreted by Bacillus anthracis str. Sterne has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound phenylpyruvic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound phenylpyruvic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound phenylpyruvic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound phenylpyruvic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound Phenylpyruvic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound Phenylpyruvic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound Phenylpyruvic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Pyochelin,Secreted by Pseudomonas aeruginosa,Pseudomonas aeruginosa,PAO1,.,.,"The compound Pyochelin Secreted by Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Pyoverdin,Secreted by Pseudomonas aeruginosa,Pseudomonas aeruginosa,PAO1,.,.,"The compound Pyoverdin Secreted by Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Rhizoferrin,Secreted by Rhizopus microsporus,Rhizopus microsporus,.,.,.,"The compound rhizoferrin secreted by Rhizopus microsporus has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salicylic acid,Secreted by Burkholderia cepacia,Burkholderia cepacia,Pc275c,.,.,"The compound Salicylic acid Secreted by Burkholderia cepacia Pc275c has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salmochelin SX,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. LT2,.,.,"The compound Salmochelin SX Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Staphyloferrin A,Secreted by Staphylococcus aureus,Staphylococcus aureus,subsp. aureus NCTC 8325,.,.,"The compound Staphyloferrin A Secreted by Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Staphylopine,Secreted by Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The compound Staphylopine Secreted by Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Vibriobactin,Secreted by Vibrio cholerae,Vibrio cholerae,Lou15,.,.,"The compound Vibriobactin Secreted by Vibrio cholerae Lou15 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Vibriobactin,Secreted by Vibrio cholerae,Vibrio cholerae,MBG14,.,.,"The compound Vibriobactin Secreted by Vibrio cholerae MBG14 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Yersiniabactin,Secreted by Yersinia pestis,Yersinia pestis,Yreka F1+VW+P1+P+,.,.,"The compound Yersiniabactin Secreted by Yersinia pestis Yreka F1+VW+P1+P+ has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Yersiniabactin,Secreted by Yersinia enterocolitica,Yersinia enterocolitica,WA-C,.,.,"The compound Yersiniabactin Secreted by Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CaFTR1,Candida albicans,Candida albicans,.,.,.,"The protein caftr1 of Candida albicans has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeU,Escherichia coli,Escherichia coli,O157:H7,.,.,"The protein efeU of Escherichia coli O157:H7 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeU,Escherichia coli,Escherichia coli,Nissle 1917,.,.,"The protein efeU of Escherichia coli Nissle 1917 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fatA,Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The protein fata of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fatB,Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The protein fatb of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Fbp,Vibrio cholerae,Vibrio cholerae,O395,.,.,"The protein Fbp of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fec,Shigella flexneri,Shigella flexneri,2a,.,.,"The protein fec of Shigella flexneri 2a has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fecA,Escherichia coli,Escherichia coli,UT5600,.,.,"The protein fecA of Escherichia coli UT5600 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feo,Vibrio cholerae,Vibrio cholerae,O395,.,.,"The protein feo of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoA,Escherichia coli,Escherichia coli,str. K-12 substr. MC4100,.,.,"The protein feoA of Escherichia coli str. K-12 substr. MC4100 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein feoB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein feoB of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Escherichia coli,Escherichia coli,str. K-12 substr. MC4100,.,.,"The protein feoB of Escherichia coli str. K-12 substr. MC4100 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoC,Klebsiella pneumoniae,Klebsiella pneumoniae,.,.,.,"The protein feoc of Klebsiella pneumoniae has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuA,Escherichia coli,Escherichia coli,K-12,.,.,"The protein fhuA of Escherichia coli K-12 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuB,Escherichia coli,Escherichia coli,DH5[alpha],.,.,"The protein fhuB of Escherichia coli DH5[alpha] has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuC,Escherichia coli,Escherichia coli,AB2847,.,.,"The protein fhuC of Escherichia coli AB2847 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCBG,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein FhuCBG of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCDB,Streptococcus agalactiae,Streptococcus agalactiae,A909,.,.,"The protein FhuCDB of Streptococcus agalactiae A909 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCDB,Haemophilus influenzae,Haemophilus influenzae,R2866,.,.,"The protein FhuCDB of Haemophilus influenzae R2866 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuD,Escherichia coli,Escherichia coli,BL21(DE3),.,.,"The protein fhuD of Escherichia coli BL21(DE3) has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuD1,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein fhuD1 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhud2,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein fhud2 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhud2,Staphylococcus aureus,Staphylococcus aureus,RN2564,.,.,"The protein fhud2 of Staphylococcus aureus RN2564 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futA1,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futa1 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futA2,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futa2 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futB,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futb of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fyuA,Yersinia enterocolitica,Yersinia enterocolitica,WA-C,.,.,"The protein fyuA of Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,IroA,Escherichia coli,Escherichia coli,CFT073,.,.,"The protein IroA of Escherichia coli CFT073 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,IrtAB,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Rv,.,.,"The protein IrtAB of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,MntABC,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus NCTC 8325,.,.,"The protein MntABC of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,p19,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuA,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfua of Serratia marcescens has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuB,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfub of Serratia marcescens has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuC,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfuc of Serratia marcescens has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sitA,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein sitA of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein SitABCD of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium JF2043,.,.,"The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium JF2043 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0518,CACNA1A,Sequestration substrate,.,Sequestration of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sll1878,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein sll1878 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.",.,.
DTD0518,CACNA1A,Co-transporter,.,Co-transport of human CACNA1A substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeABCD,Yersinia pestis,Yersinia pestis,KIM5-2031.11+,.,.,"The protein YfeABCD of Yersinia pestis KIM5-2031.11+ has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0534,CACNA1C,Sequestration substrate,Upper and lower airway disease,Sequestration of human CACNA1C substrates/drugs in upper and lower airway disease condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mtsB,Streptococcus equi,Streptococcus equi,subsp. equi NCTC 9682,Swiss Webster mice,.,"The protein mtsB of Streptococcus equi subsp. equi NCTC 9682 has been reported to sequester the substrate/drug of CACNA1C, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0534,CACNA1C,Co-transporter,.,Co-transport of human CACNA1C substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mnoP,Bradyrhizobium diazoefficiens,Bradyrhizobium diazoefficiens,USDA 110,.,.,"The protein mnoP of Bradyrhizobium diazoefficiens USDA 110 has been reported to transport similar substrates/drugs of CACNA1C, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0534,CACNA1C,Sequestration substrate,.,Sequestration of human CACNA1C substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mtsB,Streptococcus equi,Streptococcus equi,subsp. zooepidemicus NCTC 7023T,.,.,"The protein mtsB of Streptococcus equi subsp. zooepidemicus NCTC 7023T has been reported to sequester the substrate/drug of CACNA1C, which may affects its substrate/drug distribution in the body.",.,.
DTD0019,SLC10A1,Up regulating,Metabolic dysfunction-associated fatty liver disease,Up regulating of SLC10A1 expression in metabolic dysfunction-associated fatty liver disease condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Akkermansia muciniphila,Akkermansia muciniphila,Akkermansia muciniphila,ATCC BAA-835,C57BL/6 mice,.,The Akkermansia muciniphila ATCC BAA-835 has been reported to increase the expression of the drug transporter SLC10A1.,.,Liver
DTD0019,SLC10A1,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC10A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A1.,.,Liver
DTD0019,SLC10A1,Down regulating,.,Down regulating of SLC10A1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Deoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A1.,.,Liver
DTD0019,SLC10A1,Up regulating,.,Up regulating of SLC10A1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Lithocholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,IQI mice,.,The metabolite lithocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC10A1.,.,Liver
DTD0019,SLC10A1,Down regulating,.,Down regulating of SLC10A1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Trimethylamine oxide,L-carnitine metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite trimethylamine oxide generated from the metabolism of l-carnitine by the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A1.,.,Liver
DTD0020,SLC10A2,Down regulating,Health,Down regulating of SLC10A2 expression in health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Glycoursodeoxycholic acid,Metabolite from Bacteroides fragilis,Bacteroides fragilis,.,.,Human kidney human embryonic kidney 293 cells (HEK 293),The metabolite glycoursodeoxycholic acid generated from the Bacteroides fragilis has been reported to decrease the expression of the drug transporter SLC10A2.,Metformin,Kidney
DTD0020,SLC10A2,Up regulating,Metabolic dysfunction-associated fatty liver disease,Up regulating of SLC10A2 expression in metabolic dysfunction-associated fatty liver disease condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Akkermansia muciniphila,Akkermansia muciniphila,Akkermansia muciniphila,ATCC BAA-835,C57BL/6 mice,.,The Akkermansia muciniphila ATCC BAA-835 has been reported to increase the expression of the drug transporter SLC10A2.,.,Ileum
DTD0020,SLC10A2,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC10A2 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.,.,Ileum
DTD0020,SLC10A2,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC10A2 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.,.,Large intestine
DTD0020,SLC10A2,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC10A2 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC10A2.,.,Jejunum
DTD0020,SLC10A2,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC10A2 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J germ-free mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC10A2.,.,Liver
DTD0020,SLC10A2,Down regulating,.,Down regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,"2,3,7,8-tetrachlorodibenzofuran",Dietary dough pills metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,"The metabolite 2,3,7,8-tetrachlorodibenzofuran generated from the metabolism of dietary dough pills by the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.",.,Ileum
DTD0020,SLC10A2,Down regulating,.,Down regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Chenodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.,.,Ileum
DTD0020,SLC10A2,Down regulating,.,Down regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Chenodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.,.,Colon
DTD0020,SLC10A2,Up regulating,.,Up regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Chenodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC10A2.,.,Jejunum
DTD0020,SLC10A2,Down regulating,.,Down regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Cholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.,.,Ileum
DTD0020,SLC10A2,Down regulating,.,Down regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Cholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.,.,Colon
DTD0020,SLC10A2,Up regulating,.,Up regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Cholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC10A2.,.,Jejunum
DTD0020,SLC10A2,Down regulating,.,Down regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Deoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.,.,Ileum
DTD0020,SLC10A2,Down regulating,.,Down regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Deoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.,.,Colon
DTD0020,SLC10A2,Up regulating,.,Up regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Deoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC10A2.,.,Jejunum
DTD0020,SLC10A2,Down regulating,.,Down regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Hyodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.,.,Ileum
DTD0020,SLC10A2,Down regulating,.,Down regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Hyodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.,.,Colon
DTD0020,SLC10A2,Up regulating,.,Up regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Hyodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC10A2.,.,Jejunum
DTD0020,SLC10A2,Down regulating,.,Down regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Lithocholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.,.,Ileum
DTD0020,SLC10A2,Down regulating,.,Down regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Lithocholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.,.,Colon
DTD0020,SLC10A2,Up regulating,.,Up regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Lithocholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC10A2.,.,Jejunum
DTD0020,SLC10A2,Down regulating,.,Down regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Chenodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Cyp8b1 KO mice,.,The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.,.,Ileum
DTD0020,SLC10A2,Down regulating,.,Down regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Cholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Cyp8b1 KO mice,.,The metabolite cholic acid generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.,.,Ileum
DTD0020,SLC10A2,Down regulating,.,Down regulating of SLC10A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Deoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Cyp8b1 KO mice,.,The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.,.,Ileum
DTD0080,SLC11A1,Co-transporter,Pneumonic plague,Co-transport of human SLC11A1 substrates/drugs in pneumonic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Yersinia pestis,Yersinia pestis,.,Swiss Webster mice,.,"The protein mnth of Yersinia pestis has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.",.,Nose
DTD0080,SLC11A1,Sequestration substrate,.,Sequestration of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Mycobactin,Secreted by Mycobacterium avium,Mycobacterium avium,101,C57BL/6 mice,.,"The compound mycobactin secreted by Mycobacterium avium 101 has been reported to sequester the substrate/drug of SLC11A1, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0080,SLC11A1,Sequestration substrate,.,Sequestration of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Mycobactin,Secreted by Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Rv,C57BL/6 mice,.,"The compound Mycobactin Secreted by Mycobacterium tuberculosis H37Rv has been reported to sequester the substrate/drug of SLC11A1, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0080,SLC11A1,Sequestration substrate,.,Sequestration of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Mycobactin,Secreted by Mycolicibacterium smegmatis,Mycolicibacterium smegmatis,MC2 155,C57BL/6 mice,.,"The compound Mycobactin Secreted by Mycolicibacterium smegmatis MC2 155 has been reported to sequester the substrate/drug of SLC11A1, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0080,SLC11A1,Co-transporter,.,Co-transport of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus str. Newman,C57BL/6 mice,.,"The protein mntH of Staphylococcus aureus subsp. aureus str. Newman has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.",.,Liver
DTD0080,SLC11A1,Co-transporter,.,Co-transport of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,C57BL/6 mice,.,"The protein mntH of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.",.,Liver
DTD0080,SLC11A1,Co-transporter,.,Co-transport of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium,129/SvJ mice,.,"The protein mntH of Salmonella enterica subsp. enterica serovar Typhimurium has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0080,SLC11A1,Co-transporter,.,Co-transport of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Brucella abortus,Brucella abortus,2308,C57BL/6 mice,.,"The protein mnth of Brucella abortus 2308 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0080,SLC11A1,Sequestration substrate,.,Sequestration of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Mycobactin,Secreted by Mycobacterium tuberculosis,Mycobacterium tuberculosis,.,.,.,"The compound mycobactin secreted by Mycobacterium tuberculosis has been reported to sequester the substrate/drug of SLC11A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0080,SLC11A1,Co-transporter,.,Co-transport of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Yersinia pseudotuberculosis,Yersinia pseudotuberculosis,IP 32953,.,.,"The protein mntH of Yersinia pseudotuberculosis IP 32953 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0080,SLC11A1,Co-transporter,.,Co-transport of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Yersinia pestis,Yersinia pestis,KIM6,.,.,"The protein mntH of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0080,SLC11A1,Co-transporter,.,Co-transport of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein mntH of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0080,SLC11A1,Co-transporter,.,Co-transport of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Escherichia coli,Escherichia coli,EMG2,.,.,"The protein mntH of Escherichia coli EMG2 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0080,SLC11A1,Co-transporter,.,Co-transport of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Bradyrhizobium diazoefficiens,Bradyrhizobium diazoefficiens,USDA 110,.,.,"The protein mntH of Bradyrhizobium diazoefficiens has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0080,SLC11A1,Co-transporter,.,Co-transport of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus NCTC 8325,.,.,"The protein mntH of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0080,SLC11A1,Co-transporter,.,Co-transport of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Rv,.,.,"The protein mntH of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0080,SLC11A1,Co-transporter,.,Co-transport of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Mycobacterium leprae,Mycobacterium leprae,.,.,.,"The protein mnth of Mycobacterium leprae has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0080,SLC11A1,Co-transporter,.,Co-transport of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Escherichia coli,Escherichia coli,MM1925,.,.,"The protein mntH of Escherichia coli MM1925 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0080,SLC11A1,Co-transporter,.,Co-transport of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium MM1255,.,.,"The protein mntH of Salmonella enterica subsp. enterica serovar Typhimurium MM1255 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0080,SLC11A1,Co-transporter,.,Co-transport of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Bacillus subtilis,Bacillus subtilis,CU1065,.,.,"The protein mntH of Bacillus subtilis CU1065 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0080,SLC11A1,Co-transporter,.,Co-transport of human SLC11A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,nrmT,Clostridium acetobutylicum,Clostridium acetobutylicum,ATCC 824,.,.,"The protein nrmT of Clostridium acetobutylicum ATCC 824 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC11A2 expression in conventional mice compared with germ-free mice,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,"1,3-Diaminopropane",Generated by Lactobacillus reuteri,Limosilactobacillus reuteri,MM4-1A,C57BL/6 germ-free mice,Human colon carcinoma cells (HCT-116),"The compound 1,3-Diaminopropane Generated by Limosilactobacillus reuteri MM4-1A has been reported to decrease the expression of the drug transporter SLC11A2.",.,Duodenum
DTD0081,SLC11A2,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC11A2 expression in conventional mice compared with germ-free mice,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,3-Hydroxypropanal,Generated by Lactobacillus reuteri,Limosilactobacillus reuteri,MM4-1A,C57BL/6 germ-free mice,Human colon carcinoma cells (HCT-116),The compound 3-Hydroxypropanal Generated by Limosilactobacillus reuteri MM4-1A has been reported to decrease the expression of the drug transporter SLC11A2.,.,Duodenum
DTD0081,SLC11A2,Sequestration substrate,Cystic fibrosis,Sequestration of human SLC11A2 substrates/drugs in cystic fibrosis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Pyochelin,Secreted by Pseudomonas aeruginosa,Pseudomonas aeruginosa,ATCC 15692,CD-1 mice,.,"The compound Pyochelin Secreted by Pseudomonas aeruginosa ATCC 15692 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0081,SLC11A2,Sequestration substrate,Cystic fibrosis,Sequestration of human SLC11A2 substrates/drugs in cystic fibrosis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Pyoverdine F-Iib,Secreted by Pseudomonas aeruginosa,Pseudomonas aeruginosa,ATCC 15692,CD-1 mice,.,"The compound Pyoverdine F-Iib Secreted by Pseudomonas aeruginosa ATCC 15692 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0081,SLC11A2,Sequestration substrate,Lung adenocarcinoma,Sequestration of human SLC11A2 substrates/drugs in lung adenocarcinoma condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salmochelin SX,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,KP20,.,Human lung adenocarcinoma cells (A549),"The compound Salmochelin SX Secreted by Klebsiella pneumoniae KP20 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0081,SLC11A2,Sequestration substrate,Pneumonia,Sequestration of human SLC11A2 substrates/drugs in pneumonia condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Yersiniabactin,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,ATCC 43816,C57BL/6 mice,.,"The compound Yersiniabactin Secreted by Klebsiella pneumoniae ATCC 43816 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0081,SLC11A2,Co-transporter,Pneumonic plague,Co-transport of human SLC11A2 substrates/drugs in pneumonic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feo,Yersinia pestis,Yersinia pestis,KIM6,Swiss Webster mice,.,"The protein feo of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,Lung
DTD0081,SLC11A2,Co-transporter,Bacterial pneumonia,Co-transport of human SLC11A2 substrates/drugs in bacterial pneumonia condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,MtsABC,Streptococcus pyogenes,Streptococcus pyogenes,AP1,BALB/c mice,.,"The protein MtsABC of Streptococcus pyogenes AP1 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,Lung
DTD0081,SLC11A2,Sequestration substrate,Upper and lower airway disease,Sequestration of human SLC11A2 substrates/drugs in upper and lower airway disease condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mtsB,Streptococcus equi,Streptococcus equi,subsp. equi NCTC 9682,Swiss Webster mice,.,"The protein mtsB of Streptococcus equi subsp. equi NCTC 9682 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0081,SLC11A2,Co-transporter,Endocarditis,Co-transport of human SLC11A2 substrates/drugs in endocarditis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SloABC,Streptococcus mutans,Streptococcus mutans,V403,Endocarditis rats,.,"The protein SloABC of Streptococcus mutans V403 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,Heart
DTD0081,SLC11A2,Sequestration substrate,Sepsis,Sequestration of human SLC11A2 substrates/drugs in sepsis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Streptococcus suis,Streptococcus suis,serotype 9,CD-1 mice,.,"The protein troA of Streptococcus suis serotype 9 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,Liver
DTD0081,SLC11A2,Co-transporter,Pneumonic plague,Co-transport of human SLC11A2 substrates/drugs in pneumonic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yfeA,Yersinia pestis,Yersinia pestis,KIM6,Swiss Webster mice,.,"The protein yfeA of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,Nose
DTD0081,SLC11A2,Co-transporter,Pneumonic plague,Co-transport of human SLC11A2 substrates/drugs in pneumonic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeABCD,Yersinia pestis,Yersinia pestis,.,Swiss Webster mice,.,"The protein yfeabcd of Yersinia pestis has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,Nose
DTD0081,SLC11A2,Co-transporter,Pneumonic plague,Co-transport of human SLC11A2 substrates/drugs in pneumonic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeABCD,Yersinia pestis,Yersinia pestis,KIM6,Swiss Webster mice,.,"The protein YfeABCD of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,Nose
DTD0081,SLC11A2,Co-transporter,Cholera,Co-transport of human SLC11A2 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0081,SLC11A2,Co-transporter,Cholera,Co-transport of human SLC11A2 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZrgABCDE,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,C3H/HeOuJ mice,.,"The compound Enterobactin Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,Intestine
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Mycobactin,Secreted by Mycobacterium avium,Mycobacterium avium,101,C57BL/6 mice,.,"The compound mycobactin secreted by Mycobacterium avium 101 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Mycobactin,Secreted by Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Rv,C57BL/6 mice,.,"The compound Mycobactin Secreted by Mycobacterium tuberculosis H37Rv has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Mycobactin,Secreted by Mycolicibacterium smegmatis,Mycolicibacterium smegmatis,MC2 155,C57BL/6 mice,.,"The compound Mycobactin Secreted by Mycolicibacterium smegmatis MC2 155 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salmochelin SX,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,C3H/HeOuJ mice,.,"The compound Salmochelin SX Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,Intestine
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salmochelin SX,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,KPPR1,C57BL/6 mice,.,"The compound Salmochelin SX Secreted by Klebsiella pneumoniae KPPR1 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Yersiniabactin,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,KPPR1,C57BL/6 mice,.,"The compound Yersiniabactin Secreted by Klebsiella pneumoniae KPPR1 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fepD,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,C3H/HeOuJ mice,.,"The protein fepD of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,irp2,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein irp2 of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntA,Bacillus anthracis,Bacillus anthracis,str. Vollum,ICR mice,.,"The protein mntA of Bacillus anthracis str. Vollum has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,MntABC,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus str. Newman,C57BL/6 mice,.,"The protein MntABC of Staphylococcus aureus subsp. aureus str. Newman has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,Liver
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,psn,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein psn of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Sit1p,Candida albicans,Candida albicans,CAF2-1,BALB/c mice,.,"The protein Sit1p of Candida albicans CAF2-1 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,C57BL/6 mice,.,"The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,Liver
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium,129/SvJ mice,.,"The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeAB,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein YfeAB of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeABCD,Yersinia pestis,Yersinia pestis,KIM6,Swiss Webster mice,.,"The protein YfeABCD of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,Lung
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound 2-oxoadipic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound 2-oxoadipic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound 2-oxoadipic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound 2-oxoadipic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound 2-Oxoadipic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound 2-Oxoadipic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound 2-Oxoadipic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound 3-methyl-2-oxobutanoic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound 3-methyl-2-oxobutanoic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound 3-methyl-2-oxobutanoic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound 3-methyl-2-oxobutanoic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound 3-Methyl-2-oxobutanoic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound 3-Methyl-2-oxobutanoic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound 3-Methyl-2-oxobutanoic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound 4-methyl-2-oxopentanoic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound 4-methyl-2-oxopentanoic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound 4-methyl-2-oxopentanoic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound 4-methyl-2-oxopentanoic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound 4-Methyl-2-oxopentanoic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound 4-Methyl-2-oxopentanoic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound 4-Methyl-2-oxopentanoic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Aerobactin,Secreted by Escherichia coli,Escherichia coli,LG1315,.,.,"The compound Aerobactin Secreted by Escherichia coli LG1315 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Alcaligin,Secreted by Achromobacter xylosoxidans,Achromobacter xylosoxidans,subsp. xylosoxydans KN 3-1,.,.,"The compound Alcaligin Secreted by Achromobacter xylosoxidans subsp. xylosoxydans KN 3-1 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Alcaligin,Secreted by Bordetella bronchiseptica,Bordetella bronchiseptica,B013N,.,.,"The compound Alcaligin Secreted by Bordetella bronchiseptica B013N has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Alcaligin,Secreted by Bordetella pertussis,Bordetella pertussis,UT25,.,.,"The compound Alcaligin Secreted by Bordetella pertussis UT25 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Anguibactin,Secreted by Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The compound anguibactin secreted by Vibrio anguillarum 775 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Aureochelin,Secreted by Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The compound aureochelin secreted by Staphylococcus aureus has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Carboxymycobactin,Secreted by Mycobacterium avium,Mycobacterium avium,CRl/69,.,.,"The compound Carboxymycobactin Secreted by Mycobacterium avium CRl/69 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Cepabactin,Secreted by Burkholderia cepacia,Burkholderia cepacia,ATCC 25416,.,.,"The compound Cepabactin Secreted by Burkholderia cepacia ATCC 25416 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Corynebactin,Secreted by Corynebacterium diphtheriae,Corynebacterium diphtheriae,C7 (beta),.,.,"The compound Corynebactin Secreted by Corynebacterium diphtheriae C7 (beta) has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Corynebactin,Secreted by Bacillus cereus,Bacillus cereus,ATCC 14579,.,.,"The compound Corynebactin Secreted by Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Corynebactin,Secreted by Bacillus thuringiensis,Bacillus thuringiensis,ATCC 33679,.,.,"The compound Corynebactin Secreted by Bacillus thuringiensis ATCC 33679 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Corynebactin,Secreted by Bacillus anthracis,Bacillus anthracis,str. Sterne,.,.,"The compound Corynebactin Secreted by Bacillus anthracis str. Sterne has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Desferriexochelin 772MS,Secreted by Mycobacterium tuberculosis,Mycobacterium tuberculosis,str. Erdman,.,.,"The compound Desferriexochelin 772MS Secreted by Mycobacterium tuberculosis str. Erdman has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Escherichia coli,Escherichia coli,BW25113,.,.,"The compound Enterobactin Secreted by Escherichia coli BW25113 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The compound Enterobactin Secreted by Escherichia coli str. K-12 substr. W3110 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. LT2,.,.,"The compound Enterobactin Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,298/53,.,.,"The compound Enterobactin Secreted by Klebsiella pneumoniae 298/53 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Shigella sonnei,Shigella sonnei,43-GG9,.,.,"The compound Enterobactin Secreted by Shigella sonnei 43-GG9 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Escherichia coli,Escherichia coli,9.0111,.,.,"The compound enterobactin secreted by Escherichia coli 9.0111 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Escherichia coli,Escherichia coli,AB33II,.,.,"The compound Enterobactin Secreted by Escherichia coli AB33II has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Exochelin 772SM,Secreted by Mycolicibacterium vaccae,Mycolicibacterium vaccae,R877R,.,.,"The compound Exochelin 772SM Secreted by Mycolicibacterium vaccae R877R has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine B,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine B Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine E,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine E Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine G1,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine G1 Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound indole-3-pyruvic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound indole-3-pyruvic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound indole-3-pyruvic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound indole-3-pyruvic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound Indole-3-pyruvic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound Indole-3-pyruvic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound Indole-3-pyruvic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Mycobactin,Secreted by Mycobacterium tuberculosis,Mycobacterium tuberculosis,.,.,.,"The compound mycobactin secreted by Mycobacterium tuberculosis has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ornibactin,Secreted by Burkholderia cepacia,Burkholderia cepacia,TVV69,.,.,"The compound Ornibactin Secreted by Burkholderia cepacia TVV69 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Petrobactin,Secreted by Bacillus cereus,Bacillus cereus,ATCC 14579,.,.,"The compound Petrobactin Secreted by Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Petrobactin,Secreted by Bacillus anthracis,Bacillus anthracis,str. Sterne,.,.,"The compound Petrobactin Secreted by Bacillus anthracis str. Sterne has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound phenylpyruvic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound phenylpyruvic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound phenylpyruvic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound phenylpyruvic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound Phenylpyruvic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound Phenylpyruvic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound Phenylpyruvic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Pyochelin,Secreted by Pseudomonas aeruginosa,Pseudomonas aeruginosa,PAO1,.,.,"The compound Pyochelin Secreted by Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Pyoverdin,Secreted by Pseudomonas aeruginosa,Pseudomonas aeruginosa,PAO1,.,.,"The compound Pyoverdin Secreted by Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Rhizoferrin,Secreted by Rhizopus microsporus,Rhizopus microsporus,.,.,.,"The compound rhizoferrin secreted by Rhizopus microsporus has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salicylic acid,Secreted by Burkholderia cepacia,Burkholderia cepacia,Pc275c,.,.,"The compound Salicylic acid Secreted by Burkholderia cepacia Pc275c has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salmochelin SX,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. LT2,.,.,"The compound Salmochelin SX Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Staphyloferrin A,Secreted by Staphylococcus aureus,Staphylococcus aureus,subsp. aureus NCTC 8325,.,.,"The compound Staphyloferrin A Secreted by Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Staphylopine,Secreted by Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The compound Staphylopine Secreted by Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Vibriobactin,Secreted by Vibrio cholerae,Vibrio cholerae,Lou15,.,.,"The compound Vibriobactin Secreted by Vibrio cholerae Lou15 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Vibriobactin,Secreted by Vibrio cholerae,Vibrio cholerae,MBG14,.,.,"The compound Vibriobactin Secreted by Vibrio cholerae MBG14 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Yersiniabactin,Secreted by Yersinia pestis,Yersinia pestis,Yreka F1+VW+P1+P+,.,.,"The compound Yersiniabactin Secreted by Yersinia pestis Yreka F1+VW+P1+P+ has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Yersiniabactin,Secreted by Yersinia enterocolitica,Yersinia enterocolitica,WA-C,.,.,"The compound Yersiniabactin Secreted by Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcRCBA,Streptococcus gordonii,Streptococcus gordonii,str. Challis,.,.,"The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CaFTR1,Candida albicans,Candida albicans,.,.,.,"The protein caftr1 of Candida albicans has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,cfrA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein cfrA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,cfrB,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein cfrB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,cfrB,Campylobacter coli,Campylobacter coli,W13A,.,.,"The protein cfrB of Campylobacter coli W13A has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ctuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein ctuA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,desA1,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein desA1 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efaA,Enterococcus faecalis,Enterococcus faecalis,JH2-2,.,.,"The protein efaA of Enterococcus faecalis JH2-2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeO,Escherichia coli,Escherichia coli,Nissle 1917,.,.,"The protein efeO of Escherichia coli Nissle 1917 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeU,Escherichia coli,Escherichia coli,O157:H7,.,.,"The protein efeU of Escherichia coli O157:H7 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeU,Escherichia coli,Escherichia coli,Nissle 1917,.,.,"The protein efeU of Escherichia coli Nissle 1917 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fatA,Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The protein fata of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fatB,Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The protein fatb of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Fbp,Vibrio cholerae,Vibrio cholerae,O395,.,.,"The protein Fbp of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fec,Shigella flexneri,Shigella flexneri,2a,.,.,"The protein fec of Shigella flexneri 2a has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fecA,Escherichia coli,Escherichia coli,UT5600,.,.,"The protein fecA of Escherichia coli UT5600 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feo,Vibrio cholerae,Vibrio cholerae,O395,.,.,"The protein feo of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoA,Escherichia coli,Escherichia coli,str. K-12 substr. MC4100,.,.,"The protein feoA of Escherichia coli str. K-12 substr. MC4100 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein feoB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein feoB of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Escherichia coli,Escherichia coli,str. K-12 substr. MC4100,.,.,"The protein feoB of Escherichia coli str. K-12 substr. MC4100 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoC,Klebsiella pneumoniae,Klebsiella pneumoniae,.,.,.,"The protein feoc of Klebsiella pneumoniae has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuA,Escherichia coli,Escherichia coli,K-12,.,.,"The protein fhuA of Escherichia coli K-12 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuB,Escherichia coli,Escherichia coli,DH5[alpha],.,.,"The protein fhuB of Escherichia coli DH5[alpha] has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuC,Escherichia coli,Escherichia coli,AB2847,.,.,"The protein fhuC of Escherichia coli AB2847 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCBG,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein FhuCBG of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCDB,Streptococcus agalactiae,Streptococcus agalactiae,A909,.,.,"The protein FhuCDB of Streptococcus agalactiae A909 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCDB,Haemophilus influenzae,Haemophilus influenzae,R2866,.,.,"The protein FhuCDB of Haemophilus influenzae R2866 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuD,Escherichia coli,Escherichia coli,BL21(DE3),.,.,"The protein fhuD of Escherichia coli BL21(DE3) has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuD1,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein fhuD1 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhud2,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein fhud2 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhud2,Staphylococcus aureus,Staphylococcus aureus,RN2564,.,.,"The protein fhud2 of Staphylococcus aureus RN2564 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fimA,Streptococcus parasanguinis,Streptococcus parasanguinis,FW213,.,.,"The protein fimA of Streptococcus parasanguinis FW213 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futA1,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futa1 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futA2,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futa2 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futB,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futb of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fyuA,Yersinia enterocolitica,Yersinia enterocolitica,WA-C,.,.,"The protein fyuA of Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,GAPDH,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein GAPDH of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,HtsABC,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein HtsABC of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,IroA,Escherichia coli,Escherichia coli,CFT073,.,.,"The protein IroA of Escherichia coli CFT073 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,iroN,Escherichia coli,Escherichia coli,O18:H7,.,.,"The protein iroN of Escherichia coli O18:H7 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,IrtAB,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Rv,.,.,"The protein IrtAB of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein isdA of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,BB,.,.,"The protein isdA of Staphylococcus aureus BB has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,N100,.,.,"The protein isdA of Staphylococcus aureus N100 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,lbpA,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein lbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,lbpA,Neisseria gonorrhoeae,Neisseria gonorrhoeae,FA19,.,.,"The protein lbpA of Neisseria gonorrhoeae FA19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,lbpB,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein lbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mnoP,Bradyrhizobium diazoefficiens,Bradyrhizobium diazoefficiens,USDA 110,.,.,"The protein mnoP of Bradyrhizobium diazoefficiens USDA 110 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntA,Lactiplantibacillus plantarum,Lactiplantibacillus plantarum,subsp. plantarum ATCC 14917,.,.,"The protein mntA of Lactiplantibacillus plantarum subsp. plantarum ATCC 14917 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,MntABC,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus NCTC 8325,.,.,"The protein MntABC of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,MntABC,Sinorhizobium meliloti,Sinorhizobium meliloti,242,.,.,"The protein mntabc of Sinorhizobium meliloti 242 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,MntABCD,Corynebacterium diphtheriae,Corynebacterium diphtheriae,C7 (beta),.,.,"The protein MntABCD of Corynebacterium diphtheriae C7 (beta) has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Escherichia coli,Escherichia coli,EMG2,.,.,"The protein mntH of Escherichia coli EMG2 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Rv,.,.,"The protein mntH of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mtsB,Streptococcus equi,Streptococcus equi,subsp. zooepidemicus NCTC 7023T,.,.,"The protein mtsB of Streptococcus equi subsp. zooepidemicus NCTC 7023T has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,p19,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,psaA,Streptococcus pneumoniae,Streptococcus pneumoniae,D39,.,.,"The protein psaA of Streptococcus pneumoniae D39 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,PsaABC,Streptococcus pneumoniae,Streptococcus pneumoniae,D39,.,.,"The protein PsaABC of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv0641,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein Rv0641 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv0704,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein Rv0704 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv1872c,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein Rv1872c of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ScaCBA,Streptococcus gordonii,Streptococcus gordonii,str. Challis substr. CH1,.,.,"The protein ScaCBA of Streptococcus gordonii str. Challis substr. CH1 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,scaDMT,Staphylococcus capitis,Staphylococcus capitis,DSM 20326,.,.,"The protein scaDMT of Staphylococcus capitis DSM 20326 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SfaABC,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein SfaABC of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuA,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfua of Serratia marcescens has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuB,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfub of Serratia marcescens has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuC,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfuc of Serratia marcescens has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SirABC,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus RN4220,.,.,"The protein SirABC of Staphylococcus aureus subsp. aureus RN4220 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sitA,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein sitA of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein SitABCD of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Rhizobium leguminosarum,Rhizobium leguminosarum,bv. viciae 3841,.,.,"The protein SitABCD of Rhizobium leguminosarum bv. viciae 3841 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium MM1255,.,.,"The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium MM1255 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium JF2043,.,.,"The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium JF2043 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sll1878,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein sll1878 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SstABCD,Staphylococcus aureus,Staphylococcus aureus,W,.,.,"The protein SstABCD of Staphylococcus aureus W has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbp1,Neisseria meningitidis,Neisseria meningitidis,.,.,.,"The protein tbp1 of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpA,Neisseria gonorrhoeae,Neisseria gonorrhoeae,.,.,.,"The protein tbpa of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpA,Haemophilus influenzae,Haemophilus influenzae,type b,.,.,"The protein tbpA of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpA,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein tbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Neisseria gonorrhoeae,Neisseria gonorrhoeae,.,.,.,"The protein tbpb of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Neisseria meningitidis,Neisseria meningitidis,.,.,.,"The protein tbpb of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Haemophilus influenzae,Haemophilus influenzae,type b,.,.,"The protein tbpB of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein tbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tonB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The protein tonB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tonB,Pseudomonas aeruginosa,Pseudomonas aeruginosa,K199,.,.,"The protein tonB of Pseudomonas aeruginosa K199 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,TonB1,Pseudomonas aeruginosa,Pseudomonas aeruginosa,K1040,.,.,"The protein TonB1 of Pseudomonas aeruginosa K1040 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tonB3,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 19606,.,.,"The protein tonB3 of Acinetobacter baumannii ATCC 19606 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Tpn,Staphylococcus epidermidis,Staphylococcus epidermidis,138,.,.,"The protein tpn of Staphylococcus epidermidis 138 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Tpn,Staphylococcus epidermidis,Staphylococcus epidermidis,2,.,.,"The protein tpn of Staphylococcus epidermidis 2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tssS,Yersinia pseudotuberculosis,Yersinia pseudotuberculosis,YPIII,.,.,"The protein tssS of Yersinia pseudotuberculosis YPIII has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Sequestration substrate,.,Sequestration of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tuf,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein tuf of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0081,SLC11A2,Co-transporter,.,Co-transport of human SLC11A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeABCD,Yersinia pestis,Yersinia pestis,KIM5-2031.11+,.,.,"The protein YfeABCD of Yersinia pestis KIM5-2031.11+ has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0081,SLC11A2,Up regulating,Anemia,Up regulating of SLC11A2 expression in anemia condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Acetate),Dietary inulin metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Yorkshire-Hampshire-Landrace hybrid pigs,.,The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC11A2.,.,Colon
DTD0081,SLC11A2,Up regulating,Anemia,Up regulating of SLC11A2 expression in anemia condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Acetate),Dietary inulin metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Yorkshire-Hampshire-Landrace hybrid pigs,.,The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC11A2.,.,Duodenum
DTD0081,SLC11A2,Up regulating,Anemia,Up regulating of SLC11A2 expression in anemia condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Butyrate),Dietary inulin metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Yorkshire-Hampshire-Landrace hybrid pigs,.,The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC11A2.,.,Colon
DTD0081,SLC11A2,Up regulating,Anemia,Up regulating of SLC11A2 expression in anemia condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Butyrate),Dietary inulin metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Yorkshire-Hampshire-Landrace hybrid pigs,.,The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC11A2.,.,Duodenum
DTD0081,SLC11A2,Up regulating,Anemia,Up regulating of SLC11A2 expression in anemia condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Propionate),Dietary inulin metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Yorkshire-Hampshire-Landrace hybrid pigs,.,The metabolite short-chain fatty acid (propionate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC11A2.,.,Colon
DTD0081,SLC11A2,Up regulating,Anemia,Up regulating of SLC11A2 expression in anemia condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Propionate),Dietary inulin metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Yorkshire-Hampshire-Landrace hybrid pigs,.,The metabolite short-chain fatty acid (propionate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC11A2.,.,Duodenum
DTD0083,SLC12A2,Up regulating,Diarrhea associated with infection by invasive enteric pathogens,Up regulating of SLC12A2 expression in diarrhea associated with infection by invasive enteric pathogens condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Escherichia coli,Escherichia coli,Escherichia coli,O29,.,Human colon adenocarcinoma cells (HT29-Cl.19A),The Escherichia coli O29 has been reported to increase the expression of the drug transporter SLC12A2.,.,Colon
DTD0083,SLC12A2,Up regulating,Diarrhea associated with infection by invasive enteric pathogens,Up regulating of SLC12A2 expression in diarrhea associated with infection by invasive enteric pathogens condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Salmonella dublin,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Dublin,.,Human colon adenocarcinoma cells (HT29-Cl.19A),The Salmonella enterica subsp. enterica serovar Dublin has been reported to increase the expression of the drug transporter SLC12A2.,.,Colon
DTD0091,SLC13A1,Co-transporter,Health,Co-transport of human SLC13A1 substrates/drugs in health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,dcsT,Corynebacterium glutamicum,Corynebacterium glutamicum,ATCC 13032,.,.,"The protein dcsT of Corynebacterium glutamicum ATCC 13032 has been reported to transport similar substrates/drugs of SLC13A1, which affects the distribution of its substrate/drug in vivo.",Succinate; Fumarate; Malate,.
DTD0091,SLC13A1,Co-transporter,.,Co-transport of human SLC13A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,VcINDY,Vibrio cholerae,Vibrio cholerae,AAF95939,.,.,"The protein VcINDY of Vibrio cholerae AAF95939 has been reported to transport similar substrates/drugs of SLC13A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0092,SLC13A2,Co-transporter,Health,Co-transport of human SLC13A2 substrates/drugs in health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,dcsT,Corynebacterium glutamicum,Corynebacterium glutamicum,ATCC 13032,.,.,"The protein dcsT of Corynebacterium glutamicum ATCC 13032 has been reported to transport similar substrates/drugs of SLC13A2, which affects the distribution of its substrate/drug in vivo.",Succinate; Fumarate; Malate,.
DTD0092,SLC13A2,Co-transporter,.,Co-transport of human SLC13A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sdcS,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus Mu50,.,.,"The protein sdcS of Staphylococcus aureus subsp. aureus Mu50 has been reported to transport similar substrates/drugs of SLC13A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0092,SLC13A2,Co-transporter,.,Co-transport of human SLC13A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,VcINDY,Vibrio cholerae,Vibrio cholerae,AAF95939,.,.,"The protein VcINDY of Vibrio cholerae AAF95939 has been reported to transport similar substrates/drugs of SLC13A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0093,SLC13A3,Co-transporter,Health,Co-transport of human SLC13A3 substrates/drugs in health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,dcsT,Corynebacterium glutamicum,Corynebacterium glutamicum,ATCC 13032,.,.,"The protein dcsT of Corynebacterium glutamicum ATCC 13032 has been reported to transport similar substrates/drugs of SLC13A3, which affects the distribution of its substrate/drug in vivo.",Succinate; Fumarate; Malate,.
DTD0093,SLC13A3,Co-transporter,.,Co-transport of human SLC13A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sdcS,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus Mu50,.,.,"The protein sdcS of Staphylococcus aureus subsp. aureus Mu50 has been reported to transport similar substrates/drugs of SLC13A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0093,SLC13A3,Co-transporter,.,Co-transport of human SLC13A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,VcINDY,Vibrio cholerae,Vibrio cholerae,AAF95939,.,.,"The protein VcINDY of Vibrio cholerae AAF95939 has been reported to transport similar substrates/drugs of SLC13A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0094,SLC13A4,Co-transporter,Health,Co-transport of human SLC13A4 substrates/drugs in health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,dcsT,Corynebacterium glutamicum,Corynebacterium glutamicum,ATCC 13032,.,.,"The protein dcsT of Corynebacterium glutamicum ATCC 13032 has been reported to transport similar substrates/drugs of SLC13A4, which affects the distribution of its substrate/drug in vivo.",Succinate; Fumarate; Malate,.
DTD0094,SLC13A4,Co-transporter,.,Co-transport of human SLC13A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,VcINDY,Vibrio cholerae,Vibrio cholerae,AAF95939,.,.,"The protein VcINDY of Vibrio cholerae AAF95939 has been reported to transport similar substrates/drugs of SLC13A4, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0095,SLC13A5,Co-transporter,Health,Co-transport of human SLC13A5 substrates/drugs in health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,dcsT,Corynebacterium glutamicum,Corynebacterium glutamicum,ATCC 13032,.,.,"The protein dcsT of Corynebacterium glutamicum ATCC 13032 has been reported to transport similar substrates/drugs of SLC13A5, which affects the distribution of its substrate/drug in vivo.",Succinate; Fumarate; Malate,.
DTD0095,SLC13A5,Co-transporter,.,Co-transport of human SLC13A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,VcINDY,Vibrio cholerae,Vibrio cholerae,AAF95939,.,.,"The protein VcINDY of Vibrio cholerae AAF95939 has been reported to transport similar substrates/drugs of SLC13A5, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0021,SLC15A1,Co-transporter,.,Co-transport of human SLC15A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ompC,Escherichia coli,Escherichia coli,.,.,.,"The protein ompc of Escherichia coli has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.",Dipeptide; Tripeptide; Peptidomimetic drugs,.
DTD0021,SLC15A1,Co-transporter,.,Co-transport of human SLC15A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ompC,Escherichia coli,Escherichia coli,JM712,.,.,"The protein ompC of Escherichia coli JM712 has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.",Cefoxitin,.
DTD0021,SLC15A1,Co-transporter,.,Co-transport of human SLC15A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ompF,Escherichia coli,Escherichia coli,.,.,.,"The protein ompf of Escherichia coli has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.",Dipeptide; Tripeptide; Peptidomimetic drugs,.
DTD0021,SLC15A1,Co-transporter,.,Co-transport of human SLC15A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ompF,Escherichia coli,Escherichia coli,JM712,.,.,"The protein ompF of Escherichia coli JM712 has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.",Cefoxitin,.
DTD0021,SLC15A1,Co-transporter,.,Co-transport of human SLC15A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ybgH,Escherichia coli,Escherichia coli,.,.,.,"The protein ybgh of Escherichia coli has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.",Dipeptide; Tripeptide; Peptidomimetic drugs,.
DTD0021,SLC15A1,Co-transporter,.,Co-transport of human SLC15A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ydgR,Escherichia coli,Escherichia coli,BL21,.,.,"The protein ydgR of Escherichia coli BL21 has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.",Chloramphenicol; Sulpiride,.
DTD0021,SLC15A1,Co-transporter,.,Co-transport of human SLC15A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ydgR,Escherichia coli,Escherichia coli,.,.,.,"The protein ydgr of Escherichia coli has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.",Dipeptide; Tripeptide; Peptidomimetic drugs,.
DTD0021,SLC15A1,Co-transporter,.,Co-transport of human SLC15A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ydgR,Escherichia coli,Escherichia coli,.,.,.,"The protein ydgr of Escherichia coli has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.",Sulpiride; Bestatin; Valacyclovir; Ampicillin; Oseltamivir,.
DTD0021,SLC15A1,Co-transporter,.,Co-transport of human SLC15A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yhiP,Escherichia coli,Escherichia coli,.,.,.,"The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.",Dipeptide; Tripeptide; Peptidomimetic drugs,.
DTD0021,SLC15A1,Co-transporter,.,Co-transport of human SLC15A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yjdL,Escherichia coli,Escherichia coli,.,.,.,"The protein yjdl of Escherichia coli has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.",Dipeptide; Tripeptide; Peptidomimetic drugs,.
DTD0021,SLC15A1,Co-transporter,.,Co-transport of human SLC15A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,GK2020,Geobacillus kaustophilus,Geobacillus kaustophilus,.,.,.,"The protein gk2020 of Geobacillus kaustophilus has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0021,SLC15A1,Co-transporter,.,Co-transport of human SLC15A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,PepTSh,Staphylococcus hominis,Staphylococcus hominis,SK119,.,.,"The protein PepTSh of Staphylococcus hominis SK119 has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0021,SLC15A1,Co-transporter,.,Co-transport of human SLC15A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,PepTSo,Shewanella oneidensis,Shewanella oneidensis,.,.,.,"The protein peptso of Shewanella oneidensis has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0021,SLC15A1,Co-transporter,.,Co-transport of human SLC15A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,PepTSo2,Shewanella oneidensis,Shewanella oneidensis,.,.,.,"The protein peptso2 of Shewanella oneidensis has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0021,SLC15A1,Co-transporter,.,Co-transport of human SLC15A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,PepTSt,Streptococcus thermophilus,Streptococcus thermophilus,LMG 18311,.,.,"The protein PepTSt of Streptococcus thermophilus LMG 18311 has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0021,SLC15A1,Co-transporter,.,Co-transport of human SLC15A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YePEPT,Yersinia enterocolitica,Yersinia enterocolitica,.,.,.,"The protein yepept of Yersinia enterocolitica has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0021,SLC15A1,Up regulating,Colon cancer,Up regulating of SLC15A1 expression in colon cancer condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Chenodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human colon adenocarcinoma cells (Caco-2),The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC15A1.,.,Colon
DTD0021,SLC15A1,Up regulating,Colon cancer,Up regulating of SLC15A1 expression in colon cancer condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Deoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human colon adenocarcinoma cells (Caco-2),The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC15A1.,.,Colon
DTD0021,SLC15A1,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC15A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6N mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC15A1.,.,Small intestine
DTD0021,SLC15A1,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC15A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC15A1.,.,Large intestine
DTD0021,SLC15A1,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC15A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 germ-free/conventionally-raised mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC15A1.,.,Jejunum
DTD0021,SLC15A1,Down regulating,Hypoxia,Down regulating of SLC15A1 expression in hypoxia condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Sprague-Dawley rats,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC15A1.,.,Liver
DTD0022,SLC15A2,Co-transporter,.,Co-transport of human SLC15A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,PepTSh,Staphylococcus hominis,Staphylococcus hominis,SK119,.,.,"The protein PepTSh of Staphylococcus hominis SK119 has been reported to transport similar substrates/drugs of SLC15A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0022,SLC15A2,Co-transporter,.,Co-transport of human SLC15A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,PepTSo,Shewanella oneidensis,Shewanella oneidensis,.,.,.,"The protein peptso of Shewanella oneidensis has been reported to transport similar substrates/drugs of SLC15A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0022,SLC15A2,Co-transporter,.,Co-transport of human SLC15A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,PepTSo2,Shewanella oneidensis,Shewanella oneidensis,.,.,.,"The protein peptso2 of Shewanella oneidensis has been reported to transport similar substrates/drugs of SLC15A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0022,SLC15A2,Co-transporter,.,Co-transport of human SLC15A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,PepTSt,Streptococcus thermophilus,Streptococcus thermophilus,LMG 18311,.,.,"The protein PepTSt of Streptococcus thermophilus LMG 18311 has been reported to transport similar substrates/drugs of SLC15A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0022,SLC15A2,Co-transporter,.,Co-transport of human SLC15A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ybgH,Escherichia coli,Escherichia coli,BL21,.,.,"The protein ybgH of Escherichia coli BL21 has been reported to transport similar substrates/drugs of SLC15A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0100,SLC16A1,Down regulating,Starvation,Down regulating of SLC16A1 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Acetate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to decrease the expression of the drug transporter SLC16A1.,.,Kidney
DTD0100,SLC16A1,Up regulating,Starvation,Up regulating of SLC16A1 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Acetate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A1.,.,Small intestine
DTD0100,SLC16A1,Down regulating,Starvation,Down regulating of SLC16A1 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Butyrate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to decrease the expression of the drug transporter SLC16A1.,.,Kidney
DTD0100,SLC16A1,Up regulating,Starvation,Up regulating of SLC16A1 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Butyrate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A1.,.,Small intestine
DTD0100,SLC16A1,Down regulating,Starvation,Down regulating of SLC16A1 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Propionate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (propionate) generated from the metabolism of dietary food by the Prevotella copri has been reported to decrease the expression of the drug transporter SLC16A1.,.,Kidney
DTD0100,SLC16A1,Up regulating,Starvation,Up regulating of SLC16A1 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Propionate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (propionate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A1.,.,Small intestine
DTD0100,SLC16A1,Up regulating,Health,Up regulating of SLC16A1 expression in health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Acetate,Pectin metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Sprague-Dawley rats,.,The metabolite acetate generated from the metabolism of pectin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.,.,Colon
DTD0100,SLC16A1,Up regulating,Health,Up regulating of SLC16A1 expression in health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Acetate,Pectin metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Sprague-Dawley rats,.,The metabolite acetate generated from the metabolism of pectin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.,.,Duodenum
DTD0100,SLC16A1,Up regulating,Health,Up regulating of SLC16A1 expression in health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Acetate,Pectin metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Sprague-Dawley rats,.,The metabolite acetate generated from the metabolism of pectin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.,.,Stomach
DTD0100,SLC16A1,Up regulating,Health,Up regulating of SLC16A1 expression in health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Acetate,Pectin metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Sprague-Dawley rats,.,The metabolite acetate generated from the metabolism of pectin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.,.,Caecum
DTD0100,SLC16A1,Up regulating,Colon cancer,Up regulating of SLC16A1 expression in colon cancer condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Butyrate,Dietary food metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human colon adenocarcinoma cells (Caco-2),The metabolite butyrate generated from the metabolism of dietary food by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.,.,Colonic lumen
DTD0100,SLC16A1,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC16A1 expression in conventional mice compared with germ-free mice,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Butyrate,Dietary food metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Landrace-Pietrain hybrid pigs,.,The metabolite butyrate generated from the metabolism of dietary food by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.,.,Ileum
DTD0100,SLC16A1,Up regulating,Intestinal inflammation,Up regulating of SLC16A1 expression in intestinal inflammation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Butyrate,beta-glucan metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Landrace-Yorkshire pigs,.,The metabolite butyrate generated from the metabolism of beta-glucan by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.,.,Colon
DTD0100,SLC16A1,Up regulating,Intestinal inflammation,Up regulating of SLC16A1 expression in intestinal inflammation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Butyrate,beta-glucan metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Landrace-Yorkshire pigs,.,The metabolite butyrate generated from the metabolism of beta-glucan by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.,.,Caecum
DTD0100,SLC16A1,Up regulating,.,Up regulating of SLC16A1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Chenodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Rat small intestine epithelial cells (IEC-6),The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.,.,Small intestine
DTD0107,SLC16A3,Up regulating,Starvation,Up regulating of SLC16A3 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Acetate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A3.,.,Heart
DTD0107,SLC16A3,Up regulating,Starvation,Up regulating of SLC16A3 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Acetate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A3.,.,Small intestine
DTD0107,SLC16A3,Up regulating,Starvation,Up regulating of SLC16A3 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Butyrate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A3.,.,Heart
DTD0107,SLC16A3,Up regulating,Starvation,Up regulating of SLC16A3 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Butyrate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A3.,.,Small intestine
DTD0107,SLC16A3,Up regulating,Starvation,Up regulating of SLC16A3 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Propionate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (propionate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A3.,.,Heart
DTD0107,SLC16A3,Up regulating,Starvation,Up regulating of SLC16A3 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Propionate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (propionate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A3.,.,Small intestine
DTD0111,SLC16A7,Down regulating,Starvation,Down regulating of SLC16A7 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Acetate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to decrease the expression of the drug transporter SLC16A7.,.,Liver
DTD0111,SLC16A7,Up regulating,Starvation,Up regulating of SLC16A7 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Acetate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A7.,.,Heart
DTD0111,SLC16A7,Up regulating,Starvation,Up regulating of SLC16A7 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Acetate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A7.,.,Hypothalamus
DTD0111,SLC16A7,Up regulating,Starvation,Up regulating of SLC16A7 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Acetate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A7.,.,Kidney
DTD0111,SLC16A7,Down regulating,Starvation,Down regulating of SLC16A7 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Butyrate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to decrease the expression of the drug transporter SLC16A7.,.,Liver
DTD0111,SLC16A7,Up regulating,Starvation,Up regulating of SLC16A7 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Butyrate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A7.,.,Heart
DTD0111,SLC16A7,Up regulating,Starvation,Up regulating of SLC16A7 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Butyrate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A7.,.,Hypothalamus
DTD0111,SLC16A7,Up regulating,Starvation,Up regulating of SLC16A7 expression in starvation condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Butyrate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,129S1/SvImJ mice,.,The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A7.,.,Kidney
DTD0123,SLC18A1,Sequestration substrate,.,Sequestration of human SLC18A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Helicobacter pylori,Helicobacter pylori,Helicobacter pylori,ATCC 700824,.,Human gastric epithelial cells,"The Helicobacter pylori ATCC 700824 has been reported to sequester the drug L-dopamine, which limits the distribution of the drug in the body and its binding to the drug transporter SLC18A1, thereby affecting the efficacy, safety, or bioavailability of the drug.",L-dopamine,Stomach
DTD0034,SLC18A2,Sequestration substrate,.,Sequestration of human SLC18A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Helicobacter pylori,Helicobacter pylori,Helicobacter pylori,ATCC 700824,.,Human gastric epithelial cells,"The Helicobacter pylori ATCC 700824 has been reported to sequester the drug L-dopamine, which limits the distribution of the drug in the body and its binding to the drug transporter SLC18A2, thereby affecting the efficacy, safety, or bioavailability of the drug.",L-dopamine,Stomach
DTD0132,SLC1A4,Down regulating,Mastitis,Down regulating of SLC1A4 expression in mastitis condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Lipopolysaccharide,Generated by Escherichia coli,Escherichia coli,O111:B4,ICR mice,.,The compound Lipopolysaccharide Generated by Escherichia coli O111:B4 has been reported to decrease the expression of the drug transporter SLC1A4.,.,Breast
DTD0010,SLC22A1,Sequestration substrate,.,Sequestration of human SLC22A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Helicobacter pylori,Helicobacter pylori,Helicobacter pylori,ATCC 700824,.,Human gastric epithelial cells,"The Helicobacter pylori ATCC 700824 has been reported to sequester the drug L-dopamine, which limits the distribution of the drug in the body and its binding to the drug transporter SLC22A1, thereby affecting the efficacy, safety, or bioavailability of the drug.",L-dopamine,Stomach
DTD0010,SLC22A1,Co-transporter,.,Co-transport of human SLC22A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,OCT-like transport,Ligilactobacillus salivarius,Ligilactobacillus salivarius,DSM 20555 = ATCC 11741,.,.,"The protein OCT-like transport of Ligilactobacillus salivarius DSM 20555 = ATCC 11741 has been reported to transport similar substrates/drugs of SLC22A1, which affects the distribution of its substrate/drug in vivo.",Cationic drugs; Endogenous amines,.
DTD0010,SLC22A1,Up regulating,Diabetes,Up regulating of SLC22A1 expression in diabetes condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Rats,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A1.,Metformin,Liver
DTD0010,SLC22A1,Up regulating,Colon cancer,Up regulating of SLC22A1 expression in colon cancer condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Chenodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human colon adenocarcinoma cells (Caco-2),The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A1.,.,Colon
DTD0010,SLC22A1,Up regulating,Colon cancer,Up regulating of SLC22A1 expression in colon cancer condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Deoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human colon adenocarcinoma cells (HT-29),The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A1.,.,Colon
DTD0010,SLC22A1,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC22A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A1.,.,Duodenum
DTD0010,SLC22A1,Up regulating,.,Up regulating of SLC22A1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Lithocholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,IQI mice,.,The metabolite lithocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A1.,.,Liver
DTD0026,SLC22A11,Sequestration substrate,.,Sequestration of human SLC22A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Escherichia coli,Escherichia coli,Escherichia coli,str. K-12 substr. MG1655,.,.,"The Escherichia coli str. K-12 substr. MG1655 has been reported to sequester the drug Tetracycline, which limits the distribution of the drug in the body and its binding to the drug transporter SLC22A11, thereby affecting the efficacy, safety, or bioavailability of the drug.",Tetracycline,.
DTD0026,SLC22A11,Co-transporter,.,Co-transport of human SLC22A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ompF,Escherichia coli,Escherichia coli,JM712,.,.,"The protein ompF of Escherichia coli JM712 has been reported to transport similar substrates/drugs of SLC22A11, which affects the distribution of its substrate/drug in vivo.",Tetracycline,.
DTD0027,SLC22A12,Down regulating,Hyperuricaemia,Down regulating of SLC22A12 expression in hyperuricaemia condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,ICR specific-pathogen-free mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC22A12.,.,Kidney
DTD0006,SLC22A2,Sequestration substrate,.,Sequestration of human SLC22A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Helicobacter pylori,Helicobacter pylori,Helicobacter pylori,ATCC 700824,.,Human gastric epithelial cells,"The Helicobacter pylori ATCC 700824 has been reported to sequester the drug L-dopamine, which limits the distribution of the drug in the body and its binding to the drug transporter SLC22A2, thereby affecting the efficacy, safety, or bioavailability of the drug.",L-dopamine,Stomach
DTD0009,SLC22A3,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC22A3 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC22A3.,.,Liver
DTD0009,SLC22A3,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC22A3 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A3.,.,Jejunum
DTD0151,SLC22A4,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC22A4 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC22A4.,.,Large intestine
DTD0151,SLC22A4,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC22A4 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC22A4.,.,Liver
DTD0023,SLC22A5,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC22A5 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC22A5.,.,Jejunum
DTD0023,SLC22A5,Inhibition,.,Inhibition of SLC22A5 function in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,"N,N,N-trimethyl-5-aminovaleric acid",L-lysine metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,"The metabolite n,n,n-trimethyl-5-aminovaleric acid generated from the metabolism of l-lysine by the host unspecified microbiota has been reported to inhibit the function of the drug transporter SLC22A5.",.,Heart
DTD0024,SLC22A6,Up regulating,Colon cancer,Up regulating of SLC22A6 expression in colon cancer condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Escherichia coli Nissle 1917,Escherichia coli,Escherichia coli,Nissle 1917,.,Human colon adenocarcinoma cells (Caco-2),The Escherichia coli Nissle 1917 has been reported to increase the expression of the drug transporter SLC22A6.,.,Colon
DTD0024,SLC22A6,Up regulating,Chronic kidney disease,Up regulating of SLC22A6 expression in chronic kidney disease condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Indoxyl sulfate,Indole metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Sprague-Dawley rats,Human hepatoblastoma cells (HG2L7.5c1),The metabolite indoxyl sulfate generated from the metabolism of indole by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A6.,.,Kidney
DTD0005,SLC22A7,Sequestration substrate,.,Sequestration of human SLC22A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Escherichia coli,Escherichia coli,Escherichia coli,str. K-12 substr. MG1655,.,.,"The Escherichia coli str. K-12 substr. MG1655 has been reported to sequester the drug Tetracycline, which limits the distribution of the drug in the body and its binding to the drug transporter SLC22A7, thereby affecting the efficacy, safety, or bioavailability of the drug.",Tetracycline,.
DTD0005,SLC22A7,Co-transporter,.,Co-transport of human SLC22A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ompF,Escherichia coli,Escherichia coli,JM712,.,.,"The protein ompF of Escherichia coli JM712 has been reported to transport similar substrates/drugs of SLC22A7, which affects the distribution of its substrate/drug in vivo.",Tetracycline,.
DTD0025,SLC22A8,Sequestration substrate,.,Sequestration of human SLC22A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Escherichia coli,Escherichia coli,Escherichia coli,str. K-12 substr. MG1655,.,.,"The Escherichia coli str. K-12 substr. MG1655 has been reported to sequester the drug Ciprofloxacin and Tetracycline, which limits the distribution of the drug in the body and its binding to the drug transporter SLC22A8, thereby affecting the efficacy, safety, or bioavailability of the drug.",Ciprofloxacin; Tetracycline,.
DTD0025,SLC22A8,Co-transporter,.,Co-transport of human SLC22A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ompF,Escherichia coli,Escherichia coli,JM712,.,.,"The protein ompF of Escherichia coli JM712 has been reported to transport similar substrates/drugs of SLC22A8, which affects the distribution of its substrate/drug in vivo.",Tetracycline,.
DTD0025,SLC22A8,Up regulating,.,Up regulating of SLC22A8 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Dehydrolithocholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,PXR mice,Mouse embryo embryonic stem cells (ES-R1),The metabolite dehydrolithocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A8.,.,Liver
DTD0155,SLC22B3,Sequestration substrate,.,Sequestration of human SLC22B3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Helicobacter pylori,Helicobacter pylori,Helicobacter pylori,ATCC 700824,.,Human gastric epithelial cells,"The Helicobacter pylori ATCC 700824 has been reported to sequester the drug L-dopamine, which limits the distribution of the drug in the body and its binding to the drug transporter SLC22B3, thereby affecting the efficacy, safety, or bioavailability of the drug.",L-dopamine,Stomach
DTD0158,SLC23A1,Down regulating,.,Down regulating of SLC23A1 expression in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Lipopolysaccharide,Generated by the gut microbiota and Gram negative bacteria,Host unspecified microbiota,.,C57BL/6 mice,Human colon adenocarcinoma cells (Caco-2),The compound lipopolysaccharide generated by host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC23A1.,.,Colon
DTD0159,SLC23A2,Down regulating,.,Down regulating of SLC23A2 expression in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Lipopolysaccharide,Generated by the gut microbiota and Gram negative bacteria,Host unspecified microbiota,.,C57BL/6 mice,Human colon adenocarcinoma cells (Caco-2),The compound lipopolysaccharide generated by host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC23A2.,.,Colon
DTD0183,SLC25A22,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC25A22 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 germ-free/conventionally-raised mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC25A22.,.,Jejunum
DTD0189,SLC25A28,Co-transporter,Pneumonic plague,Co-transport of human SLC25A28 substrates/drugs in pneumonic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feo,Yersinia pestis,Yersinia pestis,KIM6,Swiss Webster mice,.,"The protein feo of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,Lung
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fepD,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,C3H/HeOuJ mice,.,"The protein fepD of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,psn,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein psn of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Sit1p,Candida albicans,Candida albicans,CAF2-1,BALB/c mice,.,"The protein Sit1p of Candida albicans CAF2-1 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeAB,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein YfeAB of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeABCD,Yersinia pestis,Yersinia pestis,KIM6,Swiss Webster mice,.,"The protein YfeABCD of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,Lung
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Desferriexochelin 772MS,Secreted by Mycobacterium tuberculosis,Mycobacterium tuberculosis,str. Erdman,.,.,"The compound Desferriexochelin 772MS Secreted by Mycobacterium tuberculosis str. Erdman has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine B,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine B Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine E,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine E Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine G1,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine G1 Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CaFTR1,Candida albicans,Candida albicans,.,.,.,"The protein caftr1 of Candida albicans has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,cfrA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein cfrA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,cfrB,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein cfrB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,cfrB,Campylobacter coli,Campylobacter coli,W13A,.,.,"The protein cfrB of Campylobacter coli W13A has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ctuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein ctuA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,desA1,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein desA1 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeO,Escherichia coli,Escherichia coli,Nissle 1917,.,.,"The protein efeO of Escherichia coli Nissle 1917 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeU,Escherichia coli,Escherichia coli,O157:H7,.,.,"The protein efeU of Escherichia coli O157:H7 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeU,Escherichia coli,Escherichia coli,Nissle 1917,.,.,"The protein efeU of Escherichia coli Nissle 1917 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fatA,Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The protein fata of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fatB,Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The protein fatb of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Fbp,Vibrio cholerae,Vibrio cholerae,O395,.,.,"The protein Fbp of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fec,Shigella flexneri,Shigella flexneri,2a,.,.,"The protein fec of Shigella flexneri 2a has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fecA,Escherichia coli,Escherichia coli,UT5600,.,.,"The protein fecA of Escherichia coli UT5600 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feo,Vibrio cholerae,Vibrio cholerae,O395,.,.,"The protein feo of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoA,Escherichia coli,Escherichia coli,str. K-12 substr. MC4100,.,.,"The protein feoA of Escherichia coli str. K-12 substr. MC4100 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein feoB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein feoB of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Escherichia coli,Escherichia coli,str. K-12 substr. MC4100,.,.,"The protein feoB of Escherichia coli str. K-12 substr. MC4100 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoC,Klebsiella pneumoniae,Klebsiella pneumoniae,.,.,.,"The protein feoc of Klebsiella pneumoniae has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuA,Escherichia coli,Escherichia coli,K-12,.,.,"The protein fhuA of Escherichia coli K-12 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuB,Escherichia coli,Escherichia coli,DH5[alpha],.,.,"The protein fhuB of Escherichia coli DH5[alpha] has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuC,Escherichia coli,Escherichia coli,AB2847,.,.,"The protein fhuC of Escherichia coli AB2847 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCBG,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein FhuCBG of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCDB,Streptococcus agalactiae,Streptococcus agalactiae,A909,.,.,"The protein FhuCDB of Streptococcus agalactiae A909 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCDB,Haemophilus influenzae,Haemophilus influenzae,R2866,.,.,"The protein FhuCDB of Haemophilus influenzae R2866 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuD,Escherichia coli,Escherichia coli,BL21(DE3),.,.,"The protein fhuD of Escherichia coli BL21(DE3) has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuD1,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein fhuD1 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhud2,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein fhud2 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhud2,Staphylococcus aureus,Staphylococcus aureus,RN2564,.,.,"The protein fhud2 of Staphylococcus aureus RN2564 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futA1,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futa1 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futA2,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futa2 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futB,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futb of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fyuA,Yersinia enterocolitica,Yersinia enterocolitica,WA-C,.,.,"The protein fyuA of Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,GAPDH,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein GAPDH of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,HtsABC,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein HtsABC of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,IroA,Escherichia coli,Escherichia coli,CFT073,.,.,"The protein IroA of Escherichia coli CFT073 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,iroN,Escherichia coli,Escherichia coli,O18:H7,.,.,"The protein iroN of Escherichia coli O18:H7 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,IrtAB,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Rv,.,.,"The protein IrtAB of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein isdA of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,BB,.,.,"The protein isdA of Staphylococcus aureus BB has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,N100,.,.,"The protein isdA of Staphylococcus aureus N100 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,lbpA,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein lbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,lbpA,Neisseria gonorrhoeae,Neisseria gonorrhoeae,FA19,.,.,"The protein lbpA of Neisseria gonorrhoeae FA19 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,lbpB,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein lbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,MntABC,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus NCTC 8325,.,.,"The protein MntABC of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,p19,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv0641,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein Rv0641 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv0704,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein Rv0704 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv1872c,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein Rv1872c of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SfaABC,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein SfaABC of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuA,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfua of Serratia marcescens has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuB,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfub of Serratia marcescens has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuC,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfuc of Serratia marcescens has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SirABC,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus RN4220,.,.,"The protein SirABC of Staphylococcus aureus subsp. aureus RN4220 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sitA,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein sitA of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein SitABCD of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium JF2043,.,.,"The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium JF2043 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sll1878,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein sll1878 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SstABCD,Staphylococcus aureus,Staphylococcus aureus,W,.,.,"The protein SstABCD of Staphylococcus aureus W has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbp1,Neisseria meningitidis,Neisseria meningitidis,.,.,.,"The protein tbp1 of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpA,Neisseria gonorrhoeae,Neisseria gonorrhoeae,.,.,.,"The protein tbpa of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpA,Haemophilus influenzae,Haemophilus influenzae,type b,.,.,"The protein tbpA of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpA,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein tbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Neisseria gonorrhoeae,Neisseria gonorrhoeae,.,.,.,"The protein tbpb of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Neisseria meningitidis,Neisseria meningitidis,.,.,.,"The protein tbpb of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Haemophilus influenzae,Haemophilus influenzae,type b,.,.,"The protein tbpB of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein tbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tonB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The protein tonB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tonB,Pseudomonas aeruginosa,Pseudomonas aeruginosa,K199,.,.,"The protein tonB of Pseudomonas aeruginosa K199 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,TonB1,Pseudomonas aeruginosa,Pseudomonas aeruginosa,K1040,.,.,"The protein TonB1 of Pseudomonas aeruginosa K1040 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tonB3,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 19606,.,.,"The protein tonB3 of Acinetobacter baumannii ATCC 19606 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Tpn,Staphylococcus epidermidis,Staphylococcus epidermidis,138,.,.,"The protein tpn of Staphylococcus epidermidis 138 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Tpn,Staphylococcus epidermidis,Staphylococcus epidermidis,2,.,.,"The protein tpn of Staphylococcus epidermidis 2 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Sequestration substrate,.,Sequestration of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tuf,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein tuf of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.",.,.
DTD0189,SLC25A28,Co-transporter,.,Co-transport of human SLC25A28 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeABCD,Yersinia pestis,Yersinia pestis,KIM5-2031.11+,.,.,"The protein YfeABCD of Yersinia pestis KIM5-2031.11+ has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,Pneumonic plague,Co-transport of human SLC25A37 substrates/drugs in pneumonic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feo,Yersinia pestis,Yersinia pestis,KIM6,Swiss Webster mice,.,"The protein feo of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,Lung
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fepD,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,C3H/HeOuJ mice,.,"The protein fepD of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,psn,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein psn of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Sit1p,Candida albicans,Candida albicans,CAF2-1,BALB/c mice,.,"The protein Sit1p of Candida albicans CAF2-1 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeAB,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein YfeAB of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeABCD,Yersinia pestis,Yersinia pestis,KIM6,Swiss Webster mice,.,"The protein YfeABCD of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,Lung
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Desferriexochelin 772MS,Secreted by Mycobacterium tuberculosis,Mycobacterium tuberculosis,str. Erdman,.,.,"The compound Desferriexochelin 772MS Secreted by Mycobacterium tuberculosis str. Erdman has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine B,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine B Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine E,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine E Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine G1,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine G1 Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CaFTR1,Candida albicans,Candida albicans,.,.,.,"The protein caftr1 of Candida albicans has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,cfrA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein cfrA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,cfrB,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein cfrB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,cfrB,Campylobacter coli,Campylobacter coli,W13A,.,.,"The protein cfrB of Campylobacter coli W13A has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ctuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein ctuA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,desA1,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein desA1 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeO,Escherichia coli,Escherichia coli,Nissle 1917,.,.,"The protein efeO of Escherichia coli Nissle 1917 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeU,Escherichia coli,Escherichia coli,O157:H7,.,.,"The protein efeU of Escherichia coli O157:H7 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeU,Escherichia coli,Escherichia coli,Nissle 1917,.,.,"The protein efeU of Escherichia coli Nissle 1917 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fatA,Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The protein fata of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fatB,Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The protein fatb of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Fbp,Vibrio cholerae,Vibrio cholerae,O395,.,.,"The protein Fbp of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fec,Shigella flexneri,Shigella flexneri,2a,.,.,"The protein fec of Shigella flexneri 2a has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fecA,Escherichia coli,Escherichia coli,UT5600,.,.,"The protein fecA of Escherichia coli UT5600 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feo,Vibrio cholerae,Vibrio cholerae,O395,.,.,"The protein feo of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoA,Escherichia coli,Escherichia coli,str. K-12 substr. MC4100,.,.,"The protein feoA of Escherichia coli str. K-12 substr. MC4100 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein feoB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein feoB of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Escherichia coli,Escherichia coli,str. K-12 substr. MC4100,.,.,"The protein feoB of Escherichia coli str. K-12 substr. MC4100 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoC,Klebsiella pneumoniae,Klebsiella pneumoniae,.,.,.,"The protein feoc of Klebsiella pneumoniae has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuA,Escherichia coli,Escherichia coli,K-12,.,.,"The protein fhuA of Escherichia coli K-12 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuB,Escherichia coli,Escherichia coli,DH5[alpha],.,.,"The protein fhuB of Escherichia coli DH5[alpha] has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuC,Escherichia coli,Escherichia coli,AB2847,.,.,"The protein fhuC of Escherichia coli AB2847 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCBG,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein FhuCBG of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCDB,Streptococcus agalactiae,Streptococcus agalactiae,A909,.,.,"The protein FhuCDB of Streptococcus agalactiae A909 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCDB,Haemophilus influenzae,Haemophilus influenzae,R2866,.,.,"The protein FhuCDB of Haemophilus influenzae R2866 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuD,Escherichia coli,Escherichia coli,BL21(DE3),.,.,"The protein fhuD of Escherichia coli BL21(DE3) has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuD1,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein fhuD1 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhud2,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein fhud2 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhud2,Staphylococcus aureus,Staphylococcus aureus,RN2564,.,.,"The protein fhud2 of Staphylococcus aureus RN2564 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futA1,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futa1 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futA2,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futa2 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futB,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futb of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fyuA,Yersinia enterocolitica,Yersinia enterocolitica,WA-C,.,.,"The protein fyuA of Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,GAPDH,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein GAPDH of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,HtsABC,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein HtsABC of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,IroA,Escherichia coli,Escherichia coli,CFT073,.,.,"The protein IroA of Escherichia coli CFT073 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,iroN,Escherichia coli,Escherichia coli,O18:H7,.,.,"The protein iroN of Escherichia coli O18:H7 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,IrtAB,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Rv,.,.,"The protein IrtAB of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein isdA of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,BB,.,.,"The protein isdA of Staphylococcus aureus BB has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,N100,.,.,"The protein isdA of Staphylococcus aureus N100 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,lbpA,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein lbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,lbpA,Neisseria gonorrhoeae,Neisseria gonorrhoeae,FA19,.,.,"The protein lbpA of Neisseria gonorrhoeae FA19 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,lbpB,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein lbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,MntABC,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus NCTC 8325,.,.,"The protein MntABC of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,p19,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv0641,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein Rv0641 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv0704,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein Rv0704 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv1872c,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein Rv1872c of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SfaABC,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein SfaABC of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuA,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfua of Serratia marcescens has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuB,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfub of Serratia marcescens has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuC,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfuc of Serratia marcescens has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SirABC,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus RN4220,.,.,"The protein SirABC of Staphylococcus aureus subsp. aureus RN4220 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sitA,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein sitA of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein SitABCD of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium JF2043,.,.,"The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium JF2043 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sll1878,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein sll1878 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SstABCD,Staphylococcus aureus,Staphylococcus aureus,W,.,.,"The protein SstABCD of Staphylococcus aureus W has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbp1,Neisseria meningitidis,Neisseria meningitidis,.,.,.,"The protein tbp1 of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpA,Neisseria gonorrhoeae,Neisseria gonorrhoeae,.,.,.,"The protein tbpa of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpA,Haemophilus influenzae,Haemophilus influenzae,type b,.,.,"The protein tbpA of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpA,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein tbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Neisseria gonorrhoeae,Neisseria gonorrhoeae,.,.,.,"The protein tbpb of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Neisseria meningitidis,Neisseria meningitidis,.,.,.,"The protein tbpb of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Haemophilus influenzae,Haemophilus influenzae,type b,.,.,"The protein tbpB of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein tbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tonB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The protein tonB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tonB,Pseudomonas aeruginosa,Pseudomonas aeruginosa,K199,.,.,"The protein tonB of Pseudomonas aeruginosa K199 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,TonB1,Pseudomonas aeruginosa,Pseudomonas aeruginosa,K1040,.,.,"The protein TonB1 of Pseudomonas aeruginosa K1040 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tonB3,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 19606,.,.,"The protein tonB3 of Acinetobacter baumannii ATCC 19606 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Tpn,Staphylococcus epidermidis,Staphylococcus epidermidis,138,.,.,"The protein tpn of Staphylococcus epidermidis 138 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Tpn,Staphylococcus epidermidis,Staphylococcus epidermidis,2,.,.,"The protein tpn of Staphylococcus epidermidis 2 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Sequestration substrate,.,Sequestration of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tuf,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein tuf of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.",.,.
DTD0199,SLC25A37,Co-transporter,.,Co-transport of human SLC25A37 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeABCD,Yersinia pestis,Yersinia pestis,KIM5-2031.11+,.,.,"The protein YfeABCD of Yersinia pestis KIM5-2031.11+ has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0231,SLC26A3,Up regulating,Diarrhea,Up regulating of SLC26A3 expression in diarrhea condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Lactobacillus acidophilus,Lactobacillus acidophilus,Lactobacillus acidophilus,ATCC 4357,C57BL/6J mice,Human colon adenocarcinoma cells (Caco-2),The Lactobacillus acidophilus ATCC 4357 has been reported to increase the expression of the drug transporter SLC26A3.,.,Colon
DTD0231,SLC26A3,Up regulating,Type 2 diabetes mellitus,Up regulating of SLC26A3 expression in type 2 diabetes mellitus condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Lactobacillus casei,Lacticaseibacillus casei,Lacticaseibacillus casei,str. Zhang,Sprague-Dawley rats,.,The Lacticaseibacillus casei str. Zhang has been reported to increase the expression of the drug transporter SLC26A3.,.,Kidney
DTD0231,SLC26A3,Down regulating,Fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli,Down regulating of SLC26A3 expression in fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,C57BL/6 microflora,Host unspecified microbiota,Host unspecified microbiota,.,FVB/N mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC26A3.,.,Colon
DTD0231,SLC26A3,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC26A3 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Swiss Webster germ-free mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC26A3.,.,Colon
DTD0231,SLC26A3,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC26A3 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Swiss Webster germ-free mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC26A3.,.,Ileum
DTD0231,SLC26A3,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC26A3 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Unspecified Gut microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Swiss Webster germ-free mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC26A3.,.,Ileum/colon
DTD0231,SLC26A3,Up regulating,.,Up regulating of SLC26A3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Butyrate,Dietary food metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,Human colon adenocarcinoma cells (LS174T),The metabolite butyrate generated from the metabolism of dietary food by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC26A3.,.,Colon
DTD0234,SLC26A6,Up regulating,Type 2 diabetes mellitus,Up regulating of SLC26A6 expression in type 2 diabetes mellitus condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Lactobacillus casei,Lacticaseibacillus casei,Lacticaseibacillus casei,str. Zhang,Sprague-Dawley rats,.,The Lacticaseibacillus casei str. Zhang has been reported to increase the expression of the drug transporter SLC26A6.,.,Kidney
DTD0234,SLC26A6,Down regulating,Urinary stone disease,Down regulating of SLC26A6 expression in urinary stone disease condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6N mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC26A6.,.,Kidney
DTD0234,SLC26A6,Down regulating,Urinary stone disease,Down regulating of SLC26A6 expression in urinary stone disease condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6N mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC26A6.,.,Colon
DTD0234,SLC26A6,Up regulating,Urinary stone disease,Up regulating of SLC26A6 expression in urinary stone disease condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6N mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC26A6.,.,Caecum
DTD0238,SLC27A1,Down regulating,Pregnancy,Down regulating of SLC27A1 expression in pregnancy condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Bifidobacterium breve UCC2003,Bifidobacterium breve,Bifidobacterium breve,UCC2003,C57BL/6J germ-free mice,.,The Bifidobacterium breve UCC2003 has been reported to decrease the expression of the drug transporter SLC27A1.,.,Placenta
DTD0240,SLC27A3,Down regulating,Mastitis,Down regulating of SLC27A3 expression in mastitis condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Lipopolysaccharide,Generated by Escherichia coli,Escherichia coli,O111:B4,ICR mice,.,The compound Lipopolysaccharide Generated by Escherichia coli O111:B4 has been reported to decrease the expression of the drug transporter SLC27A3.,.,Breast
DTD0241,SLC27A4,Up regulating,Pregnancy,Up regulating of SLC27A4 expression in pregnancy condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Bifidobacterium breve UCC2003,Bifidobacterium breve,Bifidobacterium breve,UCC2003,C57BL/6J germ-free mice,.,The Bifidobacterium breve UCC2003 has been reported to increase the expression of the drug transporter SLC27A4.,.,Placenta
DTD0244,SLC28A1,Co-transporter,.,Co-transport of human SLC28A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,nupC,Escherichia coli,Escherichia coli,HB101,.,.,"The protein nupC of Escherichia coli HB101 has been reported to transport similar substrates/drugs of SLC28A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0244,SLC28A1,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC28A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC28A1.,.,Ileum
DTD0244,SLC28A1,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC28A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC28A1.,.,Jejunum
DTD0245,SLC28A2,Co-transporter,.,Co-transport of human SLC28A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,nupC,Escherichia coli,Escherichia coli,HB101,.,.,"The protein nupC of Escherichia coli HB101 has been reported to transport similar substrates/drugs of SLC28A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0245,SLC28A2,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC28A2 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC28A2.,.,Ileum
DTD0245,SLC28A2,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC28A2 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC28A2.,.,Large intestine
DTD0245,SLC28A2,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC28A2 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 germ-free/conventionally-raised mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC28A2.,.,Duodenum
DTD0246,SLC28A3,Co-transporter,.,Co-transport of human SLC28A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,nupC,Escherichia coli,Escherichia coli,HB101,.,.,"The protein nupC of Escherichia coli HB101 has been reported to transport similar substrates/drugs of SLC28A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0247,SLC29A1,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC29A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J germ-free mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC29A1.,.,Liver
DTD0250,SLC29A4,Co-transporter,.,Co-transport of human SLC29A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,PMAT-like transport,Ligilactobacillus salivarius,Ligilactobacillus salivarius,DSM 20555 = ATCC 11741,.,.,"The protein PMAT-like transport of Ligilactobacillus salivarius DSM 20555 = ATCC 11741 has been reported to transport similar substrates/drugs of SLC29A4, which affects the distribution of its substrate/drug in vivo.",Cationic drugs; Endogenous amines,.
DTD0250,SLC29A4,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC29A4 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC29A4.,.,Jejunum
DTD0251,SLC2A1,Co-transporter,.,Co-transport of human SLC2A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,VIN7_1225,Saccharomyces cerevisiae,Saccharomyces cerevisiae,.,.,.,"The protein vin7_1225 of Saccharomyces cerevisiae has been reported to transport similar substrates/drugs of SLC2A1, which affects the distribution of its substrate/drug in vivo.",Arsenite,.
DTD0251,SLC2A1,Co-transporter,.,Co-transport of human SLC2A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,VIN7_3230,Saccharomyces cerevisiae,Saccharomyces cerevisiae,.,.,.,"The protein vin7_3230 of Saccharomyces cerevisiae has been reported to transport similar substrates/drugs of SLC2A1, which affects the distribution of its substrate/drug in vivo.",Arsenite,.
DTD0251,SLC2A1,Co-transporter,.,Co-transport of human SLC2A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,VIN7_5215,Saccharomyces cerevisiae,Saccharomyces cerevisiae,.,.,.,"The protein vin7_5215 of Saccharomyces cerevisiae has been reported to transport similar substrates/drugs of SLC2A1, which affects the distribution of its substrate/drug in vivo.",Arsenite,.
DTD0251,SLC2A1,Down regulating,Mastitis,Down regulating of SLC2A1 expression in mastitis condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Lipopolysaccharide,Generated by Escherichia coli,Escherichia coli,O111:B4,ICR mice,.,The compound Lipopolysaccharide Generated by Escherichia coli O111:B4 has been reported to decrease the expression of the drug transporter SLC2A1.,.,Breast
DTD0251,SLC2A1,Up regulating,Pregnancy,Up regulating of SLC2A1 expression in pregnancy condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Bifidobacterium breve UCC2003,Bifidobacterium breve,Bifidobacterium breve,UCC2003,C57BL/6J germ-free mice,.,The Bifidobacterium breve UCC2003 has been reported to increase the expression of the drug transporter SLC2A1.,.,Placenta
DTD0257,SLC2A2,Down regulating,Gastrointestinal disturbances in children with autism,Down regulating of SLC2A2 expression in gastrointestinal disturbances expression in children with autism condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Bacteroides Vulgatus isolates(down),Bacteroides Vulgatus,Bacteroides Vulgatus,.,Children with autistic disorder and GI disease,.,The Bacteroides Vulgatus has been reported to decrease the expression of the drug transporter SLC2A2.,.,Ileum
DTD0257,SLC2A2,Down regulating,Gastrointestinal disturbances in children with autism,Down regulating of SLC2A2 expression in gastrointestinal disturbances expression in children with autism condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Faecalibacterium prausnitzii isolates,Faecalibacterium prausnitzii,Faecalibacterium prausnitzii,.,Children with autistic disorder and GI disease,.,The Faecalibacterium prausnitzii has been reported to decrease the expression of the drug transporter SLC2A2.,.,Ileum
DTD0257,SLC2A2,Up regulating,.,Up regulating of SLC2A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Acetate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,Sprague-Dawley rats,.,The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC2A2.,.,Ileum
DTD0257,SLC2A2,Up regulating,.,Up regulating of SLC2A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Butyrate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,Sprague-Dawley rats,.,The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC2A2.,.,Ileum
DTD0257,SLC2A2,Up regulating,.,Up regulating of SLC2A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Propionate),Dietary food metabolite from Prevotella copri,Prevotella copri,.,Sprague-Dawley rats,.,The metabolite short-chain fatty acid (propionate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC2A2.,.,Ileum
DTD0257,SLC2A2,Up regulating,Colon cancer,Up regulating of SLC2A2 expression in colon cancer condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Butyrate,Dietary food metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Human colon adenocarcinoma cells (Caco2-BBE),The metabolite butyrate generated from the metabolism of dietary food by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC2A2.,.,Colon
DTD0257,SLC2A2,Up regulating,.,Up regulating of SLC2A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,7-Sulfocholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite 7-sulfocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC2A2.,.,Liver
DTD0257,SLC2A2,Up regulating,.,Up regulating of SLC2A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Muricholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite muricholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC2A2.,.,Liver
DTD0257,SLC2A2,Up regulating,.,Up regulating of SLC2A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Taurocholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite taurocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC2A2.,.,Liver
DTD0257,SLC2A2,Up regulating,.,Up regulating of SLC2A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Taurodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite taurodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC2A2.,.,Liver
DTD0262,SLC2A4,Co-transporter,.,Co-transport of human SLC2A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,VIN7_1225,Saccharomyces cerevisiae,Saccharomyces cerevisiae,.,.,.,"The protein vin7_1225 of Saccharomyces cerevisiae has been reported to transport similar substrates/drugs of SLC2A4, which affects the distribution of its substrate/drug in vivo.",Arsenite,.
DTD0262,SLC2A4,Co-transporter,.,Co-transport of human SLC2A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,VIN7_3230,Saccharomyces cerevisiae,Saccharomyces cerevisiae,.,.,.,"The protein vin7_3230 of Saccharomyces cerevisiae has been reported to transport similar substrates/drugs of SLC2A4, which affects the distribution of its substrate/drug in vivo.",Arsenite,.
DTD0262,SLC2A4,Co-transporter,.,Co-transport of human SLC2A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,VIN7_5215,Saccharomyces cerevisiae,Saccharomyces cerevisiae,.,.,.,"The protein vin7_5215 of Saccharomyces cerevisiae has been reported to transport similar substrates/drugs of SLC2A4, which affects the distribution of its substrate/drug in vivo.",Arsenite,.
DTD0262,SLC2A4,Up regulating,.,Up regulating of SLC2A4 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Chenodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,Mouse white adipose tissue preadipocytes cells (3T3-L1),The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC2A4.,.,Liver
DTD0267,SLC2A9,Down regulating,Hyperuricaemia,Down regulating of SLC2A9 expression in hyperuricaemia condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,ICR specific-pathogen-free mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC2A9.,.,Kidney
DTD0269,SLC30A1,Co-transporter,Acute monocytic leukemia,Co-transport of human SLC30A1 substrates/drugs in acute monocytic leukemia condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SPI-1,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. SL1344,.,Human childhood acute monocytic leukemia cells (THP-1),"The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A1, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0269,SLC30A1,Co-transporter,Health,Co-transport of human SLC30A1 substrates/drugs in health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yhiP,Escherichia coli,Escherichia coli,.,.,Human kidney human embryonic kidney 293T cells (HEK 293T),"The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A1, which affects the distribution of its substrate/drug in vivo.",.,Kidney
DTD0269,SLC30A1,Co-transporter,.,Co-transport of human SLC30A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ctpC,Mycobacterium tuberculosis,Mycobacterium tuberculosis,GC1237,.,.,"The protein ctpC of Mycobacterium tuberculosis GC1237 has been reported to transport similar substrates/drugs of SLC30A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0269,SLC30A1,Co-transporter,.,Co-transport of human SLC30A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ctpG,Mycobacterium tuberculosis,Mycobacterium tuberculosis,GC1237,.,.,"The protein ctpG of Mycobacterium tuberculosis GC1237 has been reported to transport similar substrates/drugs of SLC30A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0269,SLC30A1,Co-transporter,.,Co-transport of human SLC30A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,czcD,Streptococcus pyogenes,Streptococcus pyogenes,M1T1 5448,.,.,"The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0269,SLC30A1,Co-transporter,.,Co-transport of human SLC30A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,.,.,"The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0269,SLC30A1,Co-transporter,.,Co-transport of human SLC30A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0269,SLC30A1,Co-transporter,.,Co-transport of human SLC30A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,GR352,.,.,"The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0269,SLC30A1,Up regulating,.,Up regulating of SLC30A1 expression in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Lipopolysaccharide,Generated by the gut microbiota and Gram negative bacteria,Host unspecified microbiota,.,C57BL/6 mice,.,The compound lipopolysaccharide generated by host unspecified microbiota has been reported to increase the expression of the drug transporter SLC30A1.,.,Spleen
DTD0270,SLC30A10,Sequestration substrate,Upper and lower airway disease,Sequestration of human SLC30A10 substrates/drugs in upper and lower airway disease condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mtsB,Streptococcus equi,Streptococcus equi,subsp. equi NCTC 9682,Swiss Webster mice,.,"The protein mtsB of Streptococcus equi subsp. equi NCTC 9682 has been reported to sequester the substrate/drug of SLC30A10, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0270,SLC30A10,Co-transporter,Acute monocytic leukemia,Co-transport of human SLC30A10 substrates/drugs in acute monocytic leukemia condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SPI-1,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. SL1344,.,Human childhood acute monocytic leukemia cells (THP-1),"The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A10, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0270,SLC30A10,Sequestration substrate,Sepsis,Sequestration of human SLC30A10 substrates/drugs in sepsis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Streptococcus suis,Streptococcus suis,serotype 9,CD-1 mice,.,"The protein troA of Streptococcus suis serotype 9 has been reported to sequester the substrate/drug of SLC30A10, which may affects its substrate/drug distribution in the body.",.,Liver
DTD0270,SLC30A10,Co-transporter,Health,Co-transport of human SLC30A10 substrates/drugs in health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yhiP,Escherichia coli,Escherichia coli,.,.,Human kidney human embryonic kidney 293T cells (HEK 293T),"The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A10, which affects the distribution of its substrate/drug in vivo.",.,Kidney
DTD0270,SLC30A10,Co-transporter,.,Co-transport of human SLC30A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,czcD,Streptococcus pyogenes,Streptococcus pyogenes,M1T1 5448,.,.,"The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A10, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0270,SLC30A10,Co-transporter,.,Co-transport of human SLC30A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mnoP,Bradyrhizobium diazoefficiens,Bradyrhizobium diazoefficiens,USDA 110,.,.,"The protein mnoP of Bradyrhizobium diazoefficiens USDA 110 has been reported to transport similar substrates/drugs of SLC30A10, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0270,SLC30A10,Sequestration substrate,.,Sequestration of human SLC30A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mtsB,Streptococcus equi,Streptococcus equi,subsp. zooepidemicus NCTC 7023T,.,.,"The protein mtsB of Streptococcus equi subsp. zooepidemicus NCTC 7023T has been reported to sequester the substrate/drug of SLC30A10, which may affects its substrate/drug distribution in the body.",.,.
DTD0270,SLC30A10,Sequestration substrate,.,Sequestration of human SLC30A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC30A10, which may affects its substrate/drug distribution in the body.",.,.
DTD0270,SLC30A10,Sequestration substrate,.,Sequestration of human SLC30A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tssS,Yersinia pseudotuberculosis,Yersinia pseudotuberculosis,YPIII,.,.,"The protein tssS of Yersinia pseudotuberculosis YPIII has been reported to sequester the substrate/drug of SLC30A10, which may affects its substrate/drug distribution in the body.",.,.
DTD0270,SLC30A10,Co-transporter,.,Co-transport of human SLC30A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,.,.,"The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A10, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0270,SLC30A10,Co-transporter,.,Co-transport of human SLC30A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A10, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0270,SLC30A10,Co-transporter,.,Co-transport of human SLC30A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,GR352,.,.,"The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A10, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0271,SLC30A2,Co-transporter,Acute monocytic leukemia,Co-transport of human SLC30A2 substrates/drugs in acute monocytic leukemia condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SPI-1,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. SL1344,.,Human childhood acute monocytic leukemia cells (THP-1),"The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A2, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0271,SLC30A2,Co-transporter,Health,Co-transport of human SLC30A2 substrates/drugs in health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yhiP,Escherichia coli,Escherichia coli,.,.,Human kidney human embryonic kidney 293T cells (HEK 293T),"The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A2, which affects the distribution of its substrate/drug in vivo.",.,Kidney
DTD0271,SLC30A2,Co-transporter,.,Co-transport of human SLC30A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,czcD,Streptococcus pyogenes,Streptococcus pyogenes,M1T1 5448,.,.,"The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0271,SLC30A2,Co-transporter,.,Co-transport of human SLC30A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,.,.,"The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0271,SLC30A2,Co-transporter,.,Co-transport of human SLC30A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0271,SLC30A2,Co-transporter,.,Co-transport of human SLC30A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,GR352,.,.,"The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0272,SLC30A3,Co-transporter,Acute monocytic leukemia,Co-transport of human SLC30A3 substrates/drugs in acute monocytic leukemia condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SPI-1,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. SL1344,.,Human childhood acute monocytic leukemia cells (THP-1),"The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A3, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0272,SLC30A3,Co-transporter,Health,Co-transport of human SLC30A3 substrates/drugs in health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yhiP,Escherichia coli,Escherichia coli,.,.,Human kidney human embryonic kidney 293T cells (HEK 293T),"The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A3, which affects the distribution of its substrate/drug in vivo.",.,Kidney
DTD0272,SLC30A3,Co-transporter,.,Co-transport of human SLC30A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,czcD,Streptococcus pyogenes,Streptococcus pyogenes,M1T1 5448,.,.,"The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0272,SLC30A3,Co-transporter,.,Co-transport of human SLC30A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,.,.,"The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0272,SLC30A3,Co-transporter,.,Co-transport of human SLC30A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0272,SLC30A3,Co-transporter,.,Co-transport of human SLC30A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,GR352,.,.,"The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0273,SLC30A4,Co-transporter,Acute monocytic leukemia,Co-transport of human SLC30A4 substrates/drugs in acute monocytic leukemia condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SPI-1,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. SL1344,.,Human childhood acute monocytic leukemia cells (THP-1),"The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A4, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0273,SLC30A4,Co-transporter,Health,Co-transport of human SLC30A4 substrates/drugs in health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yhiP,Escherichia coli,Escherichia coli,.,.,Human kidney human embryonic kidney 293T cells (HEK 293T),"The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A4, which affects the distribution of its substrate/drug in vivo.",.,Kidney
DTD0273,SLC30A4,Co-transporter,.,Co-transport of human SLC30A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,czcD,Streptococcus pyogenes,Streptococcus pyogenes,M1T1 5448,.,.,"The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A4, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0273,SLC30A4,Co-transporter,.,Co-transport of human SLC30A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,.,.,"The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A4, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0273,SLC30A4,Co-transporter,.,Co-transport of human SLC30A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A4, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0273,SLC30A4,Co-transporter,.,Co-transport of human SLC30A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,GR352,.,.,"The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A4, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0273,SLC30A4,Up regulating,.,Up regulating of SLC30A4 expression in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Lipopolysaccharide,Generated by the gut microbiota and Gram negative bacteria,Host unspecified microbiota,.,C57BL/6 mice,.,The compound lipopolysaccharide generated by host unspecified microbiota has been reported to increase the expression of the drug transporter SLC30A4.,.,Spleen
DTD0274,SLC30A5,Co-transporter,Acute monocytic leukemia,Co-transport of human SLC30A5 substrates/drugs in acute monocytic leukemia condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SPI-1,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. SL1344,.,Human childhood acute monocytic leukemia cells (THP-1),"The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A5, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0274,SLC30A5,Co-transporter,Health,Co-transport of human SLC30A5 substrates/drugs in health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yhiP,Escherichia coli,Escherichia coli,.,.,Human kidney human embryonic kidney 293T cells (HEK 293T),"The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A5, which affects the distribution of its substrate/drug in vivo.",.,Kidney
DTD0274,SLC30A5,Up regulating,.,Up regulating of SLC30A5 expression in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Lipopolysaccharide,Generated by Escherichia coli,Escherichia coli,O55,CD-1 mice,.,The compound Lipopolysaccharide Generated by Escherichia coli O55 has been reported to increase the expression of the drug transporter SLC30A5.,.,Liver
DTD0274,SLC30A5,Co-transporter,.,Co-transport of human SLC30A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,czcD,Streptococcus pyogenes,Streptococcus pyogenes,M1T1 5448,.,.,"The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A5, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0274,SLC30A5,Co-transporter,.,Co-transport of human SLC30A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,.,.,"The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A5, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0274,SLC30A5,Co-transporter,.,Co-transport of human SLC30A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A5, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0274,SLC30A5,Co-transporter,.,Co-transport of human SLC30A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,GR352,.,.,"The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A5, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0275,SLC30A6,Co-transporter,Acute monocytic leukemia,Co-transport of human SLC30A6 substrates/drugs in acute monocytic leukemia condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SPI-1,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. SL1344,.,Human childhood acute monocytic leukemia cells (THP-1),"The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A6, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0275,SLC30A6,Co-transporter,Health,Co-transport of human SLC30A6 substrates/drugs in health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yhiP,Escherichia coli,Escherichia coli,.,.,Human kidney human embryonic kidney 293T cells (HEK 293T),"The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A6, which affects the distribution of its substrate/drug in vivo.",.,Kidney
DTD0275,SLC30A6,Co-transporter,.,Co-transport of human SLC30A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,czcD,Streptococcus pyogenes,Streptococcus pyogenes,M1T1 5448,.,.,"The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A6, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0275,SLC30A6,Co-transporter,.,Co-transport of human SLC30A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,.,.,"The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A6, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0275,SLC30A6,Co-transporter,.,Co-transport of human SLC30A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A6, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0275,SLC30A6,Co-transporter,.,Co-transport of human SLC30A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,GR352,.,.,"The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A6, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0275,SLC30A6,Up regulating,.,Up regulating of SLC30A6 expression in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Lipopolysaccharide,Generated by the gut microbiota and Gram negative bacteria,Host unspecified microbiota,.,C57BL/6 mice,.,The compound lipopolysaccharide generated by host unspecified microbiota has been reported to increase the expression of the drug transporter SLC30A6.,.,Spleen
DTD0276,SLC30A7,Co-transporter,Acute monocytic leukemia,Co-transport of human SLC30A7 substrates/drugs in acute monocytic leukemia condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SPI-1,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. SL1344,.,Human childhood acute monocytic leukemia cells (THP-1),"The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A7, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0276,SLC30A7,Co-transporter,Health,Co-transport of human SLC30A7 substrates/drugs in health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yhiP,Escherichia coli,Escherichia coli,.,.,Human kidney human embryonic kidney 293T cells (HEK 293T),"The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A7, which affects the distribution of its substrate/drug in vivo.",.,Kidney
DTD0276,SLC30A7,Co-transporter,.,Co-transport of human SLC30A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,czcD,Streptococcus pyogenes,Streptococcus pyogenes,M1T1 5448,.,.,"The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A7, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0276,SLC30A7,Co-transporter,.,Co-transport of human SLC30A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,.,.,"The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A7, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0276,SLC30A7,Co-transporter,.,Co-transport of human SLC30A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A7, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0276,SLC30A7,Co-transporter,.,Co-transport of human SLC30A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,GR352,.,.,"The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A7, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0035,SLC30A8,Co-transporter,Acute monocytic leukemia,Co-transport of human SLC30A8 substrates/drugs in acute monocytic leukemia condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SPI-1,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. SL1344,.,Human childhood acute monocytic leukemia cells (THP-1),"The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A8, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0035,SLC30A8,Co-transporter,Health,Co-transport of human SLC30A8 substrates/drugs in health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yhiP,Escherichia coli,Escherichia coli,.,.,Human kidney human embryonic kidney 293T cells (HEK 293T),"The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A8, which affects the distribution of its substrate/drug in vivo.",.,Kidney
DTD0035,SLC30A8,Co-transporter,.,Co-transport of human SLC30A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,czcD,Streptococcus pyogenes,Streptococcus pyogenes,M1T1 5448,.,.,"The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0035,SLC30A8,Co-transporter,.,Co-transport of human SLC30A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,.,.,"The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0035,SLC30A8,Co-transporter,.,Co-transport of human SLC30A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0035,SLC30A8,Co-transporter,.,Co-transport of human SLC30A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,GR352,.,.,"The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0277,SLC30A9,Co-transporter,Acute monocytic leukemia,Co-transport of human SLC30A9 substrates/drugs in acute monocytic leukemia condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SPI-1,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. SL1344,.,Human childhood acute monocytic leukemia cells (THP-1),"The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A9, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0277,SLC30A9,Co-transporter,Health,Co-transport of human SLC30A9 substrates/drugs in health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yhiP,Escherichia coli,Escherichia coli,.,.,Human kidney human embryonic kidney 293T cells (HEK 293T),"The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A9, which affects the distribution of its substrate/drug in vivo.",.,Kidney
DTD0277,SLC30A9,Co-transporter,.,Co-transport of human SLC30A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,czcD,Streptococcus pyogenes,Streptococcus pyogenes,M1T1 5448,.,.,"The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A9, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0277,SLC30A9,Co-transporter,.,Co-transport of human SLC30A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,.,.,"The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A9, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0277,SLC30A9,Co-transporter,.,Co-transport of human SLC30A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A9, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0277,SLC30A9,Co-transporter,.,Co-transport of human SLC30A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Escherichia coli,Escherichia coli,GR352,.,.,"The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A9, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0278,SLC31A1,Sequestration substrate,Leukemia,Sequestration of human SLC31A1 substrates/drugs in leukemia condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Methanobactin,Secreted by Yersinia pestis,Yersinia pestis,.,.,Mouse leukemia cells (RAW 264.7),"The compound methanobactin secreted by Yersinia pestis has been reported to sequester the substrate/drug of SLC31A1, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0278,SLC31A1,Sequestration substrate,.,Sequestration of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Methanobactin,Secreted by Methylosinus trichosporium,Methylosinus trichosporium,OB3b,.,.,"The compound Methanobactin Secreted by Methylosinus trichosporium OB3b has been reported to sequester the substrate/drug of SLC31A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0278,SLC31A1,Sequestration substrate,.,Sequestration of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Staphylopine,Secreted by Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The compound staphylopine secreted by Staphylococcus aureus has been reported to sequester the substrate/drug of SLC31A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0278,SLC31A1,Co-transporter,.,Co-transport of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ccoA,Cereibacter sphaeroides,Cereibacter sphaeroides,Ga,.,.,"The protein ccoA of Cereibacter sphaeroides Ga has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0278,SLC31A1,Co-transporter,.,Co-transport of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ccoA,Rhodobacter capsulatus,Rhodobacter capsulatus,MT1131,.,.,"The protein ccoA of Rhodobacter capsulatus MT1131 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0278,SLC31A1,Co-transporter,.,Co-transport of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Helicobacter pylori,Helicobacter pylori,11637,.,.,"The protein feob of Helicobacter pylori 11637 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0278,SLC31A1,Co-transporter,.,Co-transport of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fyuA,Escherichia coli,Escherichia coli,UTI89,.,.,"The protein fyuA of Escherichia coli UTI89 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0278,SLC31A1,Co-transporter,.,Co-transport of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Rv,.,.,"The protein mntH of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0278,SLC31A1,Co-transporter,.,Co-transport of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mspA,Mycolicibacterium smegmatis,Mycolicibacterium smegmatis,SMR5,.,.,"The protein mspA of Mycolicibacterium smegmatis SMR5 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0278,SLC31A1,Co-transporter,.,Co-transport of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mspB,Mycolicibacterium smegmatis,Mycolicibacterium smegmatis,SMR5,.,.,"The protein mspB of Mycolicibacterium smegmatis SMR5 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0278,SLC31A1,Co-transporter,.,Co-transport of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mspC,Mycolicibacterium smegmatis,Mycolicibacterium smegmatis,SMR5,.,.,"The protein mspC of Mycolicibacterium smegmatis SMR5 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0278,SLC31A1,Co-transporter,.,Co-transport of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mspD,Mycolicibacterium smegmatis,Mycolicibacterium smegmatis,SMR5,.,.,"The protein mspD of Mycolicibacterium smegmatis SMR5 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0278,SLC31A1,Sequestration substrate,.,Sequestration of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mymT,Mycobacterium tuberculosis,Mycobacterium tuberculosis,.,.,.,"The protein mymt of Mycobacterium tuberculosis has been reported to sequester the substrate/drug of SLC31A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0278,SLC31A1,Co-transporter,.,Co-transport of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ompF,Escherichia coli,Escherichia coli,K-12,.,.,"The protein ompF of Escherichia coli K-12 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0278,SLC31A1,Co-transporter,.,Co-transport of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,oprC,Stutzerimonas stutzeri,Stutzerimonas stutzeri,JM300,.,.,"The protein oprC of Stutzerimonas stutzeri JM300 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0278,SLC31A1,Co-transporter,.,Co-transport of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,oprC,Pseudomonas aeruginosa,Pseudomonas aeruginosa,PAO1,.,.,"The protein oprC of Pseudomonas aeruginosa PAO1 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0278,SLC31A1,Sequestration substrate,.,Sequestration of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,p19,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC31A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0278,SLC31A1,Sequestration substrate,.,Sequestration of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,smtA,Synechococcus elongatus,Synechococcus elongatus,PCC 7942,.,.,"The protein smtA of Synechococcus elongatus PCC 7942 has been reported to sequester the substrate/drug of SLC31A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0278,SLC31A1,Co-transporter,.,Co-transport of human SLC31A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ybtPQ,Escherichia coli,Escherichia coli,UTI89,.,.,"The protein ybtPQ of Escherichia coli UTI89 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0280,SLC31A2,Sequestration substrate,Leukemia,Sequestration of human SLC31A2 substrates/drugs in leukemia condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Methanobactin,Secreted by Yersinia pestis,Yersinia pestis,.,.,Mouse leukemia cells (RAW 264.7),"The compound methanobactin secreted by Yersinia pestis has been reported to sequester the substrate/drug of SLC31A2, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0280,SLC31A2,Sequestration substrate,.,Sequestration of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Methanobactin,Secreted by Methylosinus trichosporium,Methylosinus trichosporium,OB3b,.,.,"The compound Methanobactin Secreted by Methylosinus trichosporium OB3b has been reported to sequester the substrate/drug of SLC31A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0280,SLC31A2,Sequestration substrate,.,Sequestration of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Staphylopine,Secreted by Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The compound staphylopine secreted by Staphylococcus aureus has been reported to sequester the substrate/drug of SLC31A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0280,SLC31A2,Co-transporter,.,Co-transport of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ccoA,Cereibacter sphaeroides,Cereibacter sphaeroides,Ga,.,.,"The protein ccoA of Cereibacter sphaeroides Ga has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0280,SLC31A2,Co-transporter,.,Co-transport of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ccoA,Rhodobacter capsulatus,Rhodobacter capsulatus,MT1131,.,.,"The protein ccoA of Rhodobacter capsulatus MT1131 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0280,SLC31A2,Co-transporter,.,Co-transport of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Helicobacter pylori,Helicobacter pylori,11637,.,.,"The protein feob of Helicobacter pylori 11637 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0280,SLC31A2,Co-transporter,.,Co-transport of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fyuA,Escherichia coli,Escherichia coli,UTI89,.,.,"The protein fyuA of Escherichia coli UTI89 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0280,SLC31A2,Co-transporter,.,Co-transport of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mntH,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Rv,.,.,"The protein mntH of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0280,SLC31A2,Co-transporter,.,Co-transport of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mspA,Mycolicibacterium smegmatis,Mycolicibacterium smegmatis,SMR5,.,.,"The protein mspA of Mycolicibacterium smegmatis SMR5 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0280,SLC31A2,Co-transporter,.,Co-transport of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mspB,Mycolicibacterium smegmatis,Mycolicibacterium smegmatis,SMR5,.,.,"The protein mspB of Mycolicibacterium smegmatis SMR5 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0280,SLC31A2,Co-transporter,.,Co-transport of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mspC,Mycolicibacterium smegmatis,Mycolicibacterium smegmatis,SMR5,.,.,"The protein mspC of Mycolicibacterium smegmatis SMR5 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0280,SLC31A2,Co-transporter,.,Co-transport of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mspD,Mycolicibacterium smegmatis,Mycolicibacterium smegmatis,SMR5,.,.,"The protein mspD of Mycolicibacterium smegmatis SMR5 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0280,SLC31A2,Sequestration substrate,.,Sequestration of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mymT,Mycobacterium tuberculosis,Mycobacterium tuberculosis,.,.,.,"The protein mymt of Mycobacterium tuberculosis has been reported to sequester the substrate/drug of SLC31A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0280,SLC31A2,Co-transporter,.,Co-transport of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ompF,Escherichia coli,Escherichia coli,K-12,.,.,"The protein ompF of Escherichia coli K-12 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0280,SLC31A2,Co-transporter,.,Co-transport of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,oprC,Stutzerimonas stutzeri,Stutzerimonas stutzeri,JM300,.,.,"The protein oprC of Stutzerimonas stutzeri JM300 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0280,SLC31A2,Co-transporter,.,Co-transport of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,oprC,Pseudomonas aeruginosa,Pseudomonas aeruginosa,PAO1,.,.,"The protein oprC of Pseudomonas aeruginosa PAO1 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0280,SLC31A2,Sequestration substrate,.,Sequestration of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,p19,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC31A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0280,SLC31A2,Sequestration substrate,.,Sequestration of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,smtA,Synechococcus elongatus,Synechococcus elongatus,PCC 7942,.,.,"The protein smtA of Synechococcus elongatus PCC 7942 has been reported to sequester the substrate/drug of SLC31A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0280,SLC31A2,Co-transporter,.,Co-transport of human SLC31A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ybtPQ,Escherichia coli,Escherichia coli,UTI89,.,.,"The protein ybtPQ of Escherichia coli UTI89 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0298,SLC35D1,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC35D1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 germ-free/conventionally-raised mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC35D1.,.,Colon
DTD0318,SLC36A1,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC36A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 germ-free/conventionally-raised mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC36A1.,.,Jejunum
DTD0330,SLC38A3,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC38A3 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 germ-free/conventionally-raised mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC38A3.,.,Brown adipose tissue
DTD0337,SLC39A1,Sequestration substrate,Septicemic plague,Sequestration of human SLC39A1 substrates/drugs in septicemic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Yersiniabactin,Secreted by Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The compound Yersiniabactin Secreted by Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0337,SLC39A1,Sequestration substrate,Colon cancer,Sequestration of human SLC39A1 substrates/drugs in colon cancer condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,Human colon adenocarcinoma cells (Caco-2),"The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,Colon
DTD0337,SLC39A1,Sequestration substrate,Gastroenteritis,Sequestration of human SLC39A1 substrates/drugs in gastroenteritis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni 81-176,Chicken,.,"The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,Jejunum
DTD0337,SLC39A1,Co-transporter,Cholera,Co-transport of human SLC39A1 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0337,SLC39A1,Co-transporter,Septicemic plague,Co-transport of human SLC39A1 substrates/drugs in septicemic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0337,SLC39A1,Sequestration substrate,Bacterial meningitis,Sequestration of human SLC39A1 substrates/drugs in bacterial meningitis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuD,Neisseria meningitidis,Neisseria meningitidis,B16B6,C57BL/6 mice,.,"The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,Brain
DTD0337,SLC39A1,Co-transporter,Cholera,Co-transport of human SLC39A1 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZrgABCDE,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ybtX,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,Mouse leukemia cells (RAW 274.6),"The protein ybtX of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0337,SLC39A1,Sequestration substrate,.,Sequestration of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yezP,Yersinia pseudotuberculosis,Yersinia pseudotuberculosis,YPIII,C57BL/6 mice,.,"The protein yezP of Yersinia pseudotuberculosis YPIII has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0337,SLC39A1,Sequestration substrate,.,Sequestration of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zinA,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,Uterus
DTD0337,SLC39A1,Sequestration substrate,.,Sequestration of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Brucella abortus,Brucella abortus,544,BALB/c athymic Nu/Nu mice,Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa),"The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,Cervix
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,C57BL/6 mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,BALB/c mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Pasteurella multocida,Pasteurella multocida,PM25,Swiss mice,.,"The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zupT,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,C57BL/6 mice,.,"The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZurAM,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,Uterus
DTD0337,SLC39A1,Sequestration substrate,.,Sequestration of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Staphylopine,Secreted by Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The compound staphylopine secreted by Staphylococcus aureus has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcCBA,Streptococcus pneumoniae,Streptococcus pneumoniae,D39,.,.,"The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcRCBA,Streptococcus gordonii,Streptococcus gordonii,str. Challis,.,.,"The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,bmtA,Borreliella burgdorferi,Borreliella burgdorferi,297,.,.,"The protein bmta of Borreliella burgdorferi 297 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CzrA,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0337,SLC39A1,Sequestration substrate,.,Sequestration of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,PRA1,Candida albicans,Candida albicans,M134,.,.,"The protein PRA1 of Candida albicans M134 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0337,SLC39A1,Sequestration substrate,.,Sequestration of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,PZP1,Haemophilus influenzae,Haemophilus influenzae,NTHI6564,.,.,"The protein PZP1 of Haemophilus influenzae NTHI6564 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0337,SLC39A1,Sequestration substrate,.,Sequestration of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbp1,Neisseria meningitidis,Neisseria meningitidis,HB-1,.,.,"The protein tbp1 of Neisseria meningitidis HB-1 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0337,SLC39A1,Sequestration substrate,.,Sequestration of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpA,Neisseria gonorrhoeae,Neisseria gonorrhoeae,FA19,.,.,"The protein tbpA of Neisseria gonorrhoeae FA19 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0337,SLC39A1,Sequestration substrate,.,Sequestration of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tdfH,Neisseria gonorrhoeae,Neisseria gonorrhoeae,FA19,.,.,"The protein tdfH of Neisseria gonorrhoeae FA19 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0337,SLC39A1,Sequestration substrate,.,Sequestration of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0337,SLC39A1,Sequestration substrate,.,Sequestration of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,.,.,.,"The protein troa of Treponema pallidum has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0337,SLC39A1,Sequestration substrate,.,Sequestration of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ycdH,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0337,SLC39A1,Sequestration substrate,.,Sequestration of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yciC,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZitSQP,Lactococcus lactis,Lactococcus lactis,subsp. lactis Il1403,.,.,"The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0337,SLC39A1,Sequestration substrate,.,Sequestration of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,[Haemophilus] ducreyi,[Haemophilus] ducreyi,35000HP,.,.,"The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Escherichia coli,Escherichia coli,SB2847,.,.,"The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 17978,.,.,"The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfA,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfB,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfC,Aspergillus fumigatus,Aspergillus fumigatus,CEA17,.,.,"The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,.,.,.,"The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,M134,.,.,"The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0337,SLC39A1,Co-transporter,.,Co-transport of human SLC39A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT2,Candida albicans,Candida albicans,.,.,.,"The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0338,SLC39A10,Sequestration substrate,Colon cancer,Sequestration of human SLC39A10 substrates/drugs in colon cancer condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,Human colon adenocarcinoma cells (Caco-2),"The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.",.,Colon
DTD0338,SLC39A10,Sequestration substrate,Gastroenteritis,Sequestration of human SLC39A10 substrates/drugs in gastroenteritis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni 81-176,Chicken,.,"The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.",.,Jejunum
DTD0338,SLC39A10,Co-transporter,Cholera,Co-transport of human SLC39A10 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0338,SLC39A10,Co-transporter,Septicemic plague,Co-transport of human SLC39A10 substrates/drugs in septicemic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0338,SLC39A10,Sequestration substrate,Bacterial meningitis,Sequestration of human SLC39A10 substrates/drugs in bacterial meningitis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuD,Neisseria meningitidis,Neisseria meningitidis,B16B6,C57BL/6 mice,.,"The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.",.,Brain
DTD0338,SLC39A10,Co-transporter,Cholera,Co-transport of human SLC39A10 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZrgABCDE,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0338,SLC39A10,Down regulating,.,Down regulating of SLC39A10 expression in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Lipopolysaccharide,Generated by Escherichia coli,Escherichia coli,Top10,.,Human peripheral blood cells,The compound Lipopolysaccharide Generated by Escherichia coli Top10 has been reported to decrease the expression of the drug transporter SLC39A10.,.,Blood
DTD0338,SLC39A10,Sequestration substrate,.,Sequestration of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zinA,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.",.,Uterus
DTD0338,SLC39A10,Sequestration substrate,.,Sequestration of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Brucella abortus,Brucella abortus,544,BALB/c athymic Nu/Nu mice,Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa),"The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.",.,Cervix
DTD0338,SLC39A10,Co-transporter,.,Co-transport of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,C57BL/6 mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0338,SLC39A10,Co-transporter,.,Co-transport of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,BALB/c mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0338,SLC39A10,Co-transporter,.,Co-transport of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Pasteurella multocida,Pasteurella multocida,PM25,Swiss mice,.,"The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0338,SLC39A10,Co-transporter,.,Co-transport of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZurAM,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,Uterus
DTD0338,SLC39A10,Co-transporter,.,Co-transport of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcCBA,Streptococcus pneumoniae,Streptococcus pneumoniae,D39,.,.,"The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0338,SLC39A10,Co-transporter,.,Co-transport of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcRCBA,Streptococcus gordonii,Streptococcus gordonii,str. Challis,.,.,"The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0338,SLC39A10,Co-transporter,.,Co-transport of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CzrA,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0338,SLC39A10,Sequestration substrate,.,Sequestration of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.",.,.
DTD0338,SLC39A10,Sequestration substrate,.,Sequestration of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ycdH,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.",.,.
DTD0338,SLC39A10,Sequestration substrate,.,Sequestration of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yciC,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.",.,.
DTD0338,SLC39A10,Co-transporter,.,Co-transport of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZitSQP,Lactococcus lactis,Lactococcus lactis,subsp. lactis Il1403,.,.,"The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0338,SLC39A10,Sequestration substrate,.,Sequestration of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,[Haemophilus] ducreyi,[Haemophilus] ducreyi,35000HP,.,.,"The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.",.,.
DTD0338,SLC39A10,Co-transporter,.,Co-transport of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Escherichia coli,Escherichia coli,SB2847,.,.,"The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0338,SLC39A10,Co-transporter,.,Co-transport of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 17978,.,.,"The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0338,SLC39A10,Co-transporter,.,Co-transport of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfA,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0338,SLC39A10,Co-transporter,.,Co-transport of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfB,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0338,SLC39A10,Co-transporter,.,Co-transport of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfC,Aspergillus fumigatus,Aspergillus fumigatus,CEA17,.,.,"The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0338,SLC39A10,Co-transporter,.,Co-transport of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,.,.,.,"The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0338,SLC39A10,Co-transporter,.,Co-transport of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,M134,.,.,"The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0338,SLC39A10,Co-transporter,.,Co-transport of human SLC39A10 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT2,Candida albicans,Candida albicans,.,.,.,"The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0338,SLC39A10,Down regulating,.,Down regulating of SLC39A10 expression in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Lipopolysaccharide,Generated by the gut microbiota and Gram negative bacteria,Host unspecified microbiota,.,C57BL/6 mice,.,The compound lipopolysaccharide generated by host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC39A10.,.,Spleen
DTD0339,SLC39A11,Sequestration substrate,Colon cancer,Sequestration of human SLC39A11 substrates/drugs in colon cancer condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,Human colon adenocarcinoma cells (Caco-2),"The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.",.,Colon
DTD0339,SLC39A11,Sequestration substrate,Gastroenteritis,Sequestration of human SLC39A11 substrates/drugs in gastroenteritis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni 81-176,Chicken,.,"The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.",.,Jejunum
DTD0339,SLC39A11,Co-transporter,Cholera,Co-transport of human SLC39A11 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0339,SLC39A11,Co-transporter,Septicemic plague,Co-transport of human SLC39A11 substrates/drugs in septicemic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0339,SLC39A11,Sequestration substrate,Bacterial meningitis,Sequestration of human SLC39A11 substrates/drugs in bacterial meningitis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuD,Neisseria meningitidis,Neisseria meningitidis,B16B6,C57BL/6 mice,.,"The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.",.,Brain
DTD0339,SLC39A11,Co-transporter,Cholera,Co-transport of human SLC39A11 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZrgABCDE,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0339,SLC39A11,Sequestration substrate,.,Sequestration of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zinA,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.",.,Uterus
DTD0339,SLC39A11,Sequestration substrate,.,Sequestration of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Brucella abortus,Brucella abortus,544,BALB/c athymic Nu/Nu mice,Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa),"The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.",.,Cervix
DTD0339,SLC39A11,Co-transporter,.,Co-transport of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,C57BL/6 mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0339,SLC39A11,Co-transporter,.,Co-transport of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,BALB/c mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0339,SLC39A11,Co-transporter,.,Co-transport of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Pasteurella multocida,Pasteurella multocida,PM25,Swiss mice,.,"The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0339,SLC39A11,Co-transporter,.,Co-transport of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZurAM,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,Uterus
DTD0339,SLC39A11,Co-transporter,.,Co-transport of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcCBA,Streptococcus pneumoniae,Streptococcus pneumoniae,D39,.,.,"The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0339,SLC39A11,Co-transporter,.,Co-transport of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcRCBA,Streptococcus gordonii,Streptococcus gordonii,str. Challis,.,.,"The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0339,SLC39A11,Co-transporter,.,Co-transport of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CzrA,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0339,SLC39A11,Sequestration substrate,.,Sequestration of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.",.,.
DTD0339,SLC39A11,Sequestration substrate,.,Sequestration of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ycdH,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.",.,.
DTD0339,SLC39A11,Sequestration substrate,.,Sequestration of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yciC,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.",.,.
DTD0339,SLC39A11,Co-transporter,.,Co-transport of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZitSQP,Lactococcus lactis,Lactococcus lactis,subsp. lactis Il1403,.,.,"The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0339,SLC39A11,Sequestration substrate,.,Sequestration of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,[Haemophilus] ducreyi,[Haemophilus] ducreyi,35000HP,.,.,"The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.",.,.
DTD0339,SLC39A11,Co-transporter,.,Co-transport of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Escherichia coli,Escherichia coli,SB2847,.,.,"The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0339,SLC39A11,Co-transporter,.,Co-transport of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 17978,.,.,"The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0339,SLC39A11,Co-transporter,.,Co-transport of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfA,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0339,SLC39A11,Co-transporter,.,Co-transport of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfB,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0339,SLC39A11,Co-transporter,.,Co-transport of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfC,Aspergillus fumigatus,Aspergillus fumigatus,CEA17,.,.,"The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0339,SLC39A11,Co-transporter,.,Co-transport of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,.,.,.,"The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0339,SLC39A11,Co-transporter,.,Co-transport of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,M134,.,.,"The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0339,SLC39A11,Co-transporter,.,Co-transport of human SLC39A11 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT2,Candida albicans,Candida albicans,.,.,.,"The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0340,SLC39A12,Sequestration substrate,Colon cancer,Sequestration of human SLC39A12 substrates/drugs in colon cancer condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,Human colon adenocarcinoma cells (Caco-2),"The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.",.,Colon
DTD0340,SLC39A12,Sequestration substrate,Gastroenteritis,Sequestration of human SLC39A12 substrates/drugs in gastroenteritis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni 81-176,Chicken,.,"The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.",.,Jejunum
DTD0340,SLC39A12,Co-transporter,Cholera,Co-transport of human SLC39A12 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0340,SLC39A12,Co-transporter,Septicemic plague,Co-transport of human SLC39A12 substrates/drugs in septicemic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0340,SLC39A12,Sequestration substrate,Bacterial meningitis,Sequestration of human SLC39A12 substrates/drugs in bacterial meningitis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuD,Neisseria meningitidis,Neisseria meningitidis,B16B6,C57BL/6 mice,.,"The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.",.,Brain
DTD0340,SLC39A12,Co-transporter,Cholera,Co-transport of human SLC39A12 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZrgABCDE,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0340,SLC39A12,Sequestration substrate,.,Sequestration of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zinA,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.",.,Uterus
DTD0340,SLC39A12,Sequestration substrate,.,Sequestration of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Brucella abortus,Brucella abortus,544,BALB/c athymic Nu/Nu mice,Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa),"The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.",.,Cervix
DTD0340,SLC39A12,Co-transporter,.,Co-transport of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,C57BL/6 mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0340,SLC39A12,Co-transporter,.,Co-transport of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,BALB/c mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0340,SLC39A12,Co-transporter,.,Co-transport of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Pasteurella multocida,Pasteurella multocida,PM25,Swiss mice,.,"The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0340,SLC39A12,Co-transporter,.,Co-transport of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZurAM,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,Uterus
DTD0340,SLC39A12,Co-transporter,.,Co-transport of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcCBA,Streptococcus pneumoniae,Streptococcus pneumoniae,D39,.,.,"The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0340,SLC39A12,Co-transporter,.,Co-transport of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcRCBA,Streptococcus gordonii,Streptococcus gordonii,str. Challis,.,.,"The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0340,SLC39A12,Co-transporter,.,Co-transport of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CzrA,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0340,SLC39A12,Sequestration substrate,.,Sequestration of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.",.,.
DTD0340,SLC39A12,Sequestration substrate,.,Sequestration of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ycdH,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.",.,.
DTD0340,SLC39A12,Sequestration substrate,.,Sequestration of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yciC,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.",.,.
DTD0340,SLC39A12,Co-transporter,.,Co-transport of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZitSQP,Lactococcus lactis,Lactococcus lactis,subsp. lactis Il1403,.,.,"The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0340,SLC39A12,Sequestration substrate,.,Sequestration of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,[Haemophilus] ducreyi,[Haemophilus] ducreyi,35000HP,.,.,"The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.",.,.
DTD0340,SLC39A12,Co-transporter,.,Co-transport of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Escherichia coli,Escherichia coli,SB2847,.,.,"The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0340,SLC39A12,Co-transporter,.,Co-transport of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 17978,.,.,"The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0340,SLC39A12,Co-transporter,.,Co-transport of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfA,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0340,SLC39A12,Co-transporter,.,Co-transport of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfB,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0340,SLC39A12,Co-transporter,.,Co-transport of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfC,Aspergillus fumigatus,Aspergillus fumigatus,CEA17,.,.,"The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0340,SLC39A12,Co-transporter,.,Co-transport of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,.,.,.,"The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0340,SLC39A12,Co-transporter,.,Co-transport of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,M134,.,.,"The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0340,SLC39A12,Co-transporter,.,Co-transport of human SLC39A12 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT2,Candida albicans,Candida albicans,.,.,.,"The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0341,SLC39A13,Sequestration substrate,Colon cancer,Sequestration of human SLC39A13 substrates/drugs in colon cancer condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,Human colon adenocarcinoma cells (Caco-2),"The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.",.,Colon
DTD0341,SLC39A13,Sequestration substrate,Gastroenteritis,Sequestration of human SLC39A13 substrates/drugs in gastroenteritis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni 81-176,Chicken,.,"The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.",.,Jejunum
DTD0341,SLC39A13,Co-transporter,Cholera,Co-transport of human SLC39A13 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0341,SLC39A13,Co-transporter,Septicemic plague,Co-transport of human SLC39A13 substrates/drugs in septicemic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0341,SLC39A13,Sequestration substrate,Bacterial meningitis,Sequestration of human SLC39A13 substrates/drugs in bacterial meningitis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuD,Neisseria meningitidis,Neisseria meningitidis,B16B6,C57BL/6 mice,.,"The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.",.,Brain
DTD0341,SLC39A13,Co-transporter,Cholera,Co-transport of human SLC39A13 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZrgABCDE,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0341,SLC39A13,Sequestration substrate,.,Sequestration of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zinA,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.",.,Uterus
DTD0341,SLC39A13,Sequestration substrate,.,Sequestration of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Brucella abortus,Brucella abortus,544,BALB/c athymic Nu/Nu mice,Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa),"The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.",.,Cervix
DTD0341,SLC39A13,Co-transporter,.,Co-transport of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,C57BL/6 mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0341,SLC39A13,Co-transporter,.,Co-transport of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,BALB/c mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0341,SLC39A13,Co-transporter,.,Co-transport of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Pasteurella multocida,Pasteurella multocida,PM25,Swiss mice,.,"The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0341,SLC39A13,Co-transporter,.,Co-transport of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZurAM,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,Uterus
DTD0341,SLC39A13,Co-transporter,.,Co-transport of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcCBA,Streptococcus pneumoniae,Streptococcus pneumoniae,D39,.,.,"The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0341,SLC39A13,Co-transporter,.,Co-transport of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcRCBA,Streptococcus gordonii,Streptococcus gordonii,str. Challis,.,.,"The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0341,SLC39A13,Co-transporter,.,Co-transport of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CzrA,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0341,SLC39A13,Sequestration substrate,.,Sequestration of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.",.,.
DTD0341,SLC39A13,Sequestration substrate,.,Sequestration of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ycdH,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.",.,.
DTD0341,SLC39A13,Sequestration substrate,.,Sequestration of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yciC,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.",.,.
DTD0341,SLC39A13,Co-transporter,.,Co-transport of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZitSQP,Lactococcus lactis,Lactococcus lactis,subsp. lactis Il1403,.,.,"The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0341,SLC39A13,Sequestration substrate,.,Sequestration of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,[Haemophilus] ducreyi,[Haemophilus] ducreyi,35000HP,.,.,"The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.",.,.
DTD0341,SLC39A13,Co-transporter,.,Co-transport of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Escherichia coli,Escherichia coli,SB2847,.,.,"The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0341,SLC39A13,Co-transporter,.,Co-transport of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 17978,.,.,"The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0341,SLC39A13,Co-transporter,.,Co-transport of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfA,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0341,SLC39A13,Co-transporter,.,Co-transport of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfB,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0341,SLC39A13,Co-transporter,.,Co-transport of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfC,Aspergillus fumigatus,Aspergillus fumigatus,CEA17,.,.,"The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0341,SLC39A13,Co-transporter,.,Co-transport of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,.,.,.,"The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0341,SLC39A13,Co-transporter,.,Co-transport of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,M134,.,.,"The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0341,SLC39A13,Co-transporter,.,Co-transport of human SLC39A13 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT2,Candida albicans,Candida albicans,.,.,.,"The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Sequestration substrate,Cystic fibrosis,Sequestration of human SLC39A14 substrates/drugs in cystic fibrosis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Pyochelin,Secreted by Pseudomonas aeruginosa,Pseudomonas aeruginosa,ATCC 15692,CD-1 mice,.,"The compound Pyochelin Secreted by Pseudomonas aeruginosa ATCC 15692 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0342,SLC39A14,Sequestration substrate,Cystic fibrosis,Sequestration of human SLC39A14 substrates/drugs in cystic fibrosis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Pyoverdine F-Iib,Secreted by Pseudomonas aeruginosa,Pseudomonas aeruginosa,ATCC 15692,CD-1 mice,.,"The compound Pyoverdine F-Iib Secreted by Pseudomonas aeruginosa ATCC 15692 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0342,SLC39A14,Sequestration substrate,Lung adenocarcinoma,Sequestration of human SLC39A14 substrates/drugs in lung adenocarcinoma condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salmochelin SX,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,KP20,.,Human lung adenocarcinoma cells (A549),"The compound Salmochelin SX Secreted by Klebsiella pneumoniae KP20 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0342,SLC39A14,Sequestration substrate,Pneumonia,Sequestration of human SLC39A14 substrates/drugs in pneumonia condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Yersiniabactin,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,ATCC 43816,C57BL/6 mice,.,"The compound Yersiniabactin Secreted by Klebsiella pneumoniae ATCC 43816 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0342,SLC39A14,Co-transporter,Pneumonic plague,Co-transport of human SLC39A14 substrates/drugs in pneumonic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feo,Yersinia pestis,Yersinia pestis,KIM6,Swiss Webster mice,.,"The protein feo of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,Lung
DTD0342,SLC39A14,Sequestration substrate,Upper and lower airway disease,Sequestration of human SLC39A14 substrates/drugs in upper and lower airway disease condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mtsB,Streptococcus equi,Streptococcus equi,subsp. equi NCTC 9682,Swiss Webster mice,.,"The protein mtsB of Streptococcus equi subsp. equi NCTC 9682 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0342,SLC39A14,Sequestration substrate,Sepsis,Sequestration of human SLC39A14 substrates/drugs in sepsis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Streptococcus suis,Streptococcus suis,serotype 9,CD-1 mice,.,"The protein troA of Streptococcus suis serotype 9 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,Liver
DTD0342,SLC39A14,Sequestration substrate,Colon cancer,Sequestration of human SLC39A14 substrates/drugs in colon cancer condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,Human colon adenocarcinoma cells (Caco-2),"The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,Colon
DTD0342,SLC39A14,Sequestration substrate,Gastroenteritis,Sequestration of human SLC39A14 substrates/drugs in gastroenteritis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni 81-176,Chicken,.,"The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,Jejunum
DTD0342,SLC39A14,Co-transporter,Cholera,Co-transport of human SLC39A14 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0342,SLC39A14,Co-transporter,Septicemic plague,Co-transport of human SLC39A14 substrates/drugs in septicemic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0342,SLC39A14,Sequestration substrate,Bacterial meningitis,Sequestration of human SLC39A14 substrates/drugs in bacterial meningitis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuD,Neisseria meningitidis,Neisseria meningitidis,B16B6,C57BL/6 mice,.,"The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,Brain
DTD0342,SLC39A14,Co-transporter,Cholera,Co-transport of human SLC39A14 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZrgABCDE,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,C3H/HeOuJ mice,.,"The compound Enterobactin Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,Intestine
DTD0342,SLC39A14,Up regulating,.,Up regulating of SLC39A14 expression in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Lipopolysaccharide,Generated by Escherichia coli,Escherichia coli,O55,CD-1 mice,.,The compound Lipopolysaccharide Generated by Escherichia coli O55 has been reported to increase the expression of the drug transporter SLC39A14.,.,Liver
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salmochelin SX,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,C3H/HeOuJ mice,.,"The compound Salmochelin SX Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,Intestine
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salmochelin SX,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,KPPR1,C57BL/6 mice,.,"The compound Salmochelin SX Secreted by Klebsiella pneumoniae KPPR1 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Yersiniabactin,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,KPPR1,C57BL/6 mice,.,"The compound Yersiniabactin Secreted by Klebsiella pneumoniae KPPR1 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fepD,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,C3H/HeOuJ mice,.,"The protein fepD of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,irp2,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein irp2 of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,psn,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein psn of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Sit1p,Candida albicans,Candida albicans,CAF2-1,BALB/c mice,.,"The protein Sit1p of Candida albicans CAF2-1 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeAB,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein YfeAB of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeABCD,Yersinia pestis,Yersinia pestis,KIM6,Swiss Webster mice,.,"The protein YfeABCD of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,Lung
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zinA,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,Uterus
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Brucella abortus,Brucella abortus,544,BALB/c athymic Nu/Nu mice,Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa),"The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,Cervix
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,C57BL/6 mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,BALB/c mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Pasteurella multocida,Pasteurella multocida,PM25,Swiss mice,.,"The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZurAM,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,Uterus
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound 2-oxoadipic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound 2-oxoadipic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound 2-oxoadipic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound 2-oxoadipic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound 2-Oxoadipic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound 2-Oxoadipic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound 2-Oxoadipic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound 3-methyl-2-oxobutanoic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound 3-methyl-2-oxobutanoic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound 3-methyl-2-oxobutanoic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound 3-methyl-2-oxobutanoic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound 3-Methyl-2-oxobutanoic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound 3-Methyl-2-oxobutanoic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound 3-Methyl-2-oxobutanoic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound 4-methyl-2-oxopentanoic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound 4-methyl-2-oxopentanoic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound 4-methyl-2-oxopentanoic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound 4-methyl-2-oxopentanoic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound 4-Methyl-2-oxopentanoic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound 4-Methyl-2-oxopentanoic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound 4-Methyl-2-oxopentanoic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Aerobactin,Secreted by Escherichia coli,Escherichia coli,LG1315,.,.,"The compound Aerobactin Secreted by Escherichia coli LG1315 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Alcaligin,Secreted by Achromobacter xylosoxidans,Achromobacter xylosoxidans,subsp. xylosoxydans KN 3-1,.,.,"The compound Alcaligin Secreted by Achromobacter xylosoxidans subsp. xylosoxydans KN 3-1 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Alcaligin,Secreted by Bordetella bronchiseptica,Bordetella bronchiseptica,B013N,.,.,"The compound Alcaligin Secreted by Bordetella bronchiseptica B013N has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Alcaligin,Secreted by Bordetella pertussis,Bordetella pertussis,UT25,.,.,"The compound Alcaligin Secreted by Bordetella pertussis UT25 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Anguibactin,Secreted by Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The compound anguibactin secreted by Vibrio anguillarum 775 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Aureochelin,Secreted by Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The compound aureochelin secreted by Staphylococcus aureus has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Carboxymycobactin,Secreted by Mycobacterium avium,Mycobacterium avium,CRl/69,.,.,"The compound Carboxymycobactin Secreted by Mycobacterium avium CRl/69 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Cepabactin,Secreted by Burkholderia cepacia,Burkholderia cepacia,ATCC 25416,.,.,"The compound Cepabactin Secreted by Burkholderia cepacia ATCC 25416 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Corynebactin,Secreted by Corynebacterium diphtheriae,Corynebacterium diphtheriae,C7 (beta),.,.,"The compound Corynebactin Secreted by Corynebacterium diphtheriae C7 (beta) has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Corynebactin,Secreted by Bacillus cereus,Bacillus cereus,ATCC 14579,.,.,"The compound Corynebactin Secreted by Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Corynebactin,Secreted by Bacillus thuringiensis,Bacillus thuringiensis,ATCC 33679,.,.,"The compound Corynebactin Secreted by Bacillus thuringiensis ATCC 33679 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Corynebactin,Secreted by Bacillus anthracis,Bacillus anthracis,str. Sterne,.,.,"The compound Corynebactin Secreted by Bacillus anthracis str. Sterne has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Desferriexochelin 772MS,Secreted by Mycobacterium tuberculosis,Mycobacterium tuberculosis,str. Erdman,.,.,"The compound Desferriexochelin 772MS Secreted by Mycobacterium tuberculosis str. Erdman has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Escherichia coli,Escherichia coli,BW25113,.,.,"The compound Enterobactin Secreted by Escherichia coli BW25113 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The compound Enterobactin Secreted by Escherichia coli str. K-12 substr. W3110 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. LT2,.,.,"The compound Enterobactin Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,298/53,.,.,"The compound Enterobactin Secreted by Klebsiella pneumoniae 298/53 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Shigella sonnei,Shigella sonnei,43-GG9,.,.,"The compound Enterobactin Secreted by Shigella sonnei 43-GG9 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Escherichia coli,Escherichia coli,9.0111,.,.,"The compound enterobactin secreted by Escherichia coli 9.0111 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Escherichia coli,Escherichia coli,AB33II,.,.,"The compound Enterobactin Secreted by Escherichia coli AB33II has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Exochelin 772SM,Secreted by Mycolicibacterium vaccae,Mycolicibacterium vaccae,R877R,.,.,"The compound Exochelin 772SM Secreted by Mycolicibacterium vaccae R877R has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine B,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine B Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine E,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine E Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine G1,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine G1 Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound indole-3-pyruvic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound indole-3-pyruvic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound indole-3-pyruvic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound indole-3-pyruvic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound Indole-3-pyruvic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound Indole-3-pyruvic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound Indole-3-pyruvic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ornibactin,Secreted by Burkholderia cepacia,Burkholderia cepacia,TVV69,.,.,"The compound Ornibactin Secreted by Burkholderia cepacia TVV69 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Petrobactin,Secreted by Bacillus cereus,Bacillus cereus,ATCC 14579,.,.,"The compound Petrobactin Secreted by Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Petrobactin,Secreted by Bacillus anthracis,Bacillus anthracis,str. Sterne,.,.,"The compound Petrobactin Secreted by Bacillus anthracis str. Sterne has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound phenylpyruvic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound phenylpyruvic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound phenylpyruvic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound phenylpyruvic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound Phenylpyruvic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound Phenylpyruvic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound Phenylpyruvic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Pyochelin,Secreted by Pseudomonas aeruginosa,Pseudomonas aeruginosa,PAO1,.,.,"The compound Pyochelin Secreted by Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Pyoverdin,Secreted by Pseudomonas aeruginosa,Pseudomonas aeruginosa,PAO1,.,.,"The compound Pyoverdin Secreted by Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Rhizoferrin,Secreted by Rhizopus microsporus,Rhizopus microsporus,.,.,.,"The compound rhizoferrin secreted by Rhizopus microsporus has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salicylic acid,Secreted by Burkholderia cepacia,Burkholderia cepacia,Pc275c,.,.,"The compound Salicylic acid Secreted by Burkholderia cepacia Pc275c has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salmochelin SX,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. LT2,.,.,"The compound Salmochelin SX Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Staphyloferrin A,Secreted by Staphylococcus aureus,Staphylococcus aureus,subsp. aureus NCTC 8325,.,.,"The compound Staphyloferrin A Secreted by Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Staphylopine,Secreted by Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The compound Staphylopine Secreted by Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Vibriobactin,Secreted by Vibrio cholerae,Vibrio cholerae,Lou15,.,.,"The compound Vibriobactin Secreted by Vibrio cholerae Lou15 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Vibriobactin,Secreted by Vibrio cholerae,Vibrio cholerae,MBG14,.,.,"The compound Vibriobactin Secreted by Vibrio cholerae MBG14 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Yersiniabactin,Secreted by Yersinia pestis,Yersinia pestis,Yreka F1+VW+P1+P+,.,.,"The compound Yersiniabactin Secreted by Yersinia pestis Yreka F1+VW+P1+P+ has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Yersiniabactin,Secreted by Yersinia enterocolitica,Yersinia enterocolitica,WA-C,.,.,"The compound Yersiniabactin Secreted by Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcCBA,Streptococcus pneumoniae,Streptococcus pneumoniae,D39,.,.,"The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcRCBA,Streptococcus gordonii,Streptococcus gordonii,str. Challis,.,.,"The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CaFTR1,Candida albicans,Candida albicans,.,.,.,"The protein caftr1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,cfrA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein cfrA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,cfrB,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein cfrB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,cfrB,Campylobacter coli,Campylobacter coli,W13A,.,.,"The protein cfrB of Campylobacter coli W13A has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ctuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein ctuA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CzrA,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,desA1,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein desA1 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeO,Escherichia coli,Escherichia coli,Nissle 1917,.,.,"The protein efeO of Escherichia coli Nissle 1917 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeU,Escherichia coli,Escherichia coli,O157:H7,.,.,"The protein efeU of Escherichia coli O157:H7 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeU,Escherichia coli,Escherichia coli,Nissle 1917,.,.,"The protein efeU of Escherichia coli Nissle 1917 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fatA,Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The protein fata of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fatB,Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The protein fatb of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Fbp,Vibrio cholerae,Vibrio cholerae,O395,.,.,"The protein Fbp of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fec,Shigella flexneri,Shigella flexneri,2a,.,.,"The protein fec of Shigella flexneri 2a has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fecA,Escherichia coli,Escherichia coli,UT5600,.,.,"The protein fecA of Escherichia coli UT5600 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feo,Vibrio cholerae,Vibrio cholerae,O395,.,.,"The protein feo of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoA,Escherichia coli,Escherichia coli,str. K-12 substr. MC4100,.,.,"The protein feoA of Escherichia coli str. K-12 substr. MC4100 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein feoB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein feoB of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Escherichia coli,Escherichia coli,str. K-12 substr. MC4100,.,.,"The protein feoB of Escherichia coli str. K-12 substr. MC4100 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoC,Klebsiella pneumoniae,Klebsiella pneumoniae,.,.,.,"The protein feoc of Klebsiella pneumoniae has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuA,Escherichia coli,Escherichia coli,K-12,.,.,"The protein fhuA of Escherichia coli K-12 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuB,Escherichia coli,Escherichia coli,DH5[alpha],.,.,"The protein fhuB of Escherichia coli DH5[alpha] has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuC,Escherichia coli,Escherichia coli,AB2847,.,.,"The protein fhuC of Escherichia coli AB2847 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCBG,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein FhuCBG of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCDB,Streptococcus agalactiae,Streptococcus agalactiae,A909,.,.,"The protein FhuCDB of Streptococcus agalactiae A909 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCDB,Haemophilus influenzae,Haemophilus influenzae,R2866,.,.,"The protein FhuCDB of Haemophilus influenzae R2866 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuD,Escherichia coli,Escherichia coli,BL21(DE3),.,.,"The protein fhuD of Escherichia coli BL21(DE3) has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuD1,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein fhuD1 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhud2,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein fhud2 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhud2,Staphylococcus aureus,Staphylococcus aureus,RN2564,.,.,"The protein fhud2 of Staphylococcus aureus RN2564 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futA1,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futa1 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futA2,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futa2 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futB,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futb of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fyuA,Yersinia enterocolitica,Yersinia enterocolitica,WA-C,.,.,"The protein fyuA of Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,GAPDH,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein GAPDH of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,HtsABC,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein HtsABC of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,IroA,Escherichia coli,Escherichia coli,CFT073,.,.,"The protein IroA of Escherichia coli CFT073 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,iroN,Escherichia coli,Escherichia coli,O18:H7,.,.,"The protein iroN of Escherichia coli O18:H7 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,IrtAB,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Rv,.,.,"The protein IrtAB of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein isdA of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,BB,.,.,"The protein isdA of Staphylococcus aureus BB has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,N100,.,.,"The protein isdA of Staphylococcus aureus N100 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,lbpA,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein lbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,lbpA,Neisseria gonorrhoeae,Neisseria gonorrhoeae,FA19,.,.,"The protein lbpA of Neisseria gonorrhoeae FA19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,lbpB,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein lbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mnoP,Bradyrhizobium diazoefficiens,Bradyrhizobium diazoefficiens,USDA 110,.,.,"The protein mnoP of Bradyrhizobium diazoefficiens USDA 110 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,MntABC,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus NCTC 8325,.,.,"The protein MntABC of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mtsB,Streptococcus equi,Streptococcus equi,subsp. zooepidemicus NCTC 7023T,.,.,"The protein mtsB of Streptococcus equi subsp. zooepidemicus NCTC 7023T has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,p19,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv0641,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein Rv0641 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv0704,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein Rv0704 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv1872c,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein Rv1872c of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SfaABC,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein SfaABC of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuA,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfua of Serratia marcescens has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuB,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfub of Serratia marcescens has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuC,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfuc of Serratia marcescens has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SirABC,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus RN4220,.,.,"The protein SirABC of Staphylococcus aureus subsp. aureus RN4220 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sitA,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein sitA of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein SitABCD of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium JF2043,.,.,"The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium JF2043 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sll1878,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein sll1878 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SstABCD,Staphylococcus aureus,Staphylococcus aureus,W,.,.,"The protein SstABCD of Staphylococcus aureus W has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbp1,Neisseria meningitidis,Neisseria meningitidis,.,.,.,"The protein tbp1 of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpA,Neisseria gonorrhoeae,Neisseria gonorrhoeae,.,.,.,"The protein tbpa of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpA,Haemophilus influenzae,Haemophilus influenzae,type b,.,.,"The protein tbpA of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpA,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein tbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Neisseria gonorrhoeae,Neisseria gonorrhoeae,.,.,.,"The protein tbpb of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Neisseria meningitidis,Neisseria meningitidis,.,.,.,"The protein tbpb of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Haemophilus influenzae,Haemophilus influenzae,type b,.,.,"The protein tbpB of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein tbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tonB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The protein tonB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tonB,Pseudomonas aeruginosa,Pseudomonas aeruginosa,K199,.,.,"The protein tonB of Pseudomonas aeruginosa K199 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,TonB1,Pseudomonas aeruginosa,Pseudomonas aeruginosa,K1040,.,.,"The protein TonB1 of Pseudomonas aeruginosa K1040 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tonB3,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 19606,.,.,"The protein tonB3 of Acinetobacter baumannii ATCC 19606 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Tpn,Staphylococcus epidermidis,Staphylococcus epidermidis,138,.,.,"The protein tpn of Staphylococcus epidermidis 138 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Tpn,Staphylococcus epidermidis,Staphylococcus epidermidis,2,.,.,"The protein tpn of Staphylococcus epidermidis 2 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tssS,Yersinia pseudotuberculosis,Yersinia pseudotuberculosis,YPIII,.,.,"The protein tssS of Yersinia pseudotuberculosis YPIII has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tuf,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein tuf of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ycdH,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yciC,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeABCD,Yersinia pestis,Yersinia pestis,KIM5-2031.11+,.,.,"The protein YfeABCD of Yersinia pestis KIM5-2031.11+ has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZitSQP,Lactococcus lactis,Lactococcus lactis,subsp. lactis Il1403,.,.,"The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Sequestration substrate,.,Sequestration of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,[Haemophilus] ducreyi,[Haemophilus] ducreyi,35000HP,.,.,"The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Escherichia coli,Escherichia coli,SB2847,.,.,"The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 17978,.,.,"The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfA,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfB,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfC,Aspergillus fumigatus,Aspergillus fumigatus,CEA17,.,.,"The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,.,.,.,"The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,M134,.,.,"The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0342,SLC39A14,Co-transporter,.,Co-transport of human SLC39A14 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT2,Candida albicans,Candida albicans,.,.,.,"The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0343,SLC39A2,Sequestration substrate,Colon cancer,Sequestration of human SLC39A2 substrates/drugs in colon cancer condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,Human colon adenocarcinoma cells (Caco-2),"The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.",.,Colon
DTD0343,SLC39A2,Sequestration substrate,Gastroenteritis,Sequestration of human SLC39A2 substrates/drugs in gastroenteritis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni 81-176,Chicken,.,"The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.",.,Jejunum
DTD0343,SLC39A2,Co-transporter,Cholera,Co-transport of human SLC39A2 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0343,SLC39A2,Co-transporter,Septicemic plague,Co-transport of human SLC39A2 substrates/drugs in septicemic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0343,SLC39A2,Sequestration substrate,Bacterial meningitis,Sequestration of human SLC39A2 substrates/drugs in bacterial meningitis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuD,Neisseria meningitidis,Neisseria meningitidis,B16B6,C57BL/6 mice,.,"The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.",.,Brain
DTD0343,SLC39A2,Co-transporter,Cholera,Co-transport of human SLC39A2 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZrgABCDE,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0343,SLC39A2,Sequestration substrate,.,Sequestration of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zinA,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.",.,Uterus
DTD0343,SLC39A2,Sequestration substrate,.,Sequestration of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Brucella abortus,Brucella abortus,544,BALB/c athymic Nu/Nu mice,Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa),"The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.",.,Cervix
DTD0343,SLC39A2,Co-transporter,.,Co-transport of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,C57BL/6 mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0343,SLC39A2,Co-transporter,.,Co-transport of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,BALB/c mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0343,SLC39A2,Co-transporter,.,Co-transport of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Pasteurella multocida,Pasteurella multocida,PM25,Swiss mice,.,"The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0343,SLC39A2,Co-transporter,.,Co-transport of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZurAM,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,Uterus
DTD0343,SLC39A2,Co-transporter,.,Co-transport of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcCBA,Streptococcus pneumoniae,Streptococcus pneumoniae,D39,.,.,"The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0343,SLC39A2,Co-transporter,.,Co-transport of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcRCBA,Streptococcus gordonii,Streptococcus gordonii,str. Challis,.,.,"The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0343,SLC39A2,Co-transporter,.,Co-transport of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CzrA,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0343,SLC39A2,Sequestration substrate,.,Sequestration of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0343,SLC39A2,Sequestration substrate,.,Sequestration of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ycdH,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0343,SLC39A2,Sequestration substrate,.,Sequestration of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yciC,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0343,SLC39A2,Co-transporter,.,Co-transport of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZitSQP,Lactococcus lactis,Lactococcus lactis,subsp. lactis Il1403,.,.,"The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0343,SLC39A2,Sequestration substrate,.,Sequestration of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,[Haemophilus] ducreyi,[Haemophilus] ducreyi,35000HP,.,.,"The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0343,SLC39A2,Co-transporter,.,Co-transport of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Escherichia coli,Escherichia coli,SB2847,.,.,"The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0343,SLC39A2,Co-transporter,.,Co-transport of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 17978,.,.,"The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0343,SLC39A2,Co-transporter,.,Co-transport of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfA,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0343,SLC39A2,Co-transporter,.,Co-transport of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfB,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0343,SLC39A2,Co-transporter,.,Co-transport of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfC,Aspergillus fumigatus,Aspergillus fumigatus,CEA17,.,.,"The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0343,SLC39A2,Co-transporter,.,Co-transport of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,.,.,.,"The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0343,SLC39A2,Co-transporter,.,Co-transport of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,M134,.,.,"The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0343,SLC39A2,Co-transporter,.,Co-transport of human SLC39A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT2,Candida albicans,Candida albicans,.,.,.,"The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0344,SLC39A3,Sequestration substrate,Colon cancer,Sequestration of human SLC39A3 substrates/drugs in colon cancer condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,Human colon adenocarcinoma cells (Caco-2),"The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.",.,Colon
DTD0344,SLC39A3,Sequestration substrate,Gastroenteritis,Sequestration of human SLC39A3 substrates/drugs in gastroenteritis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni 81-176,Chicken,.,"The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.",.,Jejunum
DTD0344,SLC39A3,Co-transporter,Cholera,Co-transport of human SLC39A3 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0344,SLC39A3,Co-transporter,Septicemic plague,Co-transport of human SLC39A3 substrates/drugs in septicemic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0344,SLC39A3,Sequestration substrate,Bacterial meningitis,Sequestration of human SLC39A3 substrates/drugs in bacterial meningitis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuD,Neisseria meningitidis,Neisseria meningitidis,B16B6,C57BL/6 mice,.,"The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.",.,Brain
DTD0344,SLC39A3,Co-transporter,Cholera,Co-transport of human SLC39A3 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZrgABCDE,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0344,SLC39A3,Sequestration substrate,.,Sequestration of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zinA,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.",.,Uterus
DTD0344,SLC39A3,Sequestration substrate,.,Sequestration of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Brucella abortus,Brucella abortus,544,BALB/c athymic Nu/Nu mice,Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa),"The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.",.,Cervix
DTD0344,SLC39A3,Co-transporter,.,Co-transport of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,C57BL/6 mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0344,SLC39A3,Co-transporter,.,Co-transport of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,BALB/c mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0344,SLC39A3,Co-transporter,.,Co-transport of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Pasteurella multocida,Pasteurella multocida,PM25,Swiss mice,.,"The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0344,SLC39A3,Co-transporter,.,Co-transport of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZurAM,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,Uterus
DTD0344,SLC39A3,Co-transporter,.,Co-transport of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcCBA,Streptococcus pneumoniae,Streptococcus pneumoniae,D39,.,.,"The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0344,SLC39A3,Co-transporter,.,Co-transport of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcRCBA,Streptococcus gordonii,Streptococcus gordonii,str. Challis,.,.,"The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0344,SLC39A3,Co-transporter,.,Co-transport of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CzrA,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0344,SLC39A3,Sequestration substrate,.,Sequestration of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.",.,.
DTD0344,SLC39A3,Sequestration substrate,.,Sequestration of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ycdH,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.",.,.
DTD0344,SLC39A3,Sequestration substrate,.,Sequestration of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yciC,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.",.,.
DTD0344,SLC39A3,Co-transporter,.,Co-transport of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZitSQP,Lactococcus lactis,Lactococcus lactis,subsp. lactis Il1403,.,.,"The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0344,SLC39A3,Sequestration substrate,.,Sequestration of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,[Haemophilus] ducreyi,[Haemophilus] ducreyi,35000HP,.,.,"The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.",.,.
DTD0344,SLC39A3,Co-transporter,.,Co-transport of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Escherichia coli,Escherichia coli,SB2847,.,.,"The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0344,SLC39A3,Co-transporter,.,Co-transport of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 17978,.,.,"The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0344,SLC39A3,Co-transporter,.,Co-transport of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfA,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0344,SLC39A3,Co-transporter,.,Co-transport of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfB,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0344,SLC39A3,Co-transporter,.,Co-transport of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfC,Aspergillus fumigatus,Aspergillus fumigatus,CEA17,.,.,"The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0344,SLC39A3,Co-transporter,.,Co-transport of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,.,.,.,"The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0344,SLC39A3,Co-transporter,.,Co-transport of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,M134,.,.,"The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0344,SLC39A3,Co-transporter,.,Co-transport of human SLC39A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT2,Candida albicans,Candida albicans,.,.,.,"The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0345,SLC39A4,Sequestration substrate,Colon cancer,Sequestration of human SLC39A4 substrates/drugs in colon cancer condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,Human colon adenocarcinoma cells (Caco-2),"The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.",.,Colon
DTD0345,SLC39A4,Sequestration substrate,Gastroenteritis,Sequestration of human SLC39A4 substrates/drugs in gastroenteritis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni 81-176,Chicken,.,"The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.",.,Jejunum
DTD0345,SLC39A4,Co-transporter,Cholera,Co-transport of human SLC39A4 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0345,SLC39A4,Co-transporter,Septicemic plague,Co-transport of human SLC39A4 substrates/drugs in septicemic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0345,SLC39A4,Sequestration substrate,Bacterial meningitis,Sequestration of human SLC39A4 substrates/drugs in bacterial meningitis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuD,Neisseria meningitidis,Neisseria meningitidis,B16B6,C57BL/6 mice,.,"The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.",.,Brain
DTD0345,SLC39A4,Co-transporter,Cholera,Co-transport of human SLC39A4 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZrgABCDE,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0345,SLC39A4,Sequestration substrate,.,Sequestration of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zinA,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.",.,Uterus
DTD0345,SLC39A4,Sequestration substrate,.,Sequestration of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Brucella abortus,Brucella abortus,544,BALB/c athymic Nu/Nu mice,Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa),"The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.",.,Cervix
DTD0345,SLC39A4,Co-transporter,.,Co-transport of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,C57BL/6 mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0345,SLC39A4,Co-transporter,.,Co-transport of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,BALB/c mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0345,SLC39A4,Co-transporter,.,Co-transport of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Pasteurella multocida,Pasteurella multocida,PM25,Swiss mice,.,"The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0345,SLC39A4,Co-transporter,.,Co-transport of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZurAM,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,Uterus
DTD0345,SLC39A4,Co-transporter,.,Co-transport of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcCBA,Streptococcus pneumoniae,Streptococcus pneumoniae,D39,.,.,"The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0345,SLC39A4,Co-transporter,.,Co-transport of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcRCBA,Streptococcus gordonii,Streptococcus gordonii,str. Challis,.,.,"The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0345,SLC39A4,Co-transporter,.,Co-transport of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CzrA,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0345,SLC39A4,Sequestration substrate,.,Sequestration of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.",.,.
DTD0345,SLC39A4,Sequestration substrate,.,Sequestration of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ycdH,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.",.,.
DTD0345,SLC39A4,Sequestration substrate,.,Sequestration of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yciC,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.",.,.
DTD0345,SLC39A4,Co-transporter,.,Co-transport of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZitSQP,Lactococcus lactis,Lactococcus lactis,subsp. lactis Il1403,.,.,"The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0345,SLC39A4,Sequestration substrate,.,Sequestration of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,[Haemophilus] ducreyi,[Haemophilus] ducreyi,35000HP,.,.,"The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.",.,.
DTD0345,SLC39A4,Co-transporter,.,Co-transport of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Escherichia coli,Escherichia coli,SB2847,.,.,"The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0345,SLC39A4,Co-transporter,.,Co-transport of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 17978,.,.,"The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0345,SLC39A4,Co-transporter,.,Co-transport of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfA,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0345,SLC39A4,Co-transporter,.,Co-transport of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfB,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0345,SLC39A4,Co-transporter,.,Co-transport of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfC,Aspergillus fumigatus,Aspergillus fumigatus,CEA17,.,.,"The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0345,SLC39A4,Co-transporter,.,Co-transport of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,.,.,.,"The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0345,SLC39A4,Co-transporter,.,Co-transport of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,M134,.,.,"The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0345,SLC39A4,Co-transporter,.,Co-transport of human SLC39A4 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT2,Candida albicans,Candida albicans,.,.,.,"The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0346,SLC39A5,Sequestration substrate,Colon cancer,Sequestration of human SLC39A5 substrates/drugs in colon cancer condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,Human colon adenocarcinoma cells (Caco-2),"The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.",.,Colon
DTD0346,SLC39A5,Sequestration substrate,Gastroenteritis,Sequestration of human SLC39A5 substrates/drugs in gastroenteritis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni 81-176,Chicken,.,"The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.",.,Jejunum
DTD0346,SLC39A5,Co-transporter,Cholera,Co-transport of human SLC39A5 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0346,SLC39A5,Co-transporter,Septicemic plague,Co-transport of human SLC39A5 substrates/drugs in septicemic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0346,SLC39A5,Sequestration substrate,Bacterial meningitis,Sequestration of human SLC39A5 substrates/drugs in bacterial meningitis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuD,Neisseria meningitidis,Neisseria meningitidis,B16B6,C57BL/6 mice,.,"The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.",.,Brain
DTD0346,SLC39A5,Co-transporter,Cholera,Co-transport of human SLC39A5 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZrgABCDE,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0346,SLC39A5,Sequestration substrate,.,Sequestration of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zinA,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.",.,Uterus
DTD0346,SLC39A5,Sequestration substrate,.,Sequestration of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Brucella abortus,Brucella abortus,544,BALB/c athymic Nu/Nu mice,Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa),"The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.",.,Cervix
DTD0346,SLC39A5,Co-transporter,.,Co-transport of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,C57BL/6 mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0346,SLC39A5,Co-transporter,.,Co-transport of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,BALB/c mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0346,SLC39A5,Co-transporter,.,Co-transport of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Pasteurella multocida,Pasteurella multocida,PM25,Swiss mice,.,"The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0346,SLC39A5,Co-transporter,.,Co-transport of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZurAM,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,Uterus
DTD0346,SLC39A5,Co-transporter,.,Co-transport of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcCBA,Streptococcus pneumoniae,Streptococcus pneumoniae,D39,.,.,"The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0346,SLC39A5,Co-transporter,.,Co-transport of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcRCBA,Streptococcus gordonii,Streptococcus gordonii,str. Challis,.,.,"The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0346,SLC39A5,Co-transporter,.,Co-transport of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CzrA,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0346,SLC39A5,Sequestration substrate,.,Sequestration of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.",.,.
DTD0346,SLC39A5,Sequestration substrate,.,Sequestration of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ycdH,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.",.,.
DTD0346,SLC39A5,Sequestration substrate,.,Sequestration of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yciC,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.",.,.
DTD0346,SLC39A5,Co-transporter,.,Co-transport of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZitSQP,Lactococcus lactis,Lactococcus lactis,subsp. lactis Il1403,.,.,"The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0346,SLC39A5,Sequestration substrate,.,Sequestration of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,[Haemophilus] ducreyi,[Haemophilus] ducreyi,35000HP,.,.,"The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.",.,.
DTD0346,SLC39A5,Co-transporter,.,Co-transport of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Escherichia coli,Escherichia coli,SB2847,.,.,"The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0346,SLC39A5,Co-transporter,.,Co-transport of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 17978,.,.,"The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0346,SLC39A5,Co-transporter,.,Co-transport of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfA,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0346,SLC39A5,Co-transporter,.,Co-transport of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfB,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0346,SLC39A5,Co-transporter,.,Co-transport of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfC,Aspergillus fumigatus,Aspergillus fumigatus,CEA17,.,.,"The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0346,SLC39A5,Co-transporter,.,Co-transport of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,.,.,.,"The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0346,SLC39A5,Co-transporter,.,Co-transport of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,M134,.,.,"The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0346,SLC39A5,Co-transporter,.,Co-transport of human SLC39A5 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT2,Candida albicans,Candida albicans,.,.,.,"The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0347,SLC39A6,Sequestration substrate,Colon cancer,Sequestration of human SLC39A6 substrates/drugs in colon cancer condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,Human colon adenocarcinoma cells (Caco-2),"The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.",.,Colon
DTD0347,SLC39A6,Sequestration substrate,Gastroenteritis,Sequestration of human SLC39A6 substrates/drugs in gastroenteritis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni 81-176,Chicken,.,"The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.",.,Jejunum
DTD0347,SLC39A6,Co-transporter,Cholera,Co-transport of human SLC39A6 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0347,SLC39A6,Co-transporter,Septicemic plague,Co-transport of human SLC39A6 substrates/drugs in septicemic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0347,SLC39A6,Sequestration substrate,Bacterial meningitis,Sequestration of human SLC39A6 substrates/drugs in bacterial meningitis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuD,Neisseria meningitidis,Neisseria meningitidis,B16B6,C57BL/6 mice,.,"The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.",.,Brain
DTD0347,SLC39A6,Co-transporter,Cholera,Co-transport of human SLC39A6 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZrgABCDE,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0347,SLC39A6,Up regulating,.,Up regulating of SLC39A6 expression in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Lipopolysaccharide,Generated by Escherichia coli,Escherichia coli,O55,CD-1 mice,.,The compound Lipopolysaccharide Generated by Escherichia coli O55 has been reported to increase the expression of the drug transporter SLC39A6.,.,Liver
DTD0347,SLC39A6,Sequestration substrate,.,Sequestration of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zinA,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.",.,Uterus
DTD0347,SLC39A6,Sequestration substrate,.,Sequestration of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Brucella abortus,Brucella abortus,544,BALB/c athymic Nu/Nu mice,Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa),"The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.",.,Cervix
DTD0347,SLC39A6,Co-transporter,.,Co-transport of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,C57BL/6 mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0347,SLC39A6,Co-transporter,.,Co-transport of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,BALB/c mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0347,SLC39A6,Co-transporter,.,Co-transport of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Pasteurella multocida,Pasteurella multocida,PM25,Swiss mice,.,"The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0347,SLC39A6,Co-transporter,.,Co-transport of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZurAM,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,Uterus
DTD0347,SLC39A6,Co-transporter,.,Co-transport of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcCBA,Streptococcus pneumoniae,Streptococcus pneumoniae,D39,.,.,"The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0347,SLC39A6,Co-transporter,.,Co-transport of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcRCBA,Streptococcus gordonii,Streptococcus gordonii,str. Challis,.,.,"The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0347,SLC39A6,Co-transporter,.,Co-transport of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CzrA,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0347,SLC39A6,Sequestration substrate,.,Sequestration of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.",.,.
DTD0347,SLC39A6,Sequestration substrate,.,Sequestration of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ycdH,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.",.,.
DTD0347,SLC39A6,Sequestration substrate,.,Sequestration of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yciC,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.",.,.
DTD0347,SLC39A6,Co-transporter,.,Co-transport of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZitSQP,Lactococcus lactis,Lactococcus lactis,subsp. lactis Il1403,.,.,"The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0347,SLC39A6,Sequestration substrate,.,Sequestration of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,[Haemophilus] ducreyi,[Haemophilus] ducreyi,35000HP,.,.,"The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.",.,.
DTD0347,SLC39A6,Co-transporter,.,Co-transport of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Escherichia coli,Escherichia coli,SB2847,.,.,"The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0347,SLC39A6,Co-transporter,.,Co-transport of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 17978,.,.,"The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0347,SLC39A6,Co-transporter,.,Co-transport of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfA,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0347,SLC39A6,Co-transporter,.,Co-transport of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfB,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0347,SLC39A6,Co-transporter,.,Co-transport of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfC,Aspergillus fumigatus,Aspergillus fumigatus,CEA17,.,.,"The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0347,SLC39A6,Co-transporter,.,Co-transport of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,.,.,.,"The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0347,SLC39A6,Co-transporter,.,Co-transport of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,M134,.,.,"The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0347,SLC39A6,Co-transporter,.,Co-transport of human SLC39A6 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT2,Candida albicans,Candida albicans,.,.,.,"The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0347,SLC39A6,Down regulating,.,Down regulating of SLC39A6 expression in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Lipopolysaccharide,Generated by the gut microbiota and Gram negative bacteria,Host unspecified microbiota,.,C57BL/6 mice,.,The compound lipopolysaccharide generated by host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC39A6.,.,Spleen
DTD0348,SLC39A7,Sequestration substrate,Colon cancer,Sequestration of human SLC39A7 substrates/drugs in colon cancer condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,Human colon adenocarcinoma cells (Caco-2),"The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.",.,Colon
DTD0348,SLC39A7,Sequestration substrate,Gastroenteritis,Sequestration of human SLC39A7 substrates/drugs in gastroenteritis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni 81-176,Chicken,.,"The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.",.,Jejunum
DTD0348,SLC39A7,Co-transporter,Cholera,Co-transport of human SLC39A7 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0348,SLC39A7,Co-transporter,Septicemic plague,Co-transport of human SLC39A7 substrates/drugs in septicemic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0348,SLC39A7,Sequestration substrate,Bacterial meningitis,Sequestration of human SLC39A7 substrates/drugs in bacterial meningitis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuD,Neisseria meningitidis,Neisseria meningitidis,B16B6,C57BL/6 mice,.,"The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.",.,Brain
DTD0348,SLC39A7,Co-transporter,Cholera,Co-transport of human SLC39A7 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZrgABCDE,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0348,SLC39A7,Sequestration substrate,.,Sequestration of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zinA,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.",.,Uterus
DTD0348,SLC39A7,Sequestration substrate,.,Sequestration of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Brucella abortus,Brucella abortus,544,BALB/c athymic Nu/Nu mice,Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa),"The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.",.,Cervix
DTD0348,SLC39A7,Co-transporter,.,Co-transport of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,C57BL/6 mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0348,SLC39A7,Co-transporter,.,Co-transport of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,BALB/c mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0348,SLC39A7,Co-transporter,.,Co-transport of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Pasteurella multocida,Pasteurella multocida,PM25,Swiss mice,.,"The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0348,SLC39A7,Co-transporter,.,Co-transport of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZurAM,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,Uterus
DTD0348,SLC39A7,Co-transporter,.,Co-transport of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcCBA,Streptococcus pneumoniae,Streptococcus pneumoniae,D39,.,.,"The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0348,SLC39A7,Co-transporter,.,Co-transport of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcRCBA,Streptococcus gordonii,Streptococcus gordonii,str. Challis,.,.,"The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0348,SLC39A7,Co-transporter,.,Co-transport of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CzrA,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0348,SLC39A7,Sequestration substrate,.,Sequestration of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.",.,.
DTD0348,SLC39A7,Sequestration substrate,.,Sequestration of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ycdH,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.",.,.
DTD0348,SLC39A7,Sequestration substrate,.,Sequestration of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yciC,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.",.,.
DTD0348,SLC39A7,Co-transporter,.,Co-transport of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZitSQP,Lactococcus lactis,Lactococcus lactis,subsp. lactis Il1403,.,.,"The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0348,SLC39A7,Sequestration substrate,.,Sequestration of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,[Haemophilus] ducreyi,[Haemophilus] ducreyi,35000HP,.,.,"The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.",.,.
DTD0348,SLC39A7,Co-transporter,.,Co-transport of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Escherichia coli,Escherichia coli,SB2847,.,.,"The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0348,SLC39A7,Co-transporter,.,Co-transport of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 17978,.,.,"The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0348,SLC39A7,Co-transporter,.,Co-transport of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfA,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0348,SLC39A7,Co-transporter,.,Co-transport of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfB,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0348,SLC39A7,Co-transporter,.,Co-transport of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfC,Aspergillus fumigatus,Aspergillus fumigatus,CEA17,.,.,"The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0348,SLC39A7,Co-transporter,.,Co-transport of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,.,.,.,"The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0348,SLC39A7,Co-transporter,.,Co-transport of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,M134,.,.,"The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0348,SLC39A7,Co-transporter,.,Co-transport of human SLC39A7 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT2,Candida albicans,Candida albicans,.,.,.,"The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Sequestration substrate,Cystic fibrosis,Sequestration of human SLC39A8 substrates/drugs in cystic fibrosis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Pyochelin,Secreted by Pseudomonas aeruginosa,Pseudomonas aeruginosa,ATCC 15692,CD-1 mice,.,"The compound Pyochelin Secreted by Pseudomonas aeruginosa ATCC 15692 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0349,SLC39A8,Sequestration substrate,Cystic fibrosis,Sequestration of human SLC39A8 substrates/drugs in cystic fibrosis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Pyoverdine F-Iib,Secreted by Pseudomonas aeruginosa,Pseudomonas aeruginosa,ATCC 15692,CD-1 mice,.,"The compound Pyoverdine F-Iib Secreted by Pseudomonas aeruginosa ATCC 15692 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0349,SLC39A8,Sequestration substrate,Lung adenocarcinoma,Sequestration of human SLC39A8 substrates/drugs in lung adenocarcinoma condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salmochelin SX,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,KP20,.,Human lung adenocarcinoma cells (A549),"The compound Salmochelin SX Secreted by Klebsiella pneumoniae KP20 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0349,SLC39A8,Sequestration substrate,Pneumonia,Sequestration of human SLC39A8 substrates/drugs in pneumonia condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Yersiniabactin,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,ATCC 43816,C57BL/6 mice,.,"The compound Yersiniabactin Secreted by Klebsiella pneumoniae ATCC 43816 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0349,SLC39A8,Co-transporter,Pneumonic plague,Co-transport of human SLC39A8 substrates/drugs in pneumonic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feo,Yersinia pestis,Yersinia pestis,KIM6,Swiss Webster mice,.,"The protein feo of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,Lung
DTD0349,SLC39A8,Sequestration substrate,Upper and lower airway disease,Sequestration of human SLC39A8 substrates/drugs in upper and lower airway disease condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mtsB,Streptococcus equi,Streptococcus equi,subsp. equi NCTC 9682,Swiss Webster mice,.,"The protein mtsB of Streptococcus equi subsp. equi NCTC 9682 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0349,SLC39A8,Sequestration substrate,Sepsis,Sequestration of human SLC39A8 substrates/drugs in sepsis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Streptococcus suis,Streptococcus suis,serotype 9,CD-1 mice,.,"The protein troA of Streptococcus suis serotype 9 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,Liver
DTD0349,SLC39A8,Sequestration substrate,Colon cancer,Sequestration of human SLC39A8 substrates/drugs in colon cancer condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,Human colon adenocarcinoma cells (Caco-2),"The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,Colon
DTD0349,SLC39A8,Sequestration substrate,Gastroenteritis,Sequestration of human SLC39A8 substrates/drugs in gastroenteritis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni 81-176,Chicken,.,"The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,Jejunum
DTD0349,SLC39A8,Co-transporter,Cholera,Co-transport of human SLC39A8 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0349,SLC39A8,Co-transporter,Septicemic plague,Co-transport of human SLC39A8 substrates/drugs in septicemic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0349,SLC39A8,Sequestration substrate,Bacterial meningitis,Sequestration of human SLC39A8 substrates/drugs in bacterial meningitis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuD,Neisseria meningitidis,Neisseria meningitidis,B16B6,C57BL/6 mice,.,"The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,Brain
DTD0349,SLC39A8,Co-transporter,Cholera,Co-transport of human SLC39A8 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZrgABCDE,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,C3H/HeOuJ mice,.,"The compound Enterobactin Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,Intestine
DTD0349,SLC39A8,Up regulating,.,Up regulating of SLC39A8 expression in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Lipopolysaccharide,Generated by Escherichia coli,Escherichia coli,O55,C57BL/6 mice,.,The compound Lipopolysaccharide Generated by Escherichia coli O55 has been reported to increase the expression of the drug transporter SLC39A8.,.,Liver
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salmochelin SX,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,C3H/HeOuJ mice,.,"The compound Salmochelin SX Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,Intestine
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salmochelin SX,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,KPPR1,C57BL/6 mice,.,"The compound Salmochelin SX Secreted by Klebsiella pneumoniae KPPR1 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Yersiniabactin,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,KPPR1,C57BL/6 mice,.,"The compound Yersiniabactin Secreted by Klebsiella pneumoniae KPPR1 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,irp2,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein irp2 of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,psn,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein psn of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeAB,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein YfeAB of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeABCD,Yersinia pestis,Yersinia pestis,KIM6,Swiss Webster mice,.,"The protein YfeABCD of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,Lung
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zinA,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,Uterus
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Brucella abortus,Brucella abortus,544,BALB/c athymic Nu/Nu mice,Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa),"The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,Cervix
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,C57BL/6 mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,BALB/c mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Pasteurella multocida,Pasteurella multocida,PM25,Swiss mice,.,"The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZurAM,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,Uterus
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound 2-oxoadipic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound 2-oxoadipic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound 2-oxoadipic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound 2-oxoadipic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound 2-Oxoadipic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound 2-Oxoadipic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,2-Oxoadipic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound 2-Oxoadipic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound 3-methyl-2-oxobutanoic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound 3-methyl-2-oxobutanoic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound 3-methyl-2-oxobutanoic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound 3-methyl-2-oxobutanoic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound 3-Methyl-2-oxobutanoic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound 3-Methyl-2-oxobutanoic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,3-Methyl-2-oxobutanoic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound 3-Methyl-2-oxobutanoic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound 4-methyl-2-oxopentanoic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound 4-methyl-2-oxopentanoic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound 4-methyl-2-oxopentanoic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound 4-methyl-2-oxopentanoic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound 4-Methyl-2-oxopentanoic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound 4-Methyl-2-oxopentanoic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,4-Methyl-2-oxopentanoic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound 4-Methyl-2-oxopentanoic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Aerobactin,Secreted by Escherichia coli,Escherichia coli,LG1315,.,.,"The compound Aerobactin Secreted by Escherichia coli LG1315 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Alcaligin,Secreted by Achromobacter xylosoxidans,Achromobacter xylosoxidans,subsp. xylosoxydans KN 3-1,.,.,"The compound Alcaligin Secreted by Achromobacter xylosoxidans subsp. xylosoxydans KN 3-1 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Alcaligin,Secreted by Bordetella bronchiseptica,Bordetella bronchiseptica,B013N,.,.,"The compound Alcaligin Secreted by Bordetella bronchiseptica B013N has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Alcaligin,Secreted by Bordetella pertussis,Bordetella pertussis,UT25,.,.,"The compound Alcaligin Secreted by Bordetella pertussis UT25 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Anguibactin,Secreted by Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The compound anguibactin secreted by Vibrio anguillarum 775 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Aureochelin,Secreted by Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The compound aureochelin secreted by Staphylococcus aureus has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Carboxymycobactin,Secreted by Mycobacterium avium,Mycobacterium avium,CRl/69,.,.,"The compound Carboxymycobactin Secreted by Mycobacterium avium CRl/69 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Cepabactin,Secreted by Burkholderia cepacia,Burkholderia cepacia,ATCC 25416,.,.,"The compound Cepabactin Secreted by Burkholderia cepacia ATCC 25416 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Corynebactin,Secreted by Corynebacterium diphtheriae,Corynebacterium diphtheriae,C7 (beta),.,.,"The compound Corynebactin Secreted by Corynebacterium diphtheriae C7 (beta) has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Corynebactin,Secreted by Bacillus cereus,Bacillus cereus,ATCC 14579,.,.,"The compound Corynebactin Secreted by Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Corynebactin,Secreted by Bacillus thuringiensis,Bacillus thuringiensis,ATCC 33679,.,.,"The compound Corynebactin Secreted by Bacillus thuringiensis ATCC 33679 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Corynebactin,Secreted by Bacillus anthracis,Bacillus anthracis,str. Sterne,.,.,"The compound Corynebactin Secreted by Bacillus anthracis str. Sterne has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Escherichia coli,Escherichia coli,BW25113,.,.,"The compound Enterobactin Secreted by Escherichia coli BW25113 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Escherichia coli,Escherichia coli,str. K-12 substr. W3110,.,.,"The compound Enterobactin Secreted by Escherichia coli str. K-12 substr. W3110 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. LT2,.,.,"The compound Enterobactin Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Klebsiella pneumoniae,Klebsiella pneumoniae,298/53,.,.,"The compound Enterobactin Secreted by Klebsiella pneumoniae 298/53 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Shigella sonnei,Shigella sonnei,43-GG9,.,.,"The compound Enterobactin Secreted by Shigella sonnei 43-GG9 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Escherichia coli,Escherichia coli,9.0111,.,.,"The compound enterobactin secreted by Escherichia coli 9.0111 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Enterobactin,Secreted by Escherichia coli,Escherichia coli,AB33II,.,.,"The compound Enterobactin Secreted by Escherichia coli AB33II has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Exochelin 772SM,Secreted by Mycolicibacterium vaccae,Mycolicibacterium vaccae,R877R,.,.,"The compound Exochelin 772SM Secreted by Mycolicibacterium vaccae R877R has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine B,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine B Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine E,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine E Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine G1,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine G1 Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound indole-3-pyruvic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound indole-3-pyruvic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound indole-3-pyruvic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound indole-3-pyruvic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound Indole-3-pyruvic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound Indole-3-pyruvic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Indole-3-pyruvic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound Indole-3-pyruvic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ornibactin,Secreted by Burkholderia cepacia,Burkholderia cepacia,TVV69,.,.,"The compound Ornibactin Secreted by Burkholderia cepacia TVV69 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Petrobactin,Secreted by Bacillus cereus,Bacillus cereus,ATCC 14579,.,.,"The compound Petrobactin Secreted by Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Petrobactin,Secreted by Bacillus anthracis,Bacillus anthracis,str. Sterne,.,.,"The compound Petrobactin Secreted by Bacillus anthracis str. Sterne has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Providencia rustigianii,Providencia rustigianii,2,.,.,"The compound phenylpyruvic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Providencia stuartii,Providencia stuartii,19,.,.,"The compound phenylpyruvic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Providencia alcalifaciens,Providencia alcalifaciens,5487,.,.,"The compound phenylpyruvic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Proteus penneri,Proteus penneri,.,.,.,"The compound phenylpyruvic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Proteus mirabilis,Proteus mirabilis,NM 12,.,.,"The compound Phenylpyruvic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Proteus vulgaris,Proteus vulgaris,Ox 19,.,.,"The compound Phenylpyruvic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Phenylpyruvic acid,Secreted by Morganella morganii,Morganella morganii,SBK3,.,.,"The compound Phenylpyruvic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Pyochelin,Secreted by Pseudomonas aeruginosa,Pseudomonas aeruginosa,PAO1,.,.,"The compound Pyochelin Secreted by Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Pyoverdin,Secreted by Pseudomonas aeruginosa,Pseudomonas aeruginosa,PAO1,.,.,"The compound Pyoverdin Secreted by Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Rhizoferrin,Secreted by Rhizopus microsporus,Rhizopus microsporus,.,.,.,"The compound rhizoferrin secreted by Rhizopus microsporus has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salicylic acid,Secreted by Burkholderia cepacia,Burkholderia cepacia,Pc275c,.,.,"The compound Salicylic acid Secreted by Burkholderia cepacia Pc275c has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Salmochelin SX,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. LT2,.,.,"The compound Salmochelin SX Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Staphyloferrin A,Secreted by Staphylococcus aureus,Staphylococcus aureus,subsp. aureus NCTC 8325,.,.,"The compound Staphyloferrin A Secreted by Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Staphylopine,Secreted by Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The compound Staphylopine Secreted by Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Vibriobactin,Secreted by Vibrio cholerae,Vibrio cholerae,Lou15,.,.,"The compound Vibriobactin Secreted by Vibrio cholerae Lou15 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Vibriobactin,Secreted by Vibrio cholerae,Vibrio cholerae,MBG14,.,.,"The compound Vibriobactin Secreted by Vibrio cholerae MBG14 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Yersiniabactin,Secreted by Yersinia pestis,Yersinia pestis,Yreka F1+VW+P1+P+,.,.,"The compound Yersiniabactin Secreted by Yersinia pestis Yreka F1+VW+P1+P+ has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Yersiniabactin,Secreted by Yersinia enterocolitica,Yersinia enterocolitica,WA-C,.,.,"The compound Yersiniabactin Secreted by Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcCBA,Streptococcus pneumoniae,Streptococcus pneumoniae,D39,.,.,"The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcRCBA,Streptococcus gordonii,Streptococcus gordonii,str. Challis,.,.,"The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CaFTR1,Candida albicans,Candida albicans,.,.,.,"The protein caftr1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CzrA,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeU,Escherichia coli,Escherichia coli,O157:H7,.,.,"The protein efeU of Escherichia coli O157:H7 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeU,Escherichia coli,Escherichia coli,Nissle 1917,.,.,"The protein efeU of Escherichia coli Nissle 1917 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fatA,Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The protein fata of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fatB,Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The protein fatb of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Fbp,Vibrio cholerae,Vibrio cholerae,O395,.,.,"The protein Fbp of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fec,Shigella flexneri,Shigella flexneri,2a,.,.,"The protein fec of Shigella flexneri 2a has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fecA,Escherichia coli,Escherichia coli,UT5600,.,.,"The protein fecA of Escherichia coli UT5600 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feo,Vibrio cholerae,Vibrio cholerae,O395,.,.,"The protein feo of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoA,Escherichia coli,Escherichia coli,str. K-12 substr. MC4100,.,.,"The protein feoA of Escherichia coli str. K-12 substr. MC4100 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein feoB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein feoB of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Escherichia coli,Escherichia coli,str. K-12 substr. MC4100,.,.,"The protein feoB of Escherichia coli str. K-12 substr. MC4100 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoC,Klebsiella pneumoniae,Klebsiella pneumoniae,.,.,.,"The protein feoc of Klebsiella pneumoniae has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuA,Escherichia coli,Escherichia coli,K-12,.,.,"The protein fhuA of Escherichia coli K-12 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuB,Escherichia coli,Escherichia coli,DH5[alpha],.,.,"The protein fhuB of Escherichia coli DH5[alpha] has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuC,Escherichia coli,Escherichia coli,AB2847,.,.,"The protein fhuC of Escherichia coli AB2847 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCBG,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein FhuCBG of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCDB,Streptococcus agalactiae,Streptococcus agalactiae,A909,.,.,"The protein FhuCDB of Streptococcus agalactiae A909 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCDB,Haemophilus influenzae,Haemophilus influenzae,R2866,.,.,"The protein FhuCDB of Haemophilus influenzae R2866 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuD,Escherichia coli,Escherichia coli,BL21(DE3),.,.,"The protein fhuD of Escherichia coli BL21(DE3) has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuD1,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein fhuD1 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhud2,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein fhud2 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhud2,Staphylococcus aureus,Staphylococcus aureus,RN2564,.,.,"The protein fhud2 of Staphylococcus aureus RN2564 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futA1,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futa1 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futA2,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futa2 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futB,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futb of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fyuA,Yersinia enterocolitica,Yersinia enterocolitica,WA-C,.,.,"The protein fyuA of Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,IroA,Escherichia coli,Escherichia coli,CFT073,.,.,"The protein IroA of Escherichia coli CFT073 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,IrtAB,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Rv,.,.,"The protein IrtAB of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mnoP,Bradyrhizobium diazoefficiens,Bradyrhizobium diazoefficiens,USDA 110,.,.,"The protein mnoP of Bradyrhizobium diazoefficiens USDA 110 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,MntABC,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus NCTC 8325,.,.,"The protein MntABC of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mtsB,Streptococcus equi,Streptococcus equi,subsp. zooepidemicus NCTC 7023T,.,.,"The protein mtsB of Streptococcus equi subsp. zooepidemicus NCTC 7023T has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,p19,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuA,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfua of Serratia marcescens has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuB,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfub of Serratia marcescens has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuC,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfuc of Serratia marcescens has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sitA,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein sitA of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein SitABCD of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium JF2043,.,.,"The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium JF2043 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sll1878,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein sll1878 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tssS,Yersinia pseudotuberculosis,Yersinia pseudotuberculosis,YPIII,.,.,"The protein tssS of Yersinia pseudotuberculosis YPIII has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ycdH,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yciC,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeABCD,Yersinia pestis,Yersinia pestis,KIM5-2031.11+,.,.,"The protein YfeABCD of Yersinia pestis KIM5-2031.11+ has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZitSQP,Lactococcus lactis,Lactococcus lactis,subsp. lactis Il1403,.,.,"The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Sequestration substrate,.,Sequestration of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,[Haemophilus] ducreyi,[Haemophilus] ducreyi,35000HP,.,.,"The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Escherichia coli,Escherichia coli,SB2847,.,.,"The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 17978,.,.,"The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfA,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfB,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfC,Aspergillus fumigatus,Aspergillus fumigatus,CEA17,.,.,"The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,.,.,.,"The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,M134,.,.,"The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0349,SLC39A8,Co-transporter,.,Co-transport of human SLC39A8 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT2,Candida albicans,Candida albicans,.,.,.,"The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0350,SLC39A9,Sequestration substrate,Colon cancer,Sequestration of human SLC39A9 substrates/drugs in colon cancer condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,Human colon adenocarcinoma cells (Caco-2),"The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.",.,Colon
DTD0350,SLC39A9,Sequestration substrate,Gastroenteritis,Sequestration of human SLC39A9 substrates/drugs in gastroenteritis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni 81-176,Chicken,.,"The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.",.,Jejunum
DTD0350,SLC39A9,Co-transporter,Cholera,Co-transport of human SLC39A9 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0350,SLC39A9,Co-transporter,Septicemic plague,Co-transport of human SLC39A9 substrates/drugs in septicemic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0350,SLC39A9,Sequestration substrate,Bacterial meningitis,Sequestration of human SLC39A9 substrates/drugs in bacterial meningitis condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuD,Neisseria meningitidis,Neisseria meningitidis,B16B6,C57BL/6 mice,.,"The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.",.,Brain
DTD0350,SLC39A9,Co-transporter,Cholera,Co-transport of human SLC39A9 substrates/drugs in cholera condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZrgABCDE,Vibrio cholerae,Vibrio cholerae,C6706,CD-1 mice,.,"The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,Small intestine
DTD0350,SLC39A9,Sequestration substrate,.,Sequestration of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zinA,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.",.,Uterus
DTD0350,SLC39A9,Sequestration substrate,.,Sequestration of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,Brucella abortus,Brucella abortus,544,BALB/c athymic Nu/Nu mice,Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa),"The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.",.,Cervix
DTD0350,SLC39A9,Co-transporter,.,Co-transport of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium IR715,C57BL/6 mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0350,SLC39A9,Co-transporter,.,Co-transport of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,BALB/c mice,.,"The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0350,SLC39A9,Co-transporter,.,Co-transport of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Pasteurella multocida,Pasteurella multocida,PM25,Swiss mice,.,"The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0350,SLC39A9,Co-transporter,.,Co-transport of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZurAM,Listeria monocytogenes,Listeria monocytogenes,EGD-e,MF1 mice,Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M),"The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,Uterus
DTD0350,SLC39A9,Co-transporter,.,Co-transport of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcCBA,Streptococcus pneumoniae,Streptococcus pneumoniae,D39,.,.,"The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0350,SLC39A9,Co-transporter,.,Co-transport of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,AdcRCBA,Streptococcus gordonii,Streptococcus gordonii,str. Challis,.,.,"The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0350,SLC39A9,Co-transporter,.,Co-transport of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CzrA,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0350,SLC39A9,Sequestration substrate,.,Sequestration of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.",.,.
DTD0350,SLC39A9,Sequestration substrate,.,Sequestration of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ycdH,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.",.,.
DTD0350,SLC39A9,Sequestration substrate,.,Sequestration of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,yciC,Bacillus subtilis,Bacillus subtilis,ZB307A,.,.,"The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.",.,.
DTD0350,SLC39A9,Co-transporter,.,Co-transport of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZitSQP,Lactococcus lactis,Lactococcus lactis,subsp. lactis Il1403,.,.,"The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0350,SLC39A9,Sequestration substrate,.,Sequestration of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,znuA,[Haemophilus] ducreyi,[Haemophilus] ducreyi,35000HP,.,.,"The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.",.,.
DTD0350,SLC39A9,Co-transporter,.,Co-transport of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Escherichia coli,Escherichia coli,SB2847,.,.,"The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0350,SLC39A9,Co-transporter,.,Co-transport of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZnuABC,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 17978,.,.,"The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0350,SLC39A9,Co-transporter,.,Co-transport of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfA,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0350,SLC39A9,Co-transporter,.,Co-transport of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfB,Aspergillus fumigatus,Aspergillus fumigatus,CETC,.,.,"The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0350,SLC39A9,Co-transporter,.,Co-transport of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,zrfC,Aspergillus fumigatus,Aspergillus fumigatus,CEA17,.,.,"The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0350,SLC39A9,Co-transporter,.,Co-transport of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,.,.,.,"The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0350,SLC39A9,Co-transporter,.,Co-transport of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT1,Candida albicans,Candida albicans,M134,.,.,"The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0350,SLC39A9,Co-transporter,.,Co-transport of human SLC39A9 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ZRT2,Candida albicans,Candida albicans,.,.,.,"The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC40A1 expression in conventional mice compared with germ-free mice,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,"1,3-Diaminopropane",Generated by Lactobacillus reuteri,Limosilactobacillus reuteri,MM4-1A,C57BL/6 germ-free mice,Human colon carcinoma cells (HCT-116),"The compound 1,3-Diaminopropane Generated by Limosilactobacillus reuteri MM4-1A has been reported to decrease the expression of the drug transporter SLC40A1.",.,Duodenum
DTD0353,SLC40A1,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC40A1 expression in conventional mice compared with germ-free mice,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,3-Hydroxypropanal,Generated by Lactobacillus reuteri,Limosilactobacillus reuteri,MM4-1A,C57BL/6 germ-free mice,Human colon carcinoma cells (HCT-116),The compound 3-Hydroxypropanal Generated by Limosilactobacillus reuteri MM4-1A has been reported to decrease the expression of the drug transporter SLC40A1.,.,Duodenum
DTD0353,SLC40A1,Co-transporter,Pneumonic plague,Co-transport of human SLC40A1 substrates/drugs in pneumonic plague condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feo,Yersinia pestis,Yersinia pestis,KIM6,Swiss Webster mice,.,"The protein feo of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,Lung
DTD0353,SLC40A1,Sequestration substrate,Upper and lower airway disease,Sequestration of human SLC40A1 substrates/drugs in upper and lower airway disease condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mtsB,Streptococcus equi,Streptococcus equi,subsp. equi NCTC 9682,Swiss Webster mice,.,"The protein mtsB of Streptococcus equi subsp. equi NCTC 9682 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fepD,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,C3H/HeOuJ mice,.,"The protein fepD of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,Intestine
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,psn,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein psn of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,Lung
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Sit1p,Candida albicans,Candida albicans,CAF2-1,BALB/c mice,.,"The protein Sit1p of Candida albicans CAF2-1 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeAB,Yersinia pestis,Yersinia pestis,KIM5,Swiss Webster mice,.,"The protein YfeAB of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,Blood
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeABCD,Yersinia pestis,Yersinia pestis,KIM6,Swiss Webster mice,.,"The protein YfeABCD of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,Lung
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Desferriexochelin 772MS,Secreted by Mycobacterium tuberculosis,Mycobacterium tuberculosis,str. Erdman,.,.,"The compound Desferriexochelin 772MS Secreted by Mycobacterium tuberculosis str. Erdman has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine B,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine B Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine E,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine E Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Ferrioxamine G1,Secreted by Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The compound Ferrioxamine G1 Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CaFTR1,Candida albicans,Candida albicans,.,.,.,"The protein caftr1 of Candida albicans has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,cfrA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein cfrA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,cfrB,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein cfrB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,cfrB,Campylobacter coli,Campylobacter coli,W13A,.,.,"The protein cfrB of Campylobacter coli W13A has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ctuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein ctuA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,desA1,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein desA1 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeO,Escherichia coli,Escherichia coli,Nissle 1917,.,.,"The protein efeO of Escherichia coli Nissle 1917 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeU,Escherichia coli,Escherichia coli,O157:H7,.,.,"The protein efeU of Escherichia coli O157:H7 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,efeU,Escherichia coli,Escherichia coli,Nissle 1917,.,.,"The protein efeU of Escherichia coli Nissle 1917 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fatA,Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The protein fata of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fatB,Vibrio anguillarum,Vibrio anguillarum,775,.,.,"The protein fatb of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Fbp,Vibrio cholerae,Vibrio cholerae,O395,.,.,"The protein Fbp of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fec,Shigella flexneri,Shigella flexneri,2a,.,.,"The protein fec of Shigella flexneri 2a has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fecA,Escherichia coli,Escherichia coli,UT5600,.,.,"The protein fecA of Escherichia coli UT5600 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feo,Vibrio cholerae,Vibrio cholerae,O395,.,.,"The protein feo of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoA,Escherichia coli,Escherichia coli,str. K-12 substr. MC4100,.,.,"The protein feoA of Escherichia coli str. K-12 substr. MC4100 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein feoB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein feoB of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Escherichia coli,Escherichia coli,str. K-12 substr. MC4100,.,.,"The protein feoB of Escherichia coli str. K-12 substr. MC4100 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein feoC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,feoC,Klebsiella pneumoniae,Klebsiella pneumoniae,.,.,.,"The protein feoc of Klebsiella pneumoniae has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuA,Escherichia coli,Escherichia coli,K-12,.,.,"The protein fhuA of Escherichia coli K-12 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuB,Escherichia coli,Escherichia coli,DH5[alpha],.,.,"The protein fhuB of Escherichia coli DH5[alpha] has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuC,Escherichia coli,Escherichia coli,AB2847,.,.,"The protein fhuC of Escherichia coli AB2847 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCBG,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein FhuCBG of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCDB,Streptococcus agalactiae,Streptococcus agalactiae,A909,.,.,"The protein FhuCDB of Streptococcus agalactiae A909 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,FhuCDB,Haemophilus influenzae,Haemophilus influenzae,R2866,.,.,"The protein FhuCDB of Haemophilus influenzae R2866 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuD,Escherichia coli,Escherichia coli,BL21(DE3),.,.,"The protein fhuD of Escherichia coli BL21(DE3) has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhuD1,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein fhuD1 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhud2,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein fhud2 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fhud2,Staphylococcus aureus,Staphylococcus aureus,RN2564,.,.,"The protein fhud2 of Staphylococcus aureus RN2564 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futA1,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futa1 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futA2,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futa2 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,futB,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein futb of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,fyuA,Yersinia enterocolitica,Yersinia enterocolitica,WA-C,.,.,"The protein fyuA of Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,GAPDH,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein GAPDH of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,HtsABC,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein HtsABC of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,IroA,Escherichia coli,Escherichia coli,CFT073,.,.,"The protein IroA of Escherichia coli CFT073 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,iroN,Escherichia coli,Escherichia coli,O18:H7,.,.,"The protein iroN of Escherichia coli O18:H7 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,IrtAB,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Rv,.,.,"The protein IrtAB of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein isdA of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,BB,.,.,"The protein isdA of Staphylococcus aureus BB has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,N100,.,.,"The protein isdA of Staphylococcus aureus N100 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,lbpA,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein lbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,lbpA,Neisseria gonorrhoeae,Neisseria gonorrhoeae,FA19,.,.,"The protein lbpA of Neisseria gonorrhoeae FA19 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,lbpB,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein lbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mnoP,Bradyrhizobium diazoefficiens,Bradyrhizobium diazoefficiens,USDA 110,.,.,"The protein mnoP of Bradyrhizobium diazoefficiens USDA 110 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,MntABC,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus NCTC 8325,.,.,"The protein MntABC of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mtsB,Streptococcus equi,Streptococcus equi,subsp. zooepidemicus NCTC 7023T,.,.,"The protein mtsB of Streptococcus equi subsp. zooepidemicus NCTC 7023T has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,p19,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv0641,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein Rv0641 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv0704,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein Rv0704 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv1872c,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein Rv1872c of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SfaABC,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein SfaABC of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuA,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfua of Serratia marcescens has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuB,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfub of Serratia marcescens has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sfuC,Serratia marcescens,Serratia marcescens,.,.,.,"The protein sfuc of Serratia marcescens has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SirABC,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus RN4220,.,.,"The protein SirABC of Staphylococcus aureus subsp. aureus RN4220 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sitA,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein sitA of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Shigella flexneri,Shigella flexneri,SA100,.,.,"The protein SitABCD of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SitABCD,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium JF2043,.,.,"The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium JF2043 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sll1878,Synechocystis sp. PCC 6803,Synechocystis,sp. PCC 6803 6803,.,.,"The protein sll1878 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,SstABCD,Staphylococcus aureus,Staphylococcus aureus,W,.,.,"The protein SstABCD of Staphylococcus aureus W has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbp1,Neisseria meningitidis,Neisseria meningitidis,.,.,.,"The protein tbp1 of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpA,Neisseria gonorrhoeae,Neisseria gonorrhoeae,.,.,.,"The protein tbpa of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpA,Haemophilus influenzae,Haemophilus influenzae,type b,.,.,"The protein tbpA of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpA,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein tbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Neisseria gonorrhoeae,Neisseria gonorrhoeae,.,.,.,"The protein tbpb of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Neisseria meningitidis,Neisseria meningitidis,.,.,.,"The protein tbpb of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Haemophilus influenzae,Haemophilus influenzae,type b,.,.,"The protein tbpB of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tbpB,Moraxella catarrhalis,Moraxella catarrhalis,.,.,.,"The protein tbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tonB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. ATCC 14028,.,.,"The protein tonB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tonB,Pseudomonas aeruginosa,Pseudomonas aeruginosa,K199,.,.,"The protein tonB of Pseudomonas aeruginosa K199 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,TonB1,Pseudomonas aeruginosa,Pseudomonas aeruginosa,K1040,.,.,"The protein TonB1 of Pseudomonas aeruginosa K1040 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tonB3,Acinetobacter baumannii,Acinetobacter baumannii,ATCC 19606,.,.,"The protein tonB3 of Acinetobacter baumannii ATCC 19606 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Tpn,Staphylococcus epidermidis,Staphylococcus epidermidis,138,.,.,"The protein tpn of Staphylococcus epidermidis 138 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Tpn,Staphylococcus epidermidis,Staphylococcus epidermidis,2,.,.,"The protein tpn of Staphylococcus epidermidis 2 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,troA,Treponema pallidum,Treponema pallidum,subsp. pallidum str. Nichols,.,.,"The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Sequestration substrate,.,Sequestration of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,tuf,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Ra,.,.,"The protein tuf of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0353,SLC40A1,Co-transporter,.,Co-transport of human SLC40A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,YfeABCD,Yersinia pestis,Yersinia pestis,KIM5-2031.11+,.,.,"The protein YfeABCD of Yersinia pestis KIM5-2031.11+ has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0353,SLC40A1,Up regulating,Anemia,Up regulating of SLC40A1 expression in anemia condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Acetate),Dietary inulin metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Yorkshire-Hampshire-Landrace hybrid pigs,.,The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC40A1.,.,Duodenum
DTD0353,SLC40A1,Up regulating,Anemia,Up regulating of SLC40A1 expression in anemia condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Butyrate),Dietary inulin metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Yorkshire-Hampshire-Landrace hybrid pigs,.,The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC40A1.,.,Duodenum
DTD0353,SLC40A1,Up regulating,Anemia,Up regulating of SLC40A1 expression in anemia condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Short-chain fatty acid (Propionate),Dietary inulin metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Yorkshire-Hampshire-Landrace hybrid pigs,.,The metabolite short-chain fatty acid (propionate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC40A1.,.,Duodenum
DTD0354,SLC41A1,Co-transporter,.,Co-transport of human SLC41A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtA,Yersinia pestis,Yersinia pestis,KIM6,.,.,"The protein mgtA of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0354,SLC41A1,Co-transporter,.,Co-transport of human SLC41A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtA,Escherichia coli,Escherichia coli,BL21(DE3),.,.,"The protein mgtA of Escherichia coli BL21(DE3) has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0354,SLC41A1,Co-transporter,.,Co-transport of human SLC41A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium TN1379,.,.,"The protein mgtA of Salmonella enterica subsp. enterica serovar Typhimurium TN1379 has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0354,SLC41A1,Co-transporter,.,Co-transport of human SLC41A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein mgtA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0354,SLC41A1,Co-transporter,.,Co-transport of human SLC41A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium TN2540,.,.,"The protein mgtA of Salmonella enterica subsp. enterica serovar Typhimurium TN2540 has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0354,SLC41A1,Co-transporter,.,Co-transport of human SLC41A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium TN1010,.,.,"The protein mgtA of Salmonella enterica subsp. enterica serovar Typhimurium TN1010 has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0354,SLC41A1,Co-transporter,.,Co-transport of human SLC41A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium TN1379,.,.,"The protein mgtB of Salmonella enterica subsp. enterica serovar Typhimurium TN1379 has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0354,SLC41A1,Co-transporter,.,Co-transport of human SLC41A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium,.,.,"The protein mgtB of Salmonella enterica subsp. enterica serovar Typhimurium has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0354,SLC41A1,Co-transporter,.,Co-transport of human SLC41A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium TN1010,.,.,"The protein mgtB of Salmonella enterica subsp. enterica serovar Typhimurium TN1010 has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0354,SLC41A1,Co-transporter,.,Co-transport of human SLC41A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,MgtBC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein MgtBC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0354,SLC41A1,Co-transporter,.,Co-transport of human SLC41A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtE,Thermus thermophilus,Thermus thermophilus,.,.,.,"The protein mgte of Thermus thermophilus has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0354,SLC41A1,Co-transporter,.,Co-transport of human SLC41A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtE,Providencia stuartii,Providencia stuartii,.,.,.,"The protein mgte of Providencia stuartii has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0354,SLC41A1,Co-transporter,.,Co-transport of human SLC41A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtE,Alkalihalophilus pseudofirmus,Alkalihalophilus pseudofirmus,OF4,.,.,"The protein mgtE of Alkalihalophilus pseudofirmus OF4 has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0355,SLC41A2,Co-transporter,.,Co-transport of human SLC41A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtE,Thermus thermophilus,Thermus thermophilus,.,.,.,"The protein mgte of Thermus thermophilus has been reported to transport similar substrates/drugs of SLC41A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0355,SLC41A2,Co-transporter,.,Co-transport of human SLC41A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtE,Providencia stuartii,Providencia stuartii,.,.,.,"The protein mgte of Providencia stuartii has been reported to transport similar substrates/drugs of SLC41A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0355,SLC41A2,Co-transporter,.,Co-transport of human SLC41A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtE,Alkalihalophilus pseudofirmus,Alkalihalophilus pseudofirmus,OF4,.,.,"The protein mgtE of Alkalihalophilus pseudofirmus OF4 has been reported to transport similar substrates/drugs of SLC41A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0356,SLC41A3,Co-transporter,.,Co-transport of human SLC41A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtE,Thermus thermophilus,Thermus thermophilus,.,.,.,"The protein mgte of Thermus thermophilus has been reported to transport similar substrates/drugs of SLC41A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0356,SLC41A3,Co-transporter,.,Co-transport of human SLC41A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtE,Providencia stuartii,Providencia stuartii,.,.,.,"The protein mgte of Providencia stuartii has been reported to transport similar substrates/drugs of SLC41A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0356,SLC41A3,Co-transporter,.,Co-transport of human SLC41A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtE,Alkalihalophilus pseudofirmus,Alkalihalophilus pseudofirmus,OF4,.,.,"The protein mgtE of Alkalihalophilus pseudofirmus OF4 has been reported to transport similar substrates/drugs of SLC41A3, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0361,SLC43A2,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC43A2 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 germ-free/conventionally-raised mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC43A2.,.,Jejunum
DTD0007,SLC47A1,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC47A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC47A1.,.,Duodenum
DTD0007,SLC47A1,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC47A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC47A1.,.,Jejunum
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,bhuA,Brucella abortus,Brucella abortus,2308,BALB/c athymic Nu/Nu mice,.,"The protein bhua of Brucella abortus 2308 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hbpA,Haemophilus influenzae,Haemophilus influenzae,86-028NP,Sprague-Dawley rats,.,"The protein hbpA of Haemophilus influenzae 86-028NP has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sbnA,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus RN4220,Swiss Webster mice,.,"The protein sbnA of Staphylococcus aureus subsp. aureus RN4220 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Delta-Hemolysin,Secreted by Vibrio cholerae,Vibrio cholerae,Q20523,.,.,"The compound Delta-Hemolysin Secreted by Vibrio cholerae Q20523 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CeuBC,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein CeuBC of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,chuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein chuA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,chuA,Escherichia coli,Escherichia coli,O157:H7 str. EDL933,.,.,"The protein chuA of Escherichia coli O157:H7 str. EDL933 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Co-transporter,.,Co-transport of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ChuABCD,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein ChuABCD of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC48A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hasA,Serratia marcescens,Serratia marcescens,SM365,.,.,"The protein hasA of Serratia marcescens SM365 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hbp,Escherichia coli,Escherichia coli,EB1 (O8-K43),.,.,"The protein hbp of Escherichia coli EB1 (O8-K43) has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hhuA,Haemophilus influenzae,Haemophilus influenzae,TN106,.,.,"The protein hhuA of Haemophilus influenzae TN106 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hitA,Haemophilus influenzae,Haemophilus influenzae,TN106,.,.,"The protein hitA of Haemophilus influenzae TN106 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Co-transporter,.,Co-transport of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hitB,Haemophilus influenzae,Haemophilus influenzae,TN106,.,.,"The protein hitB of Haemophilus influenzae TN106 has been reported to transport similar substrates/drugs of SLC48A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0375,SLC48A1,Co-transporter,.,Co-transport of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hitC,Haemophilus influenzae,Haemophilus influenzae,TN106,.,.,"The protein hitC of Haemophilus influenzae TN106 has been reported to transport similar substrates/drugs of SLC48A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hmbR,Neisseria meningitidis,Neisseria meningitidis,IR1072,.,.,"The protein hmbR of Neisseria meningitidis IR1072 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hpuB,Neisseria meningitidis,Neisseria meningitidis,FAM18,.,.,"The protein hpuB of Neisseria meningitidis FAM18 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,htaA,Corynebacterium diphtheriae,Corynebacterium diphtheriae,1737,.,.,"The protein htaa of Corynebacterium diphtheriae 1737 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,htaB,Corynebacterium diphtheriae,Corynebacterium diphtheriae,1737,.,.,"The protein htab of Corynebacterium diphtheriae 1737 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hutA,Vibrio cholerae,Vibrio cholerae,O395,.,.,"The protein hutA of Vibrio cholerae O395 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hutA,Bartonella quintana,Bartonella quintana,JK 31,.,.,"The protein hutA of Bartonella quintana JK 31 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hxuC,Haemophilus influenzae,Haemophilus influenzae,type b DL42,.,.,"The protein hxuC of Haemophilus influenzae type b DL42 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ilsA,Bacillus cereus,Bacillus cereus,ATCC 14579,.,.,"The protein ilsA of Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein isdA of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdB,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus str. Newman,.,.,"The protein isdB of Staphylococcus aureus subsp. aureus str. Newman has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdC,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein isdc of Staphylococcus aureus has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,IsdDEF,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein IsdDEF of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdG,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein isdG of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdG,Staphylococcus lugdunensis,Staphylococcus lugdunensis,N920143,.,.,"The protein isdG of Staphylococcus lugdunensis N920143 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdH,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus NCTC 8325,.,.,"The protein isdH of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdH,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein isdh of Staphylococcus aureus has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdI,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein isdI of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Co-transporter,.,Co-transport of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdX1,Bacillus anthracis,Bacillus anthracis,str. Sterne,.,.,"The protein isdX1 of Bacillus anthracis str. Sterne has been reported to transport similar substrates/drugs of SLC48A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0375,SLC48A1,Co-transporter,.,Co-transport of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdX2,Bacillus anthracis,Bacillus anthracis,str. Sterne,.,.,"The protein isdX2 of Bacillus anthracis str. Sterne has been reported to transport similar substrates/drugs of SLC48A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mhuD,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Rv,.,.,"The protein mhuD of Mycobacterium tuberculosis H37Rv has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv0203,Mycobacterium tuberculosis,Mycobacterium tuberculosis,.,.,.,"The protein rv0203 of Mycobacterium tuberculosis has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0375,SLC48A1,Sequestration substrate,.,Sequestration of human SLC48A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,shr,Streptococcus pyogenes,Streptococcus pyogenes,JRS4,.,.,"The protein shr of Streptococcus pyogenes JRS4 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,bhuA,Brucella abortus,Brucella abortus,2308,BALB/c athymic Nu/Nu mice,.,"The protein bhua of Brucella abortus 2308 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hbpA,Haemophilus influenzae,Haemophilus influenzae,86-028NP,Sprague-Dawley rats,.,"The protein hbpA of Haemophilus influenzae 86-028NP has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sbnA,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus RN4220,Swiss Webster mice,.,"The protein sbnA of Staphylococcus aureus subsp. aureus RN4220 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Delta-Hemolysin,Secreted by Vibrio cholerae,Vibrio cholerae,Q20523,.,.,"The compound Delta-Hemolysin Secreted by Vibrio cholerae Q20523 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CeuBC,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein CeuBC of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,chuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein chuA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,chuA,Escherichia coli,Escherichia coli,O157:H7 str. EDL933,.,.,"The protein chuA of Escherichia coli O157:H7 str. EDL933 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Co-transporter,.,Co-transport of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ChuABCD,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein ChuABCD of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC49A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hasA,Serratia marcescens,Serratia marcescens,SM365,.,.,"The protein hasA of Serratia marcescens SM365 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hbp,Escherichia coli,Escherichia coli,EB1 (O8-K43),.,.,"The protein hbp of Escherichia coli EB1 (O8-K43) has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hhuA,Haemophilus influenzae,Haemophilus influenzae,TN106,.,.,"The protein hhuA of Haemophilus influenzae TN106 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hitA,Haemophilus influenzae,Haemophilus influenzae,TN106,.,.,"The protein hitA of Haemophilus influenzae TN106 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Co-transporter,.,Co-transport of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hitB,Haemophilus influenzae,Haemophilus influenzae,TN106,.,.,"The protein hitB of Haemophilus influenzae TN106 has been reported to transport similar substrates/drugs of SLC49A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0376,SLC49A1,Co-transporter,.,Co-transport of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hitC,Haemophilus influenzae,Haemophilus influenzae,TN106,.,.,"The protein hitC of Haemophilus influenzae TN106 has been reported to transport similar substrates/drugs of SLC49A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hmbR,Neisseria meningitidis,Neisseria meningitidis,IR1072,.,.,"The protein hmbR of Neisseria meningitidis IR1072 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hpuB,Neisseria meningitidis,Neisseria meningitidis,FAM18,.,.,"The protein hpuB of Neisseria meningitidis FAM18 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,htaA,Corynebacterium diphtheriae,Corynebacterium diphtheriae,1737,.,.,"The protein htaa of Corynebacterium diphtheriae 1737 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,htaB,Corynebacterium diphtheriae,Corynebacterium diphtheriae,1737,.,.,"The protein htab of Corynebacterium diphtheriae 1737 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hutA,Vibrio cholerae,Vibrio cholerae,O395,.,.,"The protein hutA of Vibrio cholerae O395 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hutA,Bartonella quintana,Bartonella quintana,JK 31,.,.,"The protein hutA of Bartonella quintana JK 31 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hxuC,Haemophilus influenzae,Haemophilus influenzae,type b DL42,.,.,"The protein hxuC of Haemophilus influenzae type b DL42 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ilsA,Bacillus cereus,Bacillus cereus,ATCC 14579,.,.,"The protein ilsA of Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein isdA of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdB,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus str. Newman,.,.,"The protein isdB of Staphylococcus aureus subsp. aureus str. Newman has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdC,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein isdc of Staphylococcus aureus has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,IsdDEF,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein IsdDEF of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdG,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein isdG of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdG,Staphylococcus lugdunensis,Staphylococcus lugdunensis,N920143,.,.,"The protein isdG of Staphylococcus lugdunensis N920143 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdH,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus NCTC 8325,.,.,"The protein isdH of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdH,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein isdh of Staphylococcus aureus has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdI,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein isdI of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Co-transporter,.,Co-transport of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdX1,Bacillus anthracis,Bacillus anthracis,str. Sterne,.,.,"The protein isdX1 of Bacillus anthracis str. Sterne has been reported to transport similar substrates/drugs of SLC49A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0376,SLC49A1,Co-transporter,.,Co-transport of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdX2,Bacillus anthracis,Bacillus anthracis,str. Sterne,.,.,"The protein isdX2 of Bacillus anthracis str. Sterne has been reported to transport similar substrates/drugs of SLC49A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mhuD,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Rv,.,.,"The protein mhuD of Mycobacterium tuberculosis H37Rv has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv0203,Mycobacterium tuberculosis,Mycobacterium tuberculosis,.,.,.,"The protein rv0203 of Mycobacterium tuberculosis has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0376,SLC49A1,Sequestration substrate,.,Sequestration of human SLC49A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,shr,Streptococcus pyogenes,Streptococcus pyogenes,JRS4,.,.,"The protein shr of Streptococcus pyogenes JRS4 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,bhuA,Brucella abortus,Brucella abortus,2308,BALB/c athymic Nu/Nu mice,.,"The protein bhua of Brucella abortus 2308 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hbpA,Haemophilus influenzae,Haemophilus influenzae,86-028NP,Sprague-Dawley rats,.,"The protein hbpA of Haemophilus influenzae 86-028NP has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,sbnA,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus RN4220,Swiss Webster mice,.,"The protein sbnA of Staphylococcus aureus subsp. aureus RN4220 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,Blood
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Compound,Delta-Hemolysin,Secreted by Vibrio cholerae,Vibrio cholerae,Q20523,.,.,"The compound Delta-Hemolysin Secreted by Vibrio cholerae Q20523 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,CeuBC,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein CeuBC of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,chuA,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein chuA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,chuA,Escherichia coli,Escherichia coli,O157:H7 str. EDL933,.,.,"The protein chuA of Escherichia coli O157:H7 str. EDL933 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Co-transporter,.,Co-transport of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ChuABCD,Campylobacter jejuni,Campylobacter jejuni,subsp. jejuni NCTC 11168,.,.,"The protein ChuABCD of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC49A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hasA,Serratia marcescens,Serratia marcescens,SM365,.,.,"The protein hasA of Serratia marcescens SM365 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hbp,Escherichia coli,Escherichia coli,EB1 (O8-K43),.,.,"The protein hbp of Escherichia coli EB1 (O8-K43) has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hhuA,Haemophilus influenzae,Haemophilus influenzae,TN106,.,.,"The protein hhuA of Haemophilus influenzae TN106 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hitA,Haemophilus influenzae,Haemophilus influenzae,TN106,.,.,"The protein hitA of Haemophilus influenzae TN106 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Co-transporter,.,Co-transport of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hitB,Haemophilus influenzae,Haemophilus influenzae,TN106,.,.,"The protein hitB of Haemophilus influenzae TN106 has been reported to transport similar substrates/drugs of SLC49A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0377,SLC49A2,Co-transporter,.,Co-transport of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hitC,Haemophilus influenzae,Haemophilus influenzae,TN106,.,.,"The protein hitC of Haemophilus influenzae TN106 has been reported to transport similar substrates/drugs of SLC49A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hmbR,Neisseria meningitidis,Neisseria meningitidis,IR1072,.,.,"The protein hmbR of Neisseria meningitidis IR1072 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hpuB,Neisseria meningitidis,Neisseria meningitidis,FAM18,.,.,"The protein hpuB of Neisseria meningitidis FAM18 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,htaA,Corynebacterium diphtheriae,Corynebacterium diphtheriae,1737,.,.,"The protein htaa of Corynebacterium diphtheriae 1737 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,htaB,Corynebacterium diphtheriae,Corynebacterium diphtheriae,1737,.,.,"The protein htab of Corynebacterium diphtheriae 1737 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hutA,Vibrio cholerae,Vibrio cholerae,O395,.,.,"The protein hutA of Vibrio cholerae O395 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hutA,Bartonella quintana,Bartonella quintana,JK 31,.,.,"The protein hutA of Bartonella quintana JK 31 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,hxuC,Haemophilus influenzae,Haemophilus influenzae,type b DL42,.,.,"The protein hxuC of Haemophilus influenzae type b DL42 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ilsA,Bacillus cereus,Bacillus cereus,ATCC 14579,.,.,"The protein ilsA of Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdA,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein isdA of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdB,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus str. Newman,.,.,"The protein isdB of Staphylococcus aureus subsp. aureus str. Newman has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdC,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein isdc of Staphylococcus aureus has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,IsdDEF,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein IsdDEF of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdG,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein isdG of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdG,Staphylococcus lugdunensis,Staphylococcus lugdunensis,N920143,.,.,"The protein isdG of Staphylococcus lugdunensis N920143 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdH,Staphylococcus aureus,Staphylococcus aureus,subsp. aureus NCTC 8325,.,.,"The protein isdH of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdH,Staphylococcus aureus,Staphylococcus aureus,.,.,.,"The protein isdh of Staphylococcus aureus has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdI,Staphylococcus aureus,Staphylococcus aureus,RN6390,.,.,"The protein isdI of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Co-transporter,.,Co-transport of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdX1,Bacillus anthracis,Bacillus anthracis,str. Sterne,.,.,"The protein isdX1 of Bacillus anthracis str. Sterne has been reported to transport similar substrates/drugs of SLC49A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0377,SLC49A2,Co-transporter,.,Co-transport of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,isdX2,Bacillus anthracis,Bacillus anthracis,str. Sterne,.,.,"The protein isdX2 of Bacillus anthracis str. Sterne has been reported to transport similar substrates/drugs of SLC49A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mhuD,Mycobacterium tuberculosis,Mycobacterium tuberculosis,H37Rv,.,.,"The protein mhuD of Mycobacterium tuberculosis H37Rv has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,Rv0203,Mycobacterium tuberculosis,Mycobacterium tuberculosis,.,.,.,"The protein rv0203 of Mycobacterium tuberculosis has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0377,SLC49A2,Sequestration substrate,.,Sequestration of human SLC49A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,shr,Streptococcus pyogenes,Streptococcus pyogenes,JRS4,.,.,"The protein shr of Streptococcus pyogenes JRS4 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.",.,.
DTD0387,SLC4A7,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC4A7 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 germ-free/conventionally-raised mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC4A7.,.,Duodenum
DTD0391,SLC51A,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC51A expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.,.,Large intestine
DTD0391,SLC51A,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC51A expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Swiss Webster mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC51A.,.,Ileum
DTD0391,SLC51A,Down regulating,.,Down regulating of SLC51A expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Chenodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.,.,Colon
DTD0391,SLC51A,Down regulating,.,Down regulating of SLC51A expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Chenodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.,.,Ileum
DTD0391,SLC51A,Down regulating,.,Down regulating of SLC51A expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Cholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.,.,Colon
DTD0391,SLC51A,Down regulating,.,Down regulating of SLC51A expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Cholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.,.,Ileum
DTD0391,SLC51A,Down regulating,.,Down regulating of SLC51A expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Deoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.,.,Colon
DTD0391,SLC51A,Down regulating,.,Down regulating of SLC51A expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Deoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.,.,Ileum
DTD0391,SLC51A,Down regulating,.,Down regulating of SLC51A expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Hyodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.,.,Colon
DTD0391,SLC51A,Down regulating,.,Down regulating of SLC51A expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Hyodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.,.,Ileum
DTD0391,SLC51A,Down regulating,.,Down regulating of SLC51A expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Lithocholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.,.,Colon
DTD0391,SLC51A,Down regulating,.,Down regulating of SLC51A expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Lithocholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.,.,Ileum
DTD0391,SLC51A,Up regulating,.,Up regulating of SLC51A expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Chenodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,Human hepatoblastoma cells (HepG2),The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC51A.,.,Liver
DTD0392,SLC51B,Up regulating,Metabolic dysfunction-associated fatty liver disease,Up regulating of SLC51B expression in metabolic dysfunction-associated fatty liver disease condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Akkermansia muciniphila,Akkermansia muciniphila,Akkermansia muciniphila,ATCC BAA-835,C57BL/6 mice,.,The Akkermansia muciniphila ATCC BAA-835 has been reported to increase the expression of the drug transporter SLC51B.,.,Ileum
DTD0392,SLC51B,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC51B expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51B.,.,Large intestine
DTD0392,SLC51B,Up regulating,.,Up regulating of SLC51B expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Chenodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,Human hepatoblastoma cells (HepG2),The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC51B.,.,Liver
DTD0414,SLC58A1,Co-transporter,.,Co-transport of human SLC58A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtA,Yersinia pestis,Yersinia pestis,KIM6,.,.,"The protein mgtA of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0414,SLC58A1,Co-transporter,.,Co-transport of human SLC58A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtA,Escherichia coli,Escherichia coli,BL21(DE3),.,.,"The protein mgtA of Escherichia coli BL21(DE3) has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0414,SLC58A1,Co-transporter,.,Co-transport of human SLC58A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium TN1379,.,.,"The protein mgtA of Salmonella enterica subsp. enterica serovar Typhimurium TN1379 has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0414,SLC58A1,Co-transporter,.,Co-transport of human SLC58A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein mgtA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0414,SLC58A1,Co-transporter,.,Co-transport of human SLC58A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium TN2540,.,.,"The protein mgtA of Salmonella enterica subsp. enterica serovar Typhimurium TN2540 has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0414,SLC58A1,Co-transporter,.,Co-transport of human SLC58A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtA,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium TN1010,.,.,"The protein mgtA of Salmonella enterica subsp. enterica serovar Typhimurium TN1010 has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0414,SLC58A1,Co-transporter,.,Co-transport of human SLC58A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium TN1379,.,.,"The protein mgtB of Salmonella enterica subsp. enterica serovar Typhimurium TN1379 has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0414,SLC58A1,Co-transporter,.,Co-transport of human SLC58A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium,.,.,"The protein mgtB of Salmonella enterica subsp. enterica serovar Typhimurium has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0414,SLC58A1,Co-transporter,.,Co-transport of human SLC58A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,mgtB,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium TN1010,.,.,"The protein mgtB of Salmonella enterica subsp. enterica serovar Typhimurium TN1010 has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0414,SLC58A1,Co-transporter,.,Co-transport of human SLC58A1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,MgtBC,Salmonella enterica,Salmonella enterica,subsp. enterica serovar Typhimurium str. 14028S,.,.,"The protein MgtBC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0418,SLC5A1,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC5A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Bacteroides thetaiotaomicron,Bacteroides thetaiotaomicron,Bacteroides thetaiotaomicron,.,Germ-free mice,.,The Bacteroides thetaiotaomicron has been reported to increase the expression of the drug transporter SLC5A1.,.,Intestine
DTD0418,SLC5A1,Down regulating,Gastrointestinal disturbances in children with autism,Down regulating of SLC5A1 expression in gastrointestinal disturbances expression in children with autism condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Bacteroides Vulgatus isolates(down),Bacteroides Vulgatus,Bacteroides Vulgatus,.,Children with autistic disorder and GI disease,.,The Bacteroides Vulgatus has been reported to decrease the expression of the drug transporter SLC5A1.,.,Ileum
DTD0418,SLC5A1,Down regulating,Gastrointestinal disturbances in children with autism,Down regulating of SLC5A1 expression in gastrointestinal disturbances expression in children with autism condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Faecalibacterium prausnitzii isolates,Faecalibacterium prausnitzii,Faecalibacterium prausnitzii,.,Children with autistic disorder and GI disease,.,The Faecalibacterium prausnitzii has been reported to decrease the expression of the drug transporter SLC5A1.,.,Ileum
DTD0418,SLC5A1,Inhibition,Watery diarrhea,Inhibition of SLC5A1 function in watery diarrhea condition,Class3: Biosynthesis of microbial molecules that affect transporters,Protein,eae,Generated by Escherichia coli,Escherichia coli,O127:H6 str. E2348/69,.,Human colon adenocarcinoma cells (Caco-2),The protein eae of Escherichia coli O127:H6 str. E2348/69 has been reported to inhibit the function of the drug transporter SLC5A1.,.,Duodenum
DTD0418,SLC5A1,Inhibition,Watery diarrhea,Inhibition of SLC5A1 function in watery diarrhea condition,Class3: Biosynthesis of microbial molecules that affect transporters,Protein,espF(U),Generated by Escherichia coli,Escherichia coli,O127:H6 str. E2348/69,.,Human colon adenocarcinoma cells (Caco-2),The protein espF(U) of Escherichia coli O127:H6 str. E2348/69 has been reported to inhibit the function of the drug transporter SLC5A1.,.,Duodenum
DTD0418,SLC5A1,Inhibition,Watery diarrhea,Inhibition of SLC5A1 function in watery diarrhea condition,Class3: Biosynthesis of microbial molecules that affect transporters,Protein,map,Generated by Escherichia coli,Escherichia coli,O127:H6 str. E2348/69,.,Human colon adenocarcinoma cells (Caco-2),The protein map of Escherichia coli O127:H6 str. E2348/69 has been reported to inhibit the function of the drug transporter SLC5A1.,.,Duodenum
DTD0418,SLC5A1,Inhibition,Diarrhea associated with infection by enteropathogenic Escherichia coli,Inhibition of SLC5A1 function in diarrhea associated with infection by enteropathogenic Escherichia coli condition,Class3: Biosynthesis of microbial molecules that affect transporters,Protein,tir,Generated by Escherichia coli,Escherichia coli,O127:H6 str. E2348/69,.,Human colon adenocarcinoma cells (Caco-2),The protein tir of Escherichia coli O127:H6 str. E2348/69 has been reported to inhibit the function of the drug transporter SLC5A1.,.,Duodenum
DTD0418,SLC5A1,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC5A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Swiss Webster germ-free mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC5A1.,.,Colon
DTD0418,SLC5A1,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC5A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Swiss Webster germ-free mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC5A1.,.,Ileum
DTD0424,SLC5A4,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC5A4 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 germ-free/conventionally-raised mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC5A4.,.,Jejunum
DTD0428,SLC5A8,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC5A8 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Swiss Webster germ-free mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC5A8.,.,Colon
DTD0428,SLC5A8,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC5A8 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Swiss Webster germ-free mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC5A8.,.,Ileum
DTD0428,SLC5A8,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC5A8 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Unspecified Gut microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Swiss Webster germ-free mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC5A8.,.,Ileum/colon
DTD0428,SLC5A8,Up regulating,.,Up regulating of SLC5A8 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Chenodeoxycholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,Rat small intestine epithelial cells (IEC-6),The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC5A8.,.,Small intestine
DTD0439,SLC65A2,Up regulating,Metabolic dysfunction-associated fatty liver disease,Up regulating of SLC65A2 expression in metabolic dysfunction-associated fatty liver disease condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Akkermansia muciniphila,Akkermansia muciniphila,Akkermansia muciniphila,ATCC BAA-835,C57BL/6 mice,.,The Akkermansia muciniphila ATCC BAA-835 has been reported to increase the expression of the drug transporter SLC65A2.,.,Ileum
DTD0439,SLC65A2,Down regulating,.,Down regulating of SLC65A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Trimethylamine oxide,L-carnitine metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Sprague-Dawley rats,.,The metabolite trimethylamine oxide generated from the metabolism of l-carnitine by the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC65A2.,.,Small intestine
DTD0439,SLC65A2,Down regulating,.,Down regulating of SLC65A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Trimethylamine oxide,L-carnitine metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite trimethylamine oxide generated from the metabolism of l-carnitine by the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC65A2.,.,Liver
DTD0439,SLC65A2,Down regulating,.,Down regulating of SLC65A2 expression in the health condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC65A2.,.,Small intestine
DTD0452,SLC6A2,Co-transporter,.,Co-transport of human SLC6A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,leuT,Aquifex aeolicus,Aquifex aeolicus,.,.,.,"The protein leut of Aquifex aeolicus has been reported to transport similar substrates/drugs of SLC6A2, which affects the distribution of its substrate/drug in vivo.",.,.
DTD0455,SLC6A3,Up regulating,Tourette syndrome,Up regulating of SLC6A3 expression in tourette syndrome condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Lactobacillus plantarum,Lactiplantibacillus plantarum,Lactiplantibacillus plantarum,PS128,Sprague-Dawley rats,.,The Lactiplantibacillus plantarum PS128 has been reported to increase the expression of the drug transporter SLC6A3.,Serotonin,Brain
DTD0455,SLC6A3,Sequestration substrate,.,Sequestration of human SLC6A3 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Helicobacter pylori,Helicobacter pylori,Helicobacter pylori,ATCC 700824,.,Human gastric epithelial cells,"The Helicobacter pylori ATCC 700824 has been reported to sequester the drug L-dopamine, which limits the distribution of the drug in the body and its binding to the drug transporter SLC6A3, thereby affecting the efficacy, safety, or bioavailability of the drug.",L-dopamine,Stomach
DTD0455,SLC6A3,Down regulating,Fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli,Down regulating of SLC6A3 expression in fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Citrobacter rodentium,Citrobacter rodentium,Citrobacter rodentium,DBS120,FVB/N mice,.,The Citrobacter rodentium DBS120 has been reported to decrease the expression of the drug transporter SLC6A3.,.,Colon
DTD0455,SLC6A3,Up regulating,Fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli,Up regulating of SLC6A3 expression in fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Lactobacillus acidophilus,Lactobacillus acidophilus,Lactobacillus acidophilus,ATCC 4357,FVB/N mice,.,The Lactobacillus acidophilus ATCC 4357 has been reported to increase the expression of the drug transporter SLC6A3.,.,Colon
DTD0455,SLC6A3,Down regulating,Watery diarrhea,Down regulating of SLC6A3 expression in watery diarrhea condition,Class3: Biosynthesis of microbial molecules that affect transporters,Protein,espG,Generated by Escherichia coli,Escherichia coli,O127:H6 str. E2348/69,.,Human colon adenocarcinoma cells (Caco-2),The protein espG form Escherichia coli O127:H6 str. E2348/69 has been reported to decrease the expression of the drug transporter SLC6A3.,.,Colon
DTD0455,SLC6A3,Inhibition,Watery diarrhea,Inhibition of SLC6A3 function in watery diarrhea condition,Class3: Biosynthesis of microbial molecules that affect transporters,Protein,espG2,Generated by Escherichia coli,Escherichia coli,O127:H6 str. E2348/69,.,Human colon adenocarcinoma cells (Caco-2),The protein espG2 of Escherichia coli O127:H6 str. E2348/69 has been reported to inhibit the function of the drug transporter SLC6A3.,.,Colon
DTD0455,SLC6A3,Down regulating,.,Down regulating of SLC6A3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Butyrate,Dietary food metabolite from Prevotella copri,Prevotella copri,.,Caucasian human,.,The metabolite butyrate generated from the metabolism of dietary food by the Prevotella copri has been reported to decrease the expression of the drug transporter SLC6A3.,.,Brain
DTD0455,SLC6A3,Up regulating,.,Up regulating of SLC6A3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Butyrate,Dietary food metabolite from Bacteroides uniformis,Bacteroides uniformis,.,Caucasian human,.,The metabolite butyrate generated from the metabolism of dietary food metabolite from Bacteroides uniformis has been reported to increase the expression of the drug transporter SLC6A3.,.,Brain
DTD0455,SLC6A3,Up regulating,.,Up regulating of SLC6A3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Butyrate,Dietary food metabolite from Host unspecified microbiota,Host unspecified microbiota,.,NMRI mice,.,The metabolite butyrate generated from the metabolism of dietary food by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC6A3.,.,Forebrain lateral septum
DTD0456,SLC6A4,Up regulating,Health,Up regulating of SLC6A4 expression in health condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Lactobaccillus plantarum,Lactiplantibacillus plantarum,Lactiplantibacillus plantarum,IS-10506,Sprague-Dawley rats,.,The Lactiplantibacillus plantarum IS-10506 has been reported to increase the expression of the drug transporter SLC6A4.,Serotonin,Brain
DTD0456,SLC6A4,Up regulating,Chronic constipation,Up regulating of SLC6A4 expression in chronic constipation condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Akkermansia,Unclassified Akkermansia,Unclassified Akkermansia,.,C57BL/6J specific-pathogen-free mice,Human colon adenocarcinoma cells (Caco-2),The Unclassified Akkermansia has been reported to increase the expression of the drug transporter SLC6A4.,.,Colon
DTD0456,SLC6A4,Up regulating,Chronic constipation,Up regulating of SLC6A4 expression in chronic constipation condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Bacteroides,Unclassified Bacteroides,Unclassified Bacteroides,.,C57BL/6J specific-pathogen-free mice,Human colon adenocarcinoma cells (Caco-2),The Unclassified Bacteroides has been reported to increase the expression of the drug transporter SLC6A4.,.,Colon
DTD0456,SLC6A4,Up regulating,Chronic constipation,Up regulating of SLC6A4 expression in chronic constipation condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Clostridium coleatum(down),Thomasclavelia cocleata,Thomasclavelia cocleata,.,C57BL/6J specific-pathogen-free mice,Human colon adenocarcinoma cells (Caco-2),The Thomasclavelia cocleata has been reported to increase the expression of the drug transporter SLC6A4.,.,Colon
DTD0456,SLC6A4,Up regulating,Chronic constipation,Up regulating of SLC6A4 expression in chronic constipation condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Desulfovibrio(down),Unclassified Desulfovibrio,Unclassified Desulfovibrio,.,C57BL/6J specific-pathogen-free mice,Human colon adenocarcinoma cells (Caco-2),The Unclassified Desulfovibrio has been reported to increase the expression of the drug transporter SLC6A4.,.,Colon
DTD0456,SLC6A4,Up regulating,Chronic constipation,Up regulating of SLC6A4 expression in chronic constipation condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Lactobacillus gasseri(down),Lactobacillus gasseri,Lactobacillus gasseri,.,C57BL/6J specific-pathogen-free mice,Human colon adenocarcinoma cells (Caco-2),The Lactobacillus gasseri has been reported to increase the expression of the drug transporter SLC6A4.,.,Colon
DTD0456,SLC6A4,Up regulating,Chronic constipation,Up regulating of SLC6A4 expression in chronic constipation condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Methylobacterium(down),Unclassified Methylobacterium,Unclassified Methylobacterium,.,C57BL/6J specific-pathogen-free mice,Human colon adenocarcinoma cells (Caco-2),The Unclassified Methylobacterium has been reported to increase the expression of the drug transporter SLC6A4.,.,Colon
DTD0456,SLC6A4,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC6A4 expression in conventional mice compared with germ-free mice,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Serotonin,Generated by Host unspecified microbiota,Host unspecified microbiota,.,Germ-free mice,Rat insulinoma cells (RIN14B),The compound serotonin generated by host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC6A4.,.,Colon
DTD0456,SLC6A4,Down regulating,.,Down regulating of SLC6A4 expression in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,Serotonin,Generated by Host unspecified microbiota,Host unspecified microbiota,.,Sprague-Dawley rats,.,The compound serotonin generated by host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC6A4.,.,Small intestine
DTD0458,SLC6A6,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC6A6 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Swiss Webster mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC6A6.,.,Liver
DTD0459,SLC6A7,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC6A7 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 germ-free/conventionally-raised mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC6A7.,.,Jejunum
DTD0460,SLC6A8,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC6A8 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 germ-free/conventionally-raised mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC6A8.,.,Jejunum
DTD0476,SLC7A9,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLC7A9 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 germ-free/conventionally-raised mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC7A9.,.,Colon
DTD0482,SLC9A2,Down regulating,Fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli,Down regulating of SLC9A2 expression in fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Citrobacter rodentium,Citrobacter rodentium,Citrobacter rodentium,DBS120,FVB/N mice,.,The Citrobacter rodentium DBS120 has been reported to decrease the expression of the drug transporter SLC9A2.,.,Colon
DTD0482,SLC9A2,Activation,Diarrhea associated with infection by enteropathogenic Escherichia coli,Activation of SLC9A2 membrane localization in diarrhea associated with infection by enteropathogenic Escherichia coli condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Escherichia coli,Escherichia coli,Escherichia coli,O127:H6 str. E2348/69,.,Human colon adenocarcinoma cells (Caco-2),The Escherichia coli O127:H6 str. E2348/69 has been reported to activate the function of the drug transporter SLC9A2.,.,Colon
DTD0482,SLC9A2,Inhibition,.,Inhibition of SLC9A2 function in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,N-Acetyl-cholera toxin peptide 3-amide,Generated by Vibrio cholerae,Vibrio cholerae,.,Sprague-Dawley rats,.,The compound n-acetyl-cholera toxin peptide 3-amide generated by Vibrio cholerae has been reported to inhibit the function of the drug transporter SLC9A2.,.,Ileum
DTD0482,SLC9A2,Inhibition,.,Inhibition of SLC9A2 function in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Protein,stx1,Generated by Escherichia coli,Escherichia coli,O157:H7,Rabbits,Human colon adenocarcinoma cells (T84),The protein stx1 of Escherichia coli O157:H7 has been reported to inhibit the function of the drug transporter SLC9A2.,.,Colon
DTD0482,SLC9A2,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLC9A2 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 germ-free/conventionally-raised mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC9A2.,.,Ileum
DTD0483,SLC9A3,Down regulating,Clostridium difficile infection,Down regulating of SLC9A3 expression in clostridium difficile infection condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Clostridium difficile,Clostridioides difficile,Clostridioides difficile,.,.,.,The Clostridioides difficile has been reported to decrease the expression of the drug transporter SLC9A3.,.,Colon
DTD0483,SLC9A3,Inhibition,Diarrhea associated with infection by enteropathogenic Escherichia coli,Inhibition of SLC9A3 function in diarrhea associated with infection by enteropathogenic Escherichia coli condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Escherichia coli,Escherichia coli,Escherichia coli,O127:H6 str. E2348/69,.,Human colon adenocarcinoma cells (Caco-2),The Escherichia coli O127:H6 str. E2348/69 has been reported to inhibit the function of the drug transporter SLC9A3.,.,Colon
DTD0483,SLC9A3,Up regulating,Fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli,Up regulating of SLC9A3 expression in fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Lactobacillus acidophilus,Lactobacillus acidophilus,Lactobacillus acidophilus,ATCC 4357,FVB/N mice,.,The Lactobacillus acidophilus ATCC 4357 has been reported to increase the expression of the drug transporter SLC9A3.,.,Colon
DTD0483,SLC9A3,Inhibition,.,Inhibition of SLC9A3 function in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Compound,N-Acetyl-cholera toxin peptide 3-amide,Generated by Vibrio cholerae,Vibrio cholerae,.,Sprague-Dawley rats,.,The compound n-acetyl-cholera toxin peptide 3-amide generated by Vibrio cholerae has been reported to inhibit the function of the drug transporter SLC9A3.,.,Ileum
DTD0483,SLC9A3,Inhibition,.,Inhibition of SLC9A3 function in the health condition,Class3: Biosynthesis of microbial molecules that affect transporters,Protein,tcdB,Generated by Clostridioides difficile,Clostridioides difficile,.,.,Pig kidney epithelial cells (LLC-PK1),The protein tcdb generated by Clostridioides difficile has been reported to inhibit the function of the drug transporter SLC9A3.,.,Kidney
DTD0483,SLC9A3,Up regulating,.,Up regulating of SLC9A3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Butyrate,Pectin metabolite from Host unspecified microbiota,Host unspecified microbiota,.,Rats,Human colon adenocarcinoma cells (C2bbe1),The metabolite butyrate generated from the metabolism of pectin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC9A3.,.,Colon
DTD0029,SLCO1A2,Sequestration substrate,.,Sequestration of human SLCO1A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Bacteroides uniformis,Bacteroides uniformis,Bacteroides uniformis,CL03T00C23,.,.,"The Bacteroides uniformis CL03T00C23 has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO1A2, thereby affecting the efficacy, safety, or bioavailability of the drug.",Montelukast,.
DTD0029,SLCO1A2,Sequestration substrate,.,Sequestration of human SLCO1A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Bifidobacterium animalis subsp. lactis,Bifidobacterium animalis,Bifidobacterium animalis,subsp. lactis Bi-07,.,.,"The Bifidobacterium animalis subsp. lactis Bi-07 has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO1A2, thereby affecting the efficacy, safety, or bioavailability of the drug.",Montelukast,.
DTD0029,SLCO1A2,Sequestration substrate,.,Sequestration of human SLCO1A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Bifidobacterium longum subsp. infantis,Bifidobacterium longum,Bifidobacterium longum,subsp. infantis,.,.,"The Bifidobacterium longum subsp. infantis has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO1A2, thereby affecting the efficacy, safety, or bioavailability of the drug.",Montelukast,.
DTD0029,SLCO1A2,Sequestration substrate,.,Sequestration of human SLCO1A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Clostridium bolteae,Enterocloster bolteae,Enterocloster bolteae,WAL 16351,.,.,"The Enterocloster bolteae WAL 16351 has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO1A2, thereby affecting the efficacy, safety, or bioavailability of the drug.",Montelukast,.
DTD0029,SLCO1A2,Sequestration substrate,.,Sequestration of human SLCO1A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Clostridium saccharolyticum,Lacrimispora saccharolytica,Lacrimispora saccharolytica,WM1,.,.,"The Lacrimispora saccharolytica WM1 has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO1A2, thereby affecting the efficacy, safety, or bioavailability of the drug.",Montelukast,.
DTD0029,SLCO1A2,Sequestration substrate,.,Sequestration of human SLCO1A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Escherichia coli,Escherichia coli,Escherichia coli,str. K-12 substr. MG1655,.,.,"The Escherichia coli str. K-12 substr. MG1655 has been reported to sequester the drug Ciprofloxacin, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO1A2, thereby affecting the efficacy, safety, or bioavailability of the drug.",Ciprofloxacin,.
DTD0029,SLCO1A2,Co-transporter,.,Co-transport of human SLCO1A2 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Protein,ompF,Escherichia coli,Escherichia coli,JM712,.,.,"The protein ompF of Escherichia coli JM712 has been reported to transport similar substrates/drugs of SLCO1A2, which affects the distribution of its substrate/drug in vivo.",Norfloxacin,.
DTD0029,SLCO1A2,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLCO1A2 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,Swiss Webster mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLCO1A2.,.,Liver
DTD0029,SLCO1A2,Up regulating,.,Up regulating of SLCO1A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Chenodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1A2.,.,Liver
DTD0029,SLCO1A2,Up regulating,.,Up regulating of SLCO1A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Cholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1A2.,.,Liver
DTD0029,SLCO1A2,Up regulating,.,Up regulating of SLCO1A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Deoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1A2.,.,Liver
DTD0029,SLCO1A2,Up regulating,.,Up regulating of SLCO1A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Hyodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1A2.,.,Liver
DTD0029,SLCO1A2,Up regulating,.,Up regulating of SLCO1A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Lithocholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1A2.,.,Liver
DTD0029,SLCO1A2,Down regulating,.,Down regulating of SLCO1A2 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Trimethylamine oxide,L-carnitine metabolite from Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6J mice,.,The metabolite trimethylamine oxide generated from the metabolism of l-carnitine by the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLCO1A2.,.,Liver
DTD0008,SLCO1B1,Up regulating,.,Up regulating of SLCO1B1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Chenodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B1.,.,Liver
DTD0008,SLCO1B1,Up regulating,.,Up regulating of SLCO1B1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Cholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B1.,.,Liver
DTD0008,SLCO1B1,Up regulating,.,Up regulating of SLCO1B1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Deoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B1.,.,Liver
DTD0008,SLCO1B1,Up regulating,.,Up regulating of SLCO1B1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Hyodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B1.,.,Liver
DTD0008,SLCO1B1,Up regulating,.,Up regulating of SLCO1B1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Lithocholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B1.,.,Liver
DTD0008,SLCO1B1,Up regulating,.,Up regulating of SLCO1B1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Dehydrolithocholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,PXR mice,Mouse embryo embryonic stem cells (ES-R1),The metabolite dehydrolithocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B1.,.,Liver
DTD0008,SLCO1B1,Up regulating,.,Up regulating of SLCO1B1 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Lithocholic acid,Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,IQI mice,.,The metabolite lithocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B1.,.,Liver
DTD0030,SLCO1B3,Up regulating,.,Up regulating of SLCO1B3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Chenodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B3.,.,Liver
DTD0030,SLCO1B3,Up regulating,.,Up regulating of SLCO1B3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Cholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B3.,.,Liver
DTD0030,SLCO1B3,Up regulating,.,Up regulating of SLCO1B3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Deoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B3.,.,Liver
DTD0030,SLCO1B3,Up regulating,.,Up regulating of SLCO1B3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Hyodeoxycholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B3.,.,Liver
DTD0030,SLCO1B3,Up regulating,.,Up regulating of SLCO1B3 expression in the health condition,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Bile acid (Lithocholic acid),Metabolite from Host unspecified microbiota,Host unspecified microbiota,.,.,.,The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B3.,.,Liver
DTD0500,SLCO2A1,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLCO2A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLCO2A1.,.,Large intestine
DTD0500,SLCO2A1,Down regulating,Conventional mice compared with germ-free mice,Down regulating of SLCO2A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLCO2A1.,.,Jejunum
DTD0500,SLCO2A1,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLCO2A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO2A1.,.,Liver
DTD0031,SLCO2B1,Up regulating,Health,Up regulating of SLCO2B1 expression in health condition,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Escherichia coli Nissle 1917,Escherichia coli,Escherichia coli,Nissle 1917,Sprague-Dawley rats,.,The Escherichia coli Nissle 1917 has been reported to increase the expression of the drug transporter SLCO2B1.,Amiodarone,Intestine
DTD0031,SLCO2B1,Sequestration substrate,.,Sequestration of human SLCO2B1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Bacteroides uniformis,Bacteroides uniformis,Bacteroides uniformis,CL03T00C23,.,.,"The Bacteroides uniformis CL03T00C23 has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO2B1, thereby affecting the efficacy, safety, or bioavailability of the drug.",Montelukast,.
DTD0031,SLCO2B1,Sequestration substrate,.,Sequestration of human SLCO2B1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Bifidobacterium animalis subsp. lactis,Bifidobacterium animalis,Bifidobacterium animalis,subsp. lactis Bi-07,.,.,"The Bifidobacterium animalis subsp. lactis Bi-07 has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO2B1, thereby affecting the efficacy, safety, or bioavailability of the drug.",Montelukast,.
DTD0031,SLCO2B1,Sequestration substrate,.,Sequestration of human SLCO2B1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Bifidobacterium longum subsp. infantis,Bifidobacterium longum,Bifidobacterium longum,subsp. infantis,.,.,"The Bifidobacterium longum subsp. infantis has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO2B1, thereby affecting the efficacy, safety, or bioavailability of the drug.",Montelukast,.
DTD0031,SLCO2B1,Sequestration substrate,.,Sequestration of human SLCO2B1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Clostridium bolteae,Enterocloster bolteae,Enterocloster bolteae,WAL 16351,.,.,"The Enterocloster bolteae WAL 16351 has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO2B1, thereby affecting the efficacy, safety, or bioavailability of the drug.",Montelukast,.
DTD0031,SLCO2B1,Sequestration substrate,.,Sequestration of human SLCO2B1 substrates/drugs in the health condition,Class1: Microbial sequestration and bioaccumulation of drugs,Interaction,Clostridium saccharolyticum,Lacrimispora saccharolytica,Lacrimispora saccharolytica,WM1,.,.,"The Lacrimispora saccharolytica WM1 has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO2B1, thereby affecting the efficacy, safety, or bioavailability of the drug.",Montelukast,.
DTD0031,SLCO2B1,Attenuated inhibition,Conventional mice compared with germ-free mice,Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,"1,7-Diamino-8-naphthol-3,6-disulphonic acid",D&C Red No. 33 metabolite from Host unspecified microbiota,Host unspecified microbiota,.,BALB/c germ-free mice,Human kidney human embryonic kidney 293 cells (HEK 293),"The metabolite 1,7-diamino-8-naphthol-3,6-disulphonic acid generated from the metabolism of d&c red no.33 by the host unspecified microbiota has been reported to reduce the ability of D&C Red No.33 to inhibit drug transporters SLCO2B1.",4'-5'-Dibromofluorescein,Kidney
DTD0031,SLCO2B1,Attenuated inhibition,Conventional mice compared with germ-free mice,Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,1-Amino-2-naphthol-6-sulfonic acid,FD&C Red No. 40 metabolite from Host unspecified microbiota,Host unspecified microbiota,.,BALB/c germ-free mice,Human kidney human embryonic kidney 293 cells (HEK 293),The metabolite 1-amino-2-naphthol-6-sulfonic acid generated from the metabolism of fd&c red no.40 by the host unspecified microbiota has been reported to reduce the ability of FD&C Red No.40 to inhibit drug transporters SLCO2B1.,Fexofenadine; Estrone sulfate,Kidney
DTD0031,SLCO2B1,Attenuated inhibition,Conventional mice compared with germ-free mice,Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,1-Amino-2-naphthol-6-sulfonic acid,FD&C Yellow No. 6 metabolite from Host unspecified microbiota,Host unspecified microbiota,.,BALB/c germ-free mice,Human kidney human embryonic kidney 293 cells (HEK 293),The metabolite 1-amino-2-naphthol-6-sulfonic acid generated from the metabolism of fd&c yellow no.6 by the host unspecified microbiota has been reported to reduce the ability of FD&C Yellow No.6 to inhibit drug transporters SLCO2B1.,4'-5'-Dibromofluorescein,Kidney
DTD0031,SLCO2B1,Attenuated inhibition,Conventional mice compared with germ-free mice,Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,"2,4-Diaminoresorcinol",D&C Brown No. 1 metabolite from Host unspecified microbiota,Host unspecified microbiota,.,BALB/c germ-free mice,Human kidney human embryonic kidney 293 cells (HEK 293),"The metabolite 2,4-diaminoresorcinol generated from the metabolism of d&c brown no.1 by the host unspecified microbiota has been reported to reduce the ability of D&C Brown No.1 to inhibit drug transporters SLCO2B1.",4'-5'-Dibromofluorescein,Kidney
DTD0031,SLCO2B1,Attenuated inhibition,Conventional mice compared with germ-free mice,Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,2-Amino-5-methylbenzenesulfonic acid,D&C Red No. 6 metabolite from Host unspecified microbiota,Host unspecified microbiota,.,BALB/c germ-free mice,Human kidney human embryonic kidney 293 cells (HEK 293),The metabolite 2-amino-5-methylbenzenesulfonic acid generated from the metabolism of d&c red no.6 by the host unspecified microbiota has been reported to reduce the ability of D&C Red No.6 to inhibit drug transporters SLCO2B1.,4'-5'-Dibromofluorescein,Kidney
DTD0031,SLCO2B1,Attenuated inhibition,Conventional mice compared with germ-free mice,Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,4-Amino-3-hydroxy-2-naphthoic acid,D&C Red No. 6 metabolite from Host unspecified microbiota,Host unspecified microbiota,.,BALB/c germ-free mice,Human kidney human embryonic kidney 293 cells (HEK 293),The metabolite 4-amino-3-hydroxy-2-naphthoic acid generated from the metabolism of d&c red no.6 by the host unspecified microbiota has been reported to reduce the ability of D&C Red No.6 to inhibit drug transporters SLCO2B1.,4'-5'-Dibromofluorescein,Kidney
DTD0031,SLCO2B1,Attenuated inhibition,Conventional mice compared with germ-free mice,Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,4-Amino-5-methoxy-2-methylbenzenesulfonic acid,FD&C Red No. 40 metabolite from Host unspecified microbiota,Host unspecified microbiota,.,BALB/c germ-free mice,Human kidney human embryonic kidney 293 cells (HEK 293),The metabolite 4-amino-5-methoxy-2-methylbenzenesulfonic acid generated from the metabolism of fd&c red no.40 by the host unspecified microbiota has been reported to reduce the ability of FD&C Red No.40 to inhibit drug transporters SLCO2B1.,Fexofenadine; Estrone sulfate,Kidney
DTD0031,SLCO2B1,Attenuated inhibition,Conventional mice compared with germ-free mice,Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,4-Nitroaniline,Naphthol Blue Black metabolite from Host unspecified microbiota,Host unspecified microbiota,.,BALB/c germ-free mice,Human kidney human embryonic kidney 293 cells (HEK 293),The metabolite 4-nitroaniline generated from the metabolism of naphthol blue black by the host unspecified microbiota has been reported to reduce the ability of Naphthol Blue Black to inhibit drug transporters SLCO2B1.,4'-5'-Dibromofluorescein,Kidney
DTD0031,SLCO2B1,Attenuated inhibition,Conventional mice compared with germ-free mice,Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,"5-Amino-2,4-dimethylbenzenesulfonic acid",FD&C Red No. 4 metabolite from Host unspecified microbiota,Host unspecified microbiota,.,BALB/c germ-free mice,Human kidney human embryonic kidney 293 cells (HEK 293),"The metabolite 5-amino-2,4-dimethylbenzenesulfonic acid generated from the metabolism of fd&c red no.4 by the host unspecified microbiota has been reported to reduce the ability of FD&C Red No.4 to inhibit drug transporters SLCO2B1.",4'-5'-Dibromofluorescein,Kidney
DTD0031,SLCO2B1,Attenuated inhibition,Conventional mice compared with germ-free mice,Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Aniline,D&C Red No. 33 metabolite from Host unspecified microbiota,Host unspecified microbiota,.,BALB/c germ-free mice,Human kidney human embryonic kidney 293 cells (HEK 293),The metabolite aniline generated from the metabolism of d&c red no.33 by the host unspecified microbiota has been reported to reduce the ability of D&C Red No.33 to inhibit drug transporters SLCO2B1.,4'-5'-Dibromofluorescein,Kidney
DTD0031,SLCO2B1,Attenuated inhibition,Conventional mice compared with germ-free mice,Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Aniline,Naphthol Blue Black metabolite from Host unspecified microbiota,Host unspecified microbiota,.,BALB/c germ-free mice,Human kidney human embryonic kidney 293 cells (HEK 293),The metabolite aniline generated from the metabolism of naphthol blue black by the host unspecified microbiota has been reported to reduce the ability of Naphthol Blue Black to inhibit drug transporters SLCO2B1.,4'-5'-Dibromofluorescein,Kidney
DTD0031,SLCO2B1,Attenuated inhibition,Conventional mice compared with germ-free mice,Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Sulfanilic acid,D&C Brown No. 1 metabolite from Host unspecified microbiota,Host unspecified microbiota,.,BALB/c germ-free mice,Human kidney human embryonic kidney 293 cells (HEK 293),The metabolite sulfanilic acid generated from the metabolism of d&c brown no.1 by the host unspecified microbiota has been reported to reduce the ability of D&C Brown No.1 to inhibit drug transporters SLCO2B1.,4'-5'-Dibromofluorescein,Kidney
DTD0031,SLCO2B1,Attenuated inhibition,Conventional mice compared with germ-free mice,Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice,Class2: Microbial biotransformation of exogenous substances that interact with drug transporters,Compound,Sulfanilic acid,FD&C Yellow No. 6 metabolite from Host unspecified microbiota,Host unspecified microbiota,.,BALB/c germ-free mice,Human kidney human embryonic kidney 293 cells (HEK 293),The metabolite sulfanilic acid generated from the metabolism of fd&c yellow no.6 by the host unspecified microbiota has been reported to reduce the ability of FD&C Yellow No.6 to inhibit drug transporters SLCO2B1.,4'-5'-Dibromofluorescein,Kidney
DTD0501,SLCO3A1,Up regulating,Conventional mice compared with germ-free mice,Up regulating of SLCO3A1 expression in conventional mice compared with germ-free mice,Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms,Interaction,Host unspecified microbiota,Host unspecified microbiota,Host unspecified microbiota,.,C57BL/6 mice,.,The host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO3A1.,.,Jejunum
DTD0428,SLC5A8,Up regulating,Colon cancer [ICD11: 2B90],Up regulating of SLC30A6 expression in the health condition,Class2: Microbiota regulating the expression and function of DT via the biosynthesis of microbial metabolites,Compound,Butyrate,Host unspecified microbiota,999999,.,.,colon adenomas cells,"The host unspecified microbial metabolite butyrate has been reported to upregulate the expression of drug transporter SLC5A8; however, in colon adenomas, this regulatory effect is blocked due to methylation-mediated silencing of the SLC5A8 promoter.",.,.
DTD0353,SLC40A1,Down regulating,Colitis [ICD11: 1A40.0],Down regulating of SLC40A1 expression in clostridium difficile infection condition,Class2: Microbiota regulating the expression and function of DT via the biosynthesis of microbial metabolites,Compound,urolithin A,Host unspecified microbiota,999999,.,.,HT29 cells,The metabolite urolithin A generated from the metabolism of dietary precursors by the host unspecified microbiota has been reported to downregulate the expression of the drug transporter SLC40A1.,.,.
DTD0117,SLC17A4,Down regulating,Colitis [ICD11: 1A40.0],Down regulating of SLC17A4 expression in clostridium difficile infection condition,Class2: Microbiota regulating the expression and function of DT via the biosynthesis of microbial metabolites,Compound,urolithin A,Host unspecified microbiota,999999,.,.,HT29 cells,The metabolite urolithin A generated from the metabolism of dietary precursors by the host unspecified microbiota has been reported to downregulate the expression of the drug transporter SLC17A4.,.,.
DTD0015,ABCC4,Down regulating,Colitis [ICD11: 1A40.0],Down regulating of ABCC4 expression in clostridium difficile infection condition,Class2: Microbiota regulating the expression and function of DT via the biosynthesis of microbial metabolites,Compound,urolithin A,Host unspecified microbiota,999999,.,.,HT29 cells,The metabolite urolithin A generated from the metabolism of dietary precursors by the host unspecified microbiota has been reported to downregulate the expression of the drug transporter ABCC4.,.,.